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ABSTRACT 
 
 
 The increasing prevalence of antibiotic-resistant bacteria, including 
Mycobacterium tuberculosis, Streptococcus pneumoniae, Staphylococcus aureus, and 
Enterococcus faecalis, pushes us to discover new antibacterial agents to maintain 
adequate patient coverage.  This body of work highlights the use of medicinal chemistry 
methodologies that encompass cross-disciplinary fields of study.  Chapter 1 gives an 
introduction to the antibacterial drug targets, resistance, and how scientists are working to 
overcome obstacles encountered with drug-resistant bacteria.  It also details modern 
medicinal chemistry applications in antimicrobial drug discovery.  Chapter 2 details the 
use of a structure-guided library approach to drug design, in which large virtual libraries 
against the target are generated and filtered, based on pharmacophoric and structural 
constraints, to produce smaller and more structurally complex libraries prioritized for 
synthesis.  In this work, bi-aryl sulfonamide libraries using contemporary medicinal 
chemistry techniques were synthesized as potential inhibitors of Mycobacterium 
tuberculosis cell wall biosynthesis via the rhamnose pathway.  Chapter 3 describes the 
discovery of novel inhibitors of the PlsX/PlsY pathway to phosphatidic acid, a key 
intermediate in the biosynthesis of phospholipids in Gram-positive bacteria.  Substrate 
mimics, incorporating various bioisosteric replacement head groups, were discovered 
demonstrating good enzyme inhibition and good antimicrobial activity against clinically 
relevant bacteria. Finally, Chapter 4 provides an overall discussion of the work detailed 
in this dissertation and future directions that will continue the advancement of these 
projects.   
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CHAPTER 1. INTRODUCTION 
 
 
Introduction to Antibiotics and Antimicrobial Agents 
 
Antibiotics are among the most frequently prescribed drugs on the market today.1  
They are informally described as substances produced by or derived from certain fungi, 
bacteria, and other organisms, that can destroy or inhibit the growth of other 
microorganisms.  However, the name antibiotics have expanded to include antimicrobial 
agents which are synthetic drugs that are unrelated to natural products but still inhibit or 
kill microorganisms.1  Historically, we’ve made use of our own powerful immune system 
and public health measures, such as good sanitation, to ward off harmful bacteria.  
However, at times these measures are insufficient creating the need for other forms of 
intervention, through the use of therapeutic agents.1  Antibiotics are generally used to 
treat bacterial infections that can affect the growth of bacteria in two ways:  by killing the 
bacteria (bactericidal) or inhibiting or impeding the growth of the bacteria (bacteriostatic) 
allowing the immune system to then clear the infection.  Antibiotic agents have only been 
around since the early 1900’s.  The first drug, prontosil, a prodrug of the sulfa drug 
sulfanilamide, was introduced in 1936.  This was soon followed by penicillin in 1942.  
Since then, more than 100 different antibiotics have been introduced to the market.  
Modifications to the known drug classes are often tripartite in scope to either improve 
their potency, pharmacokinetic/pharmacodynamic (PK/PD) properties and/or to 
overcome resistance mechanisms.  On the basis of their mechanism of action, antibiotics 
are generally classified as (1) those that block specific steps in folic acid metabolism; (2) 
those that affect bacterial cell-wall biosynthesis; (3) those that interfere with protein 
biosynthesis; and (4) those that affect nucleic acid biosynthesis and transcription.  
 
 
Inhibitors of Folic Acid Metabolism 
 
 Folic acid is a key cofactor required for the biosynthesis of many cellular 
components in all living organisms.2  It is required in DNA synthesis by serving as an 
intermediate in the transfer of methyl, formyl, and other single-carbon fragments in the 
biosynthesis of purine nucleotides.3 Microorganisms must synthesize folates de novo 
through the folate biosynthetic pathway summarized in Figure 1.1.  In contrast, mammals 
obtain folates as apart of their daily diet making this pathway attractive for antimicrobial 
drug design.2  Inhibition of folate biosynthesis results in the inability of the bacteria to 
multiply since further nucleic acid biosynthesis is impossible due to the folate 
requirement.1  Accordingly, drug discovery strategies against the folic acid pathway have 
targeted two enzymes:  dihydropteroate synthase (DHPS) and dihydrofolate reductase 
(DHFR).   
 
Sulfonamides 
 
 Sulfonamides were discovered in the mid 1930’s by a German scientist, Gerhard 
Domagk of Bayer Laboratories. As a result, Domagk was awarded the Nobel Prize in  
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Figure 1.1:  Biosynthesis of Folates  
 3  
1939 on the antibacterial nature of dyes on streptococci.4  Prontosil, the first drug of the 
class, was interestingly found to be active in vivo, but not in vitro.4  It was later 
discovered that prontosil was actually a prodrug with the active component being the 
metabolized product, p-aminobenzenesulfonamide (sulfanilamide)5 (Figure 1.2).  The 
discovery of sulfanilamide’s antibacterial properties ushered in the modern anti-infective 
era.1 
 
 The sulfonamides are bacteriostatic agents that act by inhibiting DHPS.6, 7  DHPS 
catalyses the conversion of p-aminobenzoic acid (PABA) to dihydropteroate, a key step 
in folate synthesis.8  Sulfonamides are competitive inhibitors and in some bacteria can 
also act as substrates replacing PABA, resulting in a dead-end product.9  Currently, 
sulfamethoxazole (Figure 1.3) is the most commonly used drug in the class.  It is mainly 
used in combination with the dihydrofolate reductase inhibitor, trimethoprim, to treat 
urinary tract infections (UTI’s).  This is an excellent example of synergistic drug 
combination that increases efficacy, broadens antibacterial spectrum and lowers the 
prospect for development of resistant strains. 
 
Trimethoprim 
 
 The final step in the pathway to folic acid is performed by DHFR, which converts 
dihydrofolate to tetrahydrofolate.10  This part of the pathway is found in both bacteria and 
mammals, therefore selective inhibition of bacterial DHFR is crucial.  Trimethoprim, a 
member of the diaminopyrimidine class, inhibits bacterial DHFR at much lower 
concentrations than its mammalian counterpart providing the basis for selective toxicity.1 
Alone, it is a well tolerated broad-spectrum agent active against Gram-positive bacilli and 
cocci, including S. aureus.11   
 
 
Inhibitors of Cell Wall Biosynthesis  
 
 The bacterial cell wall has several functions:  to maintain the cell’s shape; to 
provide a semi-permeable barrier; to counteract changes in the osmotic pressure of its 
environment; and to prevent digestion by host enzymes.1  All bacterial cell walls differ 
dramatically in structure and function compared to the outer layers of mammalian cells.  
Generally, enzymes found in bacterial cell walls are not found in mammalian cells, 
therefore making them attractive targets for chemotherapy of bacterial infections.  There 
are two main classes of drugs that target the bacterial cell wall:   β-lactams (penicillins, 
cephalosporins, carbapenems, and monobactams), (Figure 1.4) and glycopeptides 
(vancomycin), (Figure 1.5).  Though they differ in their site and mechanism of action, 
both kill bacteria by disrupting the normal function the bacterial cell wall causing lysis.1  
  
β-lactams 
 
 Penicillin G was the first natural product antibiotic, unlike the synthetic 
sulfonamides, to enter the market in the early 1940’s.  Its discovery began serendipitously 
in 1928 when Alexander Fleming noticed that an old agar plate originally inoculated with 
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Figure 1.2:  Prontosil and Its Active Metabolite, Sulfanilamide 
 
 
 
 
 
Figure 1.3:  Structures of Inhibitors of the Folate Biosynthesis 
 
 
 
 
 
Figure 1.4:  General Skeleton of the Four Classes of β-Lactam Antibiotics  
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Figure 1.5:  Vancomycin 
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S. aureus was contaminated with a fungus. This mold produced a clear zone of lysed 
bacteria around its colony and Fleming hypothesized that the fungus was producing a 
substance that killed the bacteria.  He identified this fungus as Penicillium notatum.  
Through many trials, Fleming was unable to isolate the active component from the mold 
and produce it in a stable form suitable to treat bacterial infections.12  Ten years later, 
Abraham, Chain, Florey, and Heatley, after considerable efforts, were able to identify the 
active component as a small molecule that they named penicillin. They were able to 
develop techniques to mass culture and isolate penicillin in a sufficient scale to prove its 
efficacy to treat topical and systematic infections.  Further developments that followed by 
US researchers significantly increased the yield and scale of the manufacture of penicillin 
in time for its use during World War II.  In 1945, Fleming, Florey, and Chain shared the 
Nobel Prize in Physiology and Medicine for their collective contributions to the 
discovery of penicillin.    
 
 The β-lactam class of antibiotics works by targeting penicillin binding proteins 
(PBPs), peptidoglycan transpeptidases, which catalyze the cross-linking of the 
peptidoglycan.  They all contain an unstable electrophilic four-membered cyclic ring that 
reacts irreversibly with a key serine residue in the active site of the transpeptidase, 
blocking the binding of the natural substrate.13  This blockade results in the death of 
bacteria by producing weakened cell walls which after time lyse.  Overall, these 
compounds gained attention as they had an increased spectrum and are bactericidal unlike 
sulfonamides which are bacteriostatic.   
 
The need to improve the shortcomings, such as acid stability, in Penicillin G led 
to the discovery of semi-synthetic penicillins.  6-aminopenicillanic acid (6-APA), isolated 
from fermentation, is used as a starting material in the synthesis of various semi-synthetic 
penicillin analogs.14  Penicillins have the general structure seen in Figure 1.4, which 
contains a fused β-lactam- thiazolidine bicyclic ring structure.  Alone, 6-APA has weak 
activity, but substitution on its primary amino group yields compounds with improved 
potency, oral bioavailability, antibacterial spectrum, and decreased sensitivity to β-
lactamases, the enzymes responsible for inactivating β-lactams and preventing them from 
executing their mechanism of action.     
   
 Cephalosporin antibiotics were isolated from Cephalosporium acremonium and 
pursued as an alternative to treatment with penicillins because of their intrinsic activity 
against penicillin-resistant cultures.1  The active portion, 7-aminocephalosporanic acid 
(7-ACA) which is analogous to 6-aminopenicillanic acid is used as a precursor for the 
development of semi-synthetic cephalosporins.15  Four generations have subsequently 
been developed with increasing coverage and β-lactamase stability.1   
 
 Carbapenem antibiotics were originally developed from thienamycin, a naturally-
derived product of Streptomyces cattleya.16  They have an extremely intense and broad-
spectrum antimicrobial activity against Gram-positive and Gram-negative bacteria 
combined with the ability to inactivate β-lactamases.  These drugs combine in one 
molecule the functional features of the best of the β-lactam antibiotics as well as the β-
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lactamase inhibitors.  Although they offer very potent broad-spectrum activity, they have 
poor oral bioavailability.1    
 
 Monobactams are monocyclic β-lactams isolated from Chromobacterium 
violaceum.17  These compounds inspired the synthesis of aztreonam, a totally synthetic 
monobactam with Gram-negative activity and ability to inactivate β-lactamases.18-22 It 
has a similar mechanism of action to other β-lactams with specificity to PBP3s.  A major 
advantage of azetreonam is its low allergenicity when compared to other β-lactams. 
    
Glycopeptides  
 
 Glycopeptides represent another class of compounds that disrupt cell wall 
synthesis.  They inhibit the last stages of cell wall assembly by forming complexes with 
the terminal D-ala-D-ala of the peptidoglycan precursors preventing the cross-linking 
reactions catalyzed by transpeptidases, transglycosylases and carboxypeptidases.1  These 
compounds are considered the “drugs of last resort” since they have outstanding broad 
spectrum of activity (Gram-positive).  Methicillin-resistant Staphylococcus aureus 
(MRSA) is in the most common hospital-acquired bacterial infection.  Vancomycin 
(Figure 1.5) resistance remains low and vancomycin is still the drug of choice for the 
treatment of MRSA infections.23   
 
 
Inhibitors of Protein Biosynthesis 
 
 This class of antibiotics exerts its effects by inhibiting ribosomally mediated 
protein biosynthesis.  Bacterial ribosomes are made up of two subunits (30S and 50S), 
which contain suitable structural differences from the eurkaryotic ribosomes that allow 
these to be targeted for drug intervention.  At normal doses, these antibiotics do not bind 
to nor interfere with the function of the human 80S ribosomal subunits, a factor that 
explains the basis for their selective toxicity.  It is found that interference with bacterial 
protein biosynthesis prevents repair, cellular growth, and reproduction and the effect, in 
clinically achievable doses, can be bacteriostatic or bactericidal depending on the class.1  
Antibiotics that inhibit protein biosynthesis include aminoglycosides, tetracyclines, and 
macrolides among others; however the aforementioned antibiotic classes will be 
discussed as these represent the major classes of protein synthesis inhibitors. 
 
Aminoglycosides 
 
 Streptomycin, usually used in treatment of tuberculosis (TB), was the first agent 
of this class to be introduced the market in 1944.  Other agents in this class include 
kanamycin and gentamycin (Figure 1.6).  The chemistry, spectrum, potency, toxicity, and 
PK of these agents are a function of the specific identity of the basic diaminoinositol unit 
and the arrangement and identity of the attachments that allows them to bind to the acidic 
RNA strands in the ribosome.1  These agents have an intrinsic broad antimicrobial 
spectrum with coverage against anaerobic, Gram-positive, and Gram-negative bacteria.  
However, due to their toxic side effects of ototoxicity and kidney tubular necrosis their  
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use is limited to severe infections by Gram-negative bacteria.24  These agents are 
bactericidal.  They bind to the A-site on the 16S-ribosomal DNA portion of the 30S 
ribosomal subunit interfering with the accurate recognition of tRNA by rRNA during 
translation.  This leads to mistranslation of RNA templates and the subsequent selection 
of wrong amino acids1 thereby preventing the joining of the 30S and 50S subunits 
impairing protein synthesis.   
 
Tetracyclines 
 
As their name indicates, tetracyclines are composed of four fused six-membered 
ring systems.  First in its class, chlorotetracycline, an isolate from an aerobic culture of 
Streptomyces aureofaciens,25, 26 was introduced in 1948 (Figure 1.7).  Tetracyclines are 
bacteriostatic agents exerting their effects by binding to the 30S subunit inhibiting the 
binding of aminoacyltransfer-RNA to the ribosomes resulting in termination of peptide 
chain growth.  They are broad spectrum antibiotics primarily used in the treatment of 
sexually transmissible bacterial infections.  Tetracyclines have unfavorable side effects 
that prevent their use in children, such as staining of teeth and impairment of bone 
structure development.27 
 
Macrolides 
 
 Erythromycin (Figure 1.8) was the first macrolide to be introduced to the market 
in 1955.  Their name is derived from the characteristic large lactone ring.  Macrolides act 
by inhibiting the translocation of aminoacyl tRNA following binding to the 50S 
subunit.28  These compounds are bacteriostatic at therapeutic doses.  Drug-drug 
interactions with macrolides are comparatively common and usually involve competition 
for oxidative liver metabolism by CYP3A4 enzyme.1  Macrolides are orally bioavailable, 
accumulate in macrophages and are anti-inflammatory in nature all positive factors for 
their use in therapy.29  They are mainly used for the treatment of upper and lower 
respiratory tract infections primarily caused by Gram-positive bacteria like Streptococcus 
pyogenes and S. pneumoniae.1  
 
 
Inhibitors of Nucleic Acid Biosynthesis  
 
 There are two principal targets associated with this class of drugs: DNA gyrase 
and topoisomerase IV.  DNA gyrase is responsible for introducing negative supercoils 
into DNA thereby allowing superhelical tension ahead of the polymerase to be released 
allowing replication to continue.30  Topoisomerase IV shares a similar function with 
DNA gyrase by also being responsible for relieving supercoils in DNA and allowing 
chromosome separation during cell division in Gram-positive bacteria.31  An analogous, 
yet structurally different enzyme, topoisomerase II, is present in eukaryotes.  However, 
topoisomerase II does not bind fluoroquinolones which binds to the bacterial counterpart.  
Inhibition of DNA gyrase and topoisomerase IV interferes with cell growth and division 
leading to cell death (bactericidal).32  Though they have similar mechanisms   
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topoisomerase IV is more important to some Gram-positive organisms and DNA gyrase 
to Gram-negative organisms.   
 
Quinolone antibiotics comprise a group of synthetic substances that inhibit DNA 
gyrase and topoisomerase IV in bacteria.  The first drug to be marketed in 1965 was 
nalidixic acid33 (Figure 1.9).  It was primarily effective against Gram-negative bacteria 
and had high serum binding.1  The quinolones were not in wide clinical use until the 
discovery of the fluoroquinolones of which norfloxacin was the first to become 
important, introduced in 1986.34  The introduction of the fluoro group increased target 
affinity over 100-fold.  Norfloxacin is a broad spectrum agent with potency equivalent to 
earlier natural product derived antibiotics.34 Future generations (I- IV) of quinolones were 
introduced over the years based on their spectrum of activities.1  Particularly, 
ciprofloxacin, levofloxacin and moxifloxacin are more potent, well tolerated, with good 
oral bioavailability and hence are some of the most successful antimicrobial agents today. 
 
 
Inhibitors of DNA-Directed RNA Polymerase 
 
 The rifamycin antibiotics are members of the ansamycin class of natural products 
produced by Streptomyces mediterranei.35-37  Semisynthetic derivatives, rifampin and 
rifapentine (Figure 1.10), were subsequently prepared having significant benefits over 
natural rifamycins with increased orally activity and spectrum of activity.1 The drugs are 
front line treatments for tuberculosis.  These agents inhibit bacterial DNA-dependent 
RNA polymerase (DDRP) by binding to the β-subunit of the enzyme and are highly 
active against rapidly dividing intracellular and extracellular bacilli.1  Inhibition of DDRP 
leads to a blocking of the initiation of chain formation in RNA synthesis.  The 
introduction of rifampin in 1967 reduced the duration of combination therapy for the 
treatment of tuberculosis from 18 to 9 months.1 
 
 
Resistance to Antibiotic Chemotherapy 
 
 Antibacterial drug resistance is currently the most significant problem facing the 
clinical use of antibiotics.  Resistance occurs when a formerly effective drug becomes no 
longer effective due to bacteria having acquired genetic changes causing resistance.  
Resistance can either be intrinsic or acquired.  Intrinsic resistance occurs naturally in the 
absence of selection pressure upon exposure to antibiotics.  Bacteria have been around for 
over 3 billion years.  Over time they have survived by equipping themselves with safety 
measures to conquer any toxicities.38  Acquired resistance occurs as a result of mutations 
that affect the structure of the drug target or acquisition of extrinsic DNA via 
transformation, transduction, or conjugation.  The acquisition of foreign DNA is the most 
common and important mechanism as it accounts for much of the development of 
resistance in bacteria.39   
 
 Sulfa drugs and penicillins were the first drugs to reach the market in late 1930s 
and early 1940’s, respectively and were thought to be the “wonder drugs” as they could  
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treat bacterial infections that were plaguing the world.  However, the development of 
resistance surfaced shortly after.  Some of the first reports involved reduced sensitivity of 
the sulfa drugs to several strains of pneumococci as observed by MacLean, Rogers, and 
Fleming. 40, 41  Thus far, bacteria have developed resistance to almost all antibiotics on 
the market today.  Cross-resistance occurs when several bacteria develop resistance to 
different members of a group of chemically related compounds by the same resistance 
mechanism.  This is exemplified as β-lactamases confer resistance to several different 
penicillins and cephalosporins.39  When bacteria become resistant to several unrelated 
bacterial agents by different resistance mechanisms they are considered to be multiply-
drug resistant as observed with Mycobacterium tuberculosis and MRSA.        
 
 Generally, there are five major mechanisms with which bacteria exhibit antibiotic 
resistance:  (1) restricted access of the antibiotic to its target by limiting uptake; (2) 
accelerated loss of antibiotic due to efflux pumps; (3) acquisition of enzymes that 
inactivate the antibiotic; (4) modification of the target; and (5) alternate pathway for 
formation of the products. 
 
 
Limiting Uptake 
 
 Antibiotics must first reach their intracellular target before exerting their effects.  
The cell walls of Gram-negative bacteria differ from Gram-positive bacteria in that it has 
an outer membrane separating it from the cytoplasmic membrane in which many drug 
targets reside.42  This outer membrane is responsible for protecting the bacteria from 
harmful substances.  Porins within the outer membranes allow molecules to enter into the 
cell to reach its site of action.  Resistance occurs when mutations of the porin restrict the 
entry of antibiotics as seen with imipenem, a β-lactam antibiotic, in Pseudomonas. 
aeruginosa.23, 43   
 
 
Efflux Pumps    
 
Efflux pumps are important determinants of intrinsic and acquired resistance to 
antimicrobial agents.44  They work by quickly pumping drugs out of the cytoplasm before 
they have a chance to reach high enough concentrations to exert their effects.  
Quinolones, macrolides, and tetracyclines are all classes of drugs that are susceptible to 
the same efflux pump.45  The first efflux mechanism to be discovered mediated resistance 
to tetracyclines in E. coli.44, 46, 47  Efflux is the primary mechanism of tetracycline 
resistance in Gram-negative pathogens, including Salmonella spp., Shigella spp., and 
Acinetobacter spp.44, 45 via tet genes.   
 
 
Antibiotic-Altering Enzymes 
 
 Several classes of antibiotics have enzymes whose role is to disrupt the function 
of the drug.  The major mechanism of resistance in Gram-negative bacteria to β-lactam 
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antibiotics is inactivation by β-lactamase, an enzyme that hydrolyzes the β-lactam ring 
thus preventing the β-lactam from binding to its target.  β-lactamase resistance was first 
confirmed in the 1960s against S. aureus.23  Currently, over 90% of S. aureus are 
resistant to penicillin as a result of β-lactamase production.39  Resistance to 
aminoglycosides is executed by modifying enzymes that inactivate antibiotics by O-
phosphorylation, O-adenylation, or N-acetylation.48  These modifications change their 
overall structure compromising their binding to the ribosome.  These drug destroying 
enzymes have been a key target in drug design, as will be described in the next section on 
overcoming resistance.   
 
 
Modification of the Target 
 
 The most threatening mechanisms of resistance involve changes to the target site 
for antibiotic interaction; because it confers resistance to all compounds with the same 
mechanism of action.12  Modifications to target enzymes are the second most common 
form of resistance for antibiotics targeting the cell wall, especially for Gram-positive 
bacteria.  Vancomycin resistance in enterococci is conferred by alteration of the 
peptidoglycan precursor pathway from D-ala-D-ala to D-ala-D-lac through the 
acquisition of multigene cassette.  The new D-ala-D-lac has a lower binding affinity to 
the glycopeptides, producing resistance.49  Point mutations alter the affinity of quinolones 
to DNA gyrase and rifamycin to RNA polymerase.  Resistance to the antibiotics that 
target folic acid synthesis arises from mutations to the active site of the drugs’ target.   
 
 
Bypass Pathways 
 
 Bacteria can develop a novel metabolic pathway that bypasses the effect of the 
antibiotic rendering the drug ineffective.12, 50  Mupirocin, a drug widely used for the 
treatment of topical Gram-positive skin infections, kills bacteria by binding to isoleucyl-
tRNA sythetases (IleRS) thereby inhibiting protein synthesis.51  The acquisition of an 
alternate IleRS enzyme confers high-level resistance to S. aureus.52  In addition, 
trimethoprim resistance usually involves a plasmid-mediated synthesis of altered DHFR 
enzymes with reduced affinity for this drug.50 
 
 
Overcoming Resistance 
 
 There is significant concern that the continual rise in drug resistance will lead us 
back to the pre-antibiotic era with high fatality rates.  This is particularly worrisome for 
organisms such as Pseudomonas, Acinetobacter and MRSA for which we already have 
few treatment options and could conceivably become completely untreatable.  It is 
necessary to implement strategies to reverse or slow down resistance against current 
chemotherapies.  These measures require joint efforts from the clinic, the public, and 
research arenas.  The improper or overuse of antibiotics is the leading explanation for 
increases in antibiotic-resistant bacteria.44, 53  Clinicians have to make sure that they are 
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appropriately prescribing antibiotics for proper use.  In turn, patients have to make sure 
they cooperate with current regimens to ensure resistant bacteria don’t develop by non-
compliance.  Infection control is also very important as one in ten patients acquires an 
infection during their hospital stay.  Better infection control could reduce the number of 
infections, reduce costs due to increased hospital stays, and limit the need for more 
antibiotics.38, 53  Lastly, the research community is responsible for developing new agents 
to combat the emergence of antimicrobial resistance.  The next section will describe the 
efforts that the research community has taken so far and where we have left to go. 
 
 
Inhibiting Drug-Destroying Enzymes 
 
 The predominate mechanism of resistance to β-lactam antibiotics is β-lactamases.  
There are currently four recognized molecular classes of β–lactamases (Class A 
penicillinases, Class B metallo- β-lactamases, Class C cephalosporinases and Class D 
oxacillinases).54, 55  The main focus has traditionally been to develop agents that are 
stable to hydrolysis by known β-lactmases or that irreversibly inhibit β-lactmases in 
which three, tazobactam, sulbactam, and clavulanate, are currently approved for use in 
the clinic (Figure 1.11).  Unfortunately, these agents only work against Class A β-
lactamases.55  There is ongoing work in the development of specific and broad spectrum 
β-lactamase inhibitors to work synergistically with current β-lactam antibiotics.56-65  One 
such recent discovery is NXL-104, a representative of a new class of potent inhibitors of 
class A and Class C β-lactamases with broad Gram-negative coverage65 (Figure 1.11). 
 
Chemical inactivation of aminoglycosides, catalyzed by O-phosphotransferases, 
O-adenyltransferases, and N-acetyltransferases are the primary mode of resistance by 
compromising the binding of the drug to the target site.66  These enzymes are amenable to 
inhibition as inhibitors of adenyltransferases and acetyltransferases have been reported.67-
69  “Unfortunately, only one, the 7-hydroxytropolone inhibitor (Figure 1.12) of an 
aminoglycoside-2”-O-adenyltransferase, actually demonstrated potentiation of 
aminoglycoside activity against resistant organisms expressing the corresponding 
transferase.”55  Attempts to modify existing aminoglycosides that have reduced binding 
to corresponding modifying enzymes has been a more successful approach in the 
development of new antimicrobial agents for this class.55, 70   
 
 
Inhibiting Multi-Drug Efflux Pumps   
 
 In Gram-negative bacteria, resistance appears to be affiliated with limited access 
to the target site by multi-drug efflux systems.55  Fluoroquinolones and tetracyclines have 
resistance mechanisms involving efflux pumps.  There have been extensive efforts in the 
discovery of efflux pump inhibitors.  Inhibition of efflux pumps is expected to decrease 
the level of intrinsic resistance and significantly reverse acquired resistance.  Reserpine 
(Figure 1.13), an inhibitor of the fluoroquinolone pump, NorA, has been described.71  
Reserpine treatment of S. aureus and S. pneumoniae prevented emergence of 
fluroquinolone resistance in these organisms.  Another inhibitor, MC-207,110 (Figure 
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Figure 1.13:  Reserpine, an Inhibitor of Multi-Drug Efflux Pumps 
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1.14), discovered from a screen of natural product and synthetic compound libraries, has 
been described that potentiated the action of levofloxacin in P. aeruginosa.72-74  MC-
207,110 is active against several resistance-nodulation-cell-division (RND) pumps found 
in a variety of Gram-negative pathogens giving the potential for broad-spectrum efflux 
pump inhibitors.72  In addition, several teteracycline derivatives have been reported as 
inhibitors of tet efflux systems (Figure 1.15).  Some inhibitors were found to work 
“synergistically with doxycycline against E. coli, S. aureus, and E. faecalis strains 
expressing efflux determinants of tetracycline resistance, while others acted as potent 
growth inhibitors of S. aureus expressing tet efflux.”55, 75, 76          
 
 
Introducing New Chemical Entities (NCE) 
 
 Oxazolidinones were the first new class of antibiotics to enter the market since the 
introduction of rifamycins in the 1970s.  The first oxazolidinones were discovered by 
DuPont in the late 1970’s.77  These compounds had significant activity against a wide 
range of Gram-positive sensitive and resistant strains of bacteria.  However, they showed 
lethal toxicity in animal models, which suspended the work on these compounds.77, 78  
Pharmacia and UpJohn picked up this project in the early 1990’s, which led to the 
discovery of Linezolid.77  Linezolid (Figure 1.16) is the first drug of its class to be 
introduced into the market in 2000.  It is a purely synthetic antibiotic that is effective 
against a wide spectrum of Gram-positive bacteria, including MRSA and vancomycin 
intermediate S. aureus (VISA) for the treatment of nosocomial pneumonia, complicated 
skin infections.77  However, it still has limited duration of use due to side effects 
involving myeloid suppression.77, 78  Its mechanism of action involves inhibition of 
protein synthesis (bacteriostatic) but at a stage different from that of other protein 
synthesis inhibitors.1  It binds to the bacterial 23S ribosomal RNA of the 50S subunit, 
blocking the formation of a functional 70S initiation complex, which is essential in the 
bacterial translation process.78   
  
 Daptomycin (Figure 1.17), a fermentation product produced by Streptomyces 
roseosporus, is a novel cyclic lipopeptide antibiotic used to treat infections caused by 
Gram-positive bacteria including multiple antibiotic-resistant and susceptible strains.79  
FDA approval was granted in 2003 for the treatment of complicated skin and skin 
structure infections caused by Gram-positive bacteria.  Its unique structure consists of a 
13-member amino acid cyclic lipopeptide with a decanoyl side-chain conferring its novel 
mechanism of action.79  Its unique mechanism of inactivation involves insertion of     
daptomycins lipophilic tail into the membrane causing depolarization, resulting in the 
loss of membrane potential required for synthesis of DNA, RNA, and proteins.79  It has 
concentration-dependent bactericidal activity, but time-dependent side effects; therefore 
it is dosed at high concentrations on an infrequent basis.79 
 
A less direct way of targeting resistance is to develop macrolides that overcomes 
or are less impacted by existing resistance mechanisms.  Telithromycin (Figure 1.18), 
used to treat mild to moderate respiratory infections, is a member of a new class of agents 
termed ketolides.80  It is a semi-synthetic derivative of erythromycin A containing a 14-  
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Figure 1.18:Telithromycin 
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membered ring that lacks the cladinose sugar unit.  Ribosomal methylation confers cross-
resistance to the macrolide–lincosamide–streptogramin B (MLSB) antibiotics.80  The methylation leads to a conformational change in the ribosome, resulting in decreased 
affinity for all MLSB antibiotics.80  Ketolides with a carbamate, in replacement of the cladinose sugar ring, remain active against most resistant strains due to changes in the 
drug-binding site.80  Telithromycin shows increased activity against a number of Gram-
positive pathogens expressing efflux resistance.  This new addition to the MLSB group 
was developed specifically for the treatment of community-acquired respiratory tract 
infections; however hepatotoxicity limits its use.80  Telithromycin was developed at 
Aventis (Romainville, France) and reached the market (Germany and Spain) as Ketek 
late in 2001.80  Its approval in the US wasn’t granted until 2004.  Similar to 
erythromycin, telithromycin is bacteriostatic targeting protein synthesis by binding to the 
50S subunit of the ribosome, blocking progression of the growing peptide.   
 
Tigecycline (Figure 1.19) is the first commercially available member of the 
glycylcyclines, a new class of antimicrobial agents similar to tetracyclines, marketed by 
Wyeth in 2005 as a response to the growing antibiotic resistance seen in bacteria such as 
S. auerus.81, 82 The glycyclines have potent Gram-positive, Gram-negative, and anaerobic 
activity, including certain multi-drug resistant strains.82  This antibiotic is a semi- 
synthetic derivative of minocycline by the substitution of a 9-tbutylglycylamido group at 
the 9 position on the D ring.81, 82  Because of structural modifications, tigecycline is stable 
against the two main forms of tetracycline resistance:  efflux pumps and ribosomal 
protection.  Tigecycline displays distinct advantages as an antimicrobial agent and 
presents a new therapeutic option for the treatment of multi-drug resistant infections.81, 82  
It is bacteriostatic targeting the 30S subunit on the ribosome inhibiting protein 
translation.  This blockade prevents the entry of amino-acyl transfer RNA molecules into 
the A site of the ribosome, resulting in the loss of peptide formation.81-83  Tigecycline is 
indicated for the treatment of complicated skin and soft tissue infections and complicated 
intra-abdominal infections.    
 
 
Pursuing Novel Targets with Novel Modes of Action 
 
 There is concern that resistance will rapidly develop to new agents that are 
derivatives of existing antimicrobial agents.83  One approach to overcome this problem is 
to develop new chemical entities, which has already been addressed above.  Another 
approach involves the discovery and development of new compounds with novel modes 
of action while trying to avoid cross-resistance.  Development of these new targets will 
less likely harbor pre-existing resistance mutations in their target since they have not 
been exposed to the natural selection pressure of antibiotics.  Proof of concept exists with 
two agents currently on the market:  mupirocin, a potent inhibitor of isoleucyl-tRNA 
synthetase; and isoniazid, an inhibitor of enoyl-ACP reductase in Mycobacterium 
tuberculosis.84   
 
As briefly mentioned, mupirocin (Figure 1.20) is a member of the class of 
antibiotics that inhibit protein synthesis.52  It was isolated from Pseudomona 
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Figure 1.20:  Mupirocin  
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fluorescens85 for use as a topical agent to treat bacterial skin infections51, such as 
impetigo caused by Gram-positive bacteria.  Mupirocin selectively binds to bacterial 
isoleucyl-tRNA synthetase, which prevents the incorporation of isoleucine into bacterial 
proteins.  Because its mechanism of action is unique, it has few problems with cross-
resistance.51  Since the discovery of this target with its unique mechanism of action, much 
work has been done on the discovery of new aminoacyl-tRNA synthetase (aa-RS) 
inhibitors as potential antibiotics.86, 87  Aa-RSs represent ideal targets for drug design 
because (1) they are essential for survival of bacteria; (2) there are major differences in 
the human and bacterial enzymes that enable the development of compounds with 
selective toxicity; (3) they are highly conserved across many bacterial species providing 
the possibility of broad spectrum antibiotics; (4) their properties are amenable to high-
throughput screening; and  (5) there exists several distinct enzymes for development of 
discrete antimicrobial agents.86, 87   
 
Fatty acid synthesis (FAS) enzymes are essential to the vitality of bacteria, 
therefore providing a suitable target for antimicrobial drug design (Figure 1.21).88  The 
bacterial FAS-II pathway, in which each step is performed by individual enzymes, differs 
from the multi-enzyme FAS-I complex found in mammals and are highly conserved 
across many bacterial species giving rise to their potential for the development of broad 
spectrum antibiotics.89-92  Isoniazid, discovered in 1952 is used as a first-line agent in the 
treatment of tuberculosis. It is a prodrug that must be activated, and then reacts with  
NADH to form a complex that binds tightly to one of the bacterial fatty acid enzymes, 
keto-enoylreductase (InhA), a homologue of the E.coli enoyl-ACP reductase (FabI) 
enzyme, blocking the access of the natural substrate.91  Triclosan, an inhibitor of enoyl-
ACP reductase I, is used as a consumer antibiotic incorporated into a plethora of 
household products.89  Apart from these clinically used agents, several other potent 
inhibitors have been discovered with proven efficacy which include cerulenin, 
thiolactomycin, and the diazoborines.91  Cerulenin and thiolactomycin are potent natural 
product inhibitors of the 3-keto-ACP synthetases (KAS) and the diazoborine derivatives 
are inhibitors of enoyl-ACP reductase.  Over the past years, there has been extensive 
efforts to develop novel antimicrobial agents targeting fatty acid biosynthesis using 
natural product screening, structure-based drug design, and compound library screening 
that have led to clinical candidates, such as API-125293 and CG40054994 that target FabI 
(Figure 1.22).90     
 
 The targets mentioned above came before the introduction of the new genomic 
era, which appeared in 1995 after the publishing of the complete genome sequence of 
Haemophilus influenzae.95  Since then over 200 bacterial genome sequences have become 
available.  Genomics has promised to provide a plethora of novel targets and hence a 
flood of new therapeutic agents.84  Ideally, a target for antimicrobial drug design must be 
essential to the survival of the bacteria and have no close homolog in the human genome.  
Genomics does not work alone as other technologies are required.  In the next section 
will describe how medicinal chemists use the information from genomics to develop new 
antimicrobial agents. 
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Figure 1.21:  Fatty Acid Biosynthesis 
 
 
 
 
 
Figure 1.22:  Clinical Candidates that Inhibit Bacterial Fatty Acid Synthesis 
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Medicinal Chemistry Applications in Antimicrobial Drug Discovery 
 
 A medicinal chemist involved in drug discovery requires a highly 
interdisciplinary environment combining organic chemistry, biochemistry, computational 
chemistry, pharmacology, pharmacognosy, and molecular and structural biology.96  This 
section will discuss the use of medicinal chemistry techniques in the drug discovery 
process which include:  structure-based drug design for lead discovery and optimization; 
combinatorial chemistry techniques for lead optimization; and the importance of drug-
likeness during the lead optimization process.   
 
 
Structure-Based Drug Design 
 
The first project, which is outline in Chapter 2, made use of structure-based drug 
design (SBDD) techniques in the discovery of potential inhibitors of Mycobacterium 
tuberculosis cell wall biosynthesis.  SBDD involves the use of structural knowledge of 
proteins or other macromolecules to assist in the development of new drug candidates.  It 
represents the idea that you can see exactly how your molecule interacts with its target 
protein.  X-ray crystallography remains the gold standard for structure elucidation, 
affording high precision and the ability to look at complex systems.97  In drug design, it is 
desirable and most effective when a high resolution co-crystal structure of a receptor with 
a ligand bound is available as it gives the most structural information regarding how the 
ligand interacts in solution with the receptor.  NMR and homology modeling offer 
alternative routes to structure based design.97  Structure-based design can be applied in a 
variety of ways once a structure is available:  (1) identification of chemical starting points 
for lead optimization; (2) docking of commercial or virtual compounds; or (3) de novo 
design.  It is an enrichment tool in medicinal chemistry, aiding the chemist in the 
prioritization of compounds throughout the lead optimization process.97  An early 
example of structure-based design was of trimethoprim analogs with significantly 
improved affinities to DHFR.  However, the trimethoprim analogs could not be optimized 
to become drugs for human therapy.98  The first success story in structure-based design 
was the antihypertensive drug, captopril (Bristol-Myers Squibb).98   
 
SBDD can be approached in two ways:  receptor based design or ligand-based 
design.  My project mostly involved the receptor-based approach which involves the use 
of structural knowledge of the target site to design drug-like molecules with specific 
binding activity.  Virtual screening (VS) and docking are often methodologies used in 
receptor-based design.  Virtual screening is a term used to describe the process of 
computationally analyzing large compound collections in order to prioritize compounds 
for synthesis or assay.  Virtual screening can be used with or as an alternative to high-
throughput screening (HTS).  The major difference between HTS and virtual screening 
involves the use of tangible compounds and targets in HTS versus the in silico generated 
compounds and targets in virtual screening.  Virtual screening has been used mainly in 
two ways:  to find new compounds for drug design and also to improve current leads in 
hopes to find better drugs.  Docking is often used in conjunction with virtual screening.  
This strategy requires a 3-D database of ligands, a 3-D structure of the target receptor, 
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either derived experimentally or from a homology model, and a docking code comprising 
an efficient searching algorithm with an accurate scoring function.99  In this process large 
databases of compounds are “fit” into the active site of the enzyme and the interactions 
are scored.  The compounds in a given conformation that “fit” best are ranked highest 
with a scoring function.  These highest ranked compounds are often those chosen for 
synthesis or assay.   
 
The ligand-based approach makes use of known receptor ligands and their 
structure-activity relationship (SAR) to form hypotheses about the target site.  
Quantitative structure activity relationship (QSAR) is a well known ligand-based 
approach currently used in drug design when the structural information about the target is 
missing.12  Three-dimensional QSAR shows the relationship between biological activity 
of a molecule and its geometric and chemical characteristics.12  Comparative molecular 
field analysis (CoMFA) and comparative molecular similarity indicies (CoMSIA) are 3D-
QSAR methods that search for relationships between the biological activity of a set of 
compounds (with specific alignment) and their 3-D electronic, steric, and hydrophobic 
properties.12  QSAR allows you to predict properties and activities of untested molecules 
based on preexisting molecules; optimize the properties of a lead compound; generate 
hypotheses about the characteristics of a receptor binding site; and prioritize compounds 
for synthesis or screening.12     
 
 
Combinatorial Chemistry and HTS 
 
 Traditional synthesis involved one compound at a time, which was very time 
consuming.  In order to get a drug to market, many compounds during the optimization 
stages need to be made.  At the rate of one compound at a time, the time to market could 
be extended beyond the current 10-15 year mark.  One way to improve the output came 
with the methodology of combinatorial chemistry.  Combinatorial chemistry involves the 
synthesis of large structurally distinct chemical libraries of molecules for screening in the 
lead discovery or lead modification process.12  Unique to combinatorial chemistry is the 
synthesis of a wide range of analogues synthesized under the same conditions in the same 
reaction vessel.  This technology has allowed scientist to synthesize many compounds 
quickly and at a reduced cost.  Combinatorial chemistry was initially designed for peptide 
libraries, but has moved on to small compound synthesis, especially for discovery of new 
antimicrobial agents.  12All combinatorial library methods involve three main steps: 
preparation of the library, screening of the library components, and determination of the 
chemical structures of active compounds.100  Libraries are prepared in a systematic and 
repetitive fashion by the assembly of building blocks to give a diverse array of molecules 
with a common scaffold.12  They are carried out on solid support (one compound per 
bead).  This is advantageous in that excess reagents can be used to drive the reactions to 
completion and isolation and purification of the products can be done by simple filtration 
and washing.12  Though combinatorial chemistry is advantageous in producing large 
numbers of compounds for screening, it has a bottle neck involving deconvolution of the 
active compounds.  Since many compounds are often synthesized in one well, it is often 
difficult and time consuming to determine exactly which compound is active.  Alternative 
 26  
strategies involve the synthesis of individual compounds in separate vessels called 
parallel synthesis.12  Parallel synthesis usually involves the use of solution phase 
synthesis using solid phase reagents such as scavenger resins or solid support reagents.100  
In this strategy, compounds can be synthesized in parallel incorporating different sets of 
commercially available building blocks to provide a large number of diverse structures.  
This methodology has become the dominant method for high-throughput synthesis today. 
 
Traditionally, many drugs on the market today were discovered serendipitously 
from the screening of natural products, namely from plants, animals, or fermentation or 
from synthetic compound libraries.100  A complementary method to combinatorial 
chemistry in the 1990s involved high-throughput screening (HTS).  HTS is an in vitro 
screen, developed around 1990, that is capable of screening large libraries of compounds 
in hopes to discover hit molecules for lead development.100  As previously mentioned, 
HTS it is an alternative to or used in combination with virtual screening.  HTS can be 
carried out robotically on small amounts of compound allowing for screening of large 
numbers of compounds.12  The overall idea theoretically should produce a great number 
of hits therefore providing more leads. As technology has improved screening in 96-well 
plates has moved to 1536- well plates allowing for rapid development.100  The hit 
libraries can come from a number of sources including combinatorial chemistry libraries 
as discussed previously.   
 
 
Filters for Drug Likeness 
 
Absorption, distribution, metabolism, excretion, and toxicity (ADMET) 
characteristics of compounds are very important because a large percentage of drug 
candidates that reaches clinical trials are discontinued as a result of ADMET problems.  
If these properties can be predicted early in the drug discovery process, much time and 
expense would be saved in designing, synthesizing and testing compounds.12  Drug-
likeness is now widely used to filter out compounds likely to have poor pharmacokinetic 
(PK) properties early on in drug discovery.  Christopher Lipinski and co-workers at 
Pfizer studied the physical properties of orally active compounds in the World Drug 
Index (WDI).101  From this study he developed the “rule of five” which is often used to 
determine what compounds would be likely drug candidates for further development.  
This guide was used to improve oral bioavailability during lead modification which was 
based on a large database of known drugs.  The “rule of five” states that in order to have 
drugs that will have good absorption or permeation the following properties should exist:  
(1) molecular weight < 500 Daltons; (2) calculated Log P (octanol/water partition 
constant) < 5; (3) molecule should have ≤ 5 hydrogen-bond donors (consisting of OH and 
NH groups); and (4) molecule should have ≤ 10 hydrogen-bond acceptors (consisting of 
N and O atoms).  There are a few orally available therapeutic classes with several drugs 
outside the ‘rule of 5’:  antibiotics, antifungals, vitamins and cardiac glycosides.12  
Generally speaking, these classes tend to be the exception to the rule because they have 
active transporters to carry them across membranes.  Other predictors of good oral 
bioavailability include number of rotatable bonds (≤ 7) and a low polar surface area 
 27  
(<140Å2).102, 103  Using such filters early in drug discovery proved to cut down on time 
and cost of producing a drug to pre-clinical trials.   
 
Lead-likeness has been a new concept adopted in the past few years.  It considers 
smaller compounds or fragments that can be modified to enhance effectiveness during 
lead optimization.  Fragments are small organic molecules (100–250 Da) that exhibit low 
binding affinities against target proteins, and, as such, would not usually be identified by 
HTS.104  Once a hit has been identified in this way, and its exact binding mode 
elucidated, the fragment could provide a novel template that can be developed into a 
more complex, higher potency ligand.  Despite the low affinity of these small molecule 
hits, fragments tend to exhibit high ‘ligand efficiency,’ a high value for the average free 
energy of binding per heavy atom.104  This property makes fragments attractive starting 
points for iterative medicinal chemistry optimization.  It is apparent that a lead, with 
respect to its properties, differs significantly from a drug.  For this reason, Congreve and 
workers104 developed another set of rules to develop a lead fragment called the “rule of 
3.” This rule states that a fragment lead molecule should have the following properties:  
(1) molecular weight < 300; (2) calculated logP < 3; and (3) molecule should have < 3 
hydrogen bond donors and/or acceptors.  These numbers are lower, because often times 
groups are added to a lead compound to improve activity, therefore starting smaller will 
avoid surpassing Lipinski’s rules.   Again, these rules don’t work for all drugs, but is 
often the rule of thumb of small molecule drugs.   
 
 
Research Objectives 
 
 In the continuing efforts for the discovery of novel candidates in the treatment of 
bacterial infections, two targets have been exploited:  (1) the biosynthesis of rhamose, a 
key sugar residue in the cell wall of Mycobacterium tuberculosis; and (2) the biosynthesis 
of phosphatidic acid, a key intermediate in the synthesis of phospholipids in bacteria.     
 
 
Sulfonamide Libraries as Inhibitors of Mycobacterium tuberculosis Cell Wall 
Biosynthesis 
 
 Chapter 2 deals with the design, synthesis, and biological evaluation of bi-aryl 
sulfonamide libraries as potential anti-tuberculosis drugs.  We targeted rhamnose 
biosynthesis, a key sugar residue in the makeup of the mycobacterium cell wall.  The 
libraries were based on a hit pyrazolone compound from a high-throughput screen 
performed by our collaborators at Colorado State University.  I will describe our work 
using a structure-guided library approach, in which large virtual libraries against the 
target enzymes were generated and filtered, based on pharmacophoric and structural 
constraints, to produce smaller and more structurally complex libraries prioritized for 
synthesis.  Several methods were evaluated to prepare for the parallel synthesis of the 
target sulfonamide libraries.  After optimization, these libraries of sulfonamides were 
synthesized and screened for inhibition of M. tuberculosis cell wall biosynthesis and for 
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anti-tuberculosis activity.  In this study, several sulfonamide inhibitors were discovered 
with plans to obtain co-crystal structures for future library developments.   
 
 
 Discovery of Novel Inhibitors in Phospholipid Biosynthesis 
 
 Chapter 3 deals with the importance of the development of new antimicrobial 
agents to overcome resistance problems seen with Gram-positive bacteria.  As previously 
mentioned, one way to overcome resistance is to develop new drugs for novel targets.  
This approach should slow down resistance, and because it is novel should also avoid 
cross-resistance.  This work targets the newly discovered PlsX/PlsY pathway to 
phospholipids biosynthesis in Gram-positive bacteria.  I will describe the design, 
synthesis, and evaluation of stable substrate-based mimics that led to the discovery of the 
first known inhibitors for the PlsX/PlsY system.  Compounds from this study showed 
significant enzyme inhibition activity at S. pneumoniae and B. anthracis as well as 
significant anti-anthrax activity. 
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CHAPTER 2:  STRUCTURE-GUIDED SULFONAMIDE LIBRARIES AS 
INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS CELL WALL 
BIOSYNTHESIS 
 
 
Introduction to Tuberculosis 
 
 The bacterium, Mycobacterium tuberculosis, is the causative agent of human 
tuberculosis (TB).  It was first described in 1882 by Robert Koch, who subsequently 
received the Nobel Prize in physiology or medicine for this discovery in 1905.105, 106  TB 
is a respiratory tract infection that is transmissible through aresol droplets resulting from 
coughing, sneezing, speaking, etc.107  The risk of transmission of the disease is higher for 
children who are still developing a healthy immune system and for individuals with 
disorders that impair immunity, such as the human immunodeficiency virus (HIV).  
Although TB most commonly attacks the lungs, it can also affect the central nervous 
system, the lymphatic system, the circulatory system, bones, joints, and even the skin.107  
There are two general stages of the disease:  latent TB and active TB.108, 109  Individuals 
with the latent form of TB are generally asymptomatic and not contagious.  In contrast, 
individuals with active TB display symptoms and are contagious.  Not everyone infected 
with the tubercule bacilli develops the full-blown disease.  Only about 5-10% of 
individuals who have the latent infection will progress to the active TB disease during 
their lifetime, unless the patient becomes immunosuppressed, such as with HIV, which 
produces a reactivity rate of 10% per year.110  According to the World Health 
Organization (WHO), tuberculosis is the second leading cause of deaths from infectious 
diseases in the world second to HIV.111  Tuberculosis is a leading killer among HIV-
infected people; about 200,000 people living with HIV/AIDS die from TB every year, 
most of them living in the sub-Saharan African region.111  Over one-third of the world's 
population (2 billion people) is infected with TB bacilli with an estimated 1.5 million 
deaths in 2006.111   
 
 
Tuberculosis Treatment 
 
 Once a person has developed and is diagnosed with active TB, chemotherapeutic 
agents are required for treatment.  Prior to the introduction of streptomycin in the 1940s, 
there was no effective treatment for tuberculosis.107  Now, treatment of the active form of 
TB generally utilizes rifampicin (RIF), isoniazid (INH), pyrazinamide (PZA), 
streptomycin (SM), and ethambutol (EMB), which are first-line agents107 (Figure 2.1).   
However, owing to the nature of TB’s slow growth and ability to manifest in a latent 
state, the regiment for treatment is usually 6-9 months to completely eliminate the 
bacteria from the body.107  With the current drugs being used, regimens shorter than 6 
months are not acceptable due to high relapse rates.112  The current treatment consists of a 
2-month initial bactericidal phase of the daily use of INH, RIF, PZA, and SM or EMB to 
rapidly eliminate the bulk of tubercle bacilli.107  Pyrazinamide and rifampicin is crucial 
for the first 2 months of therapy, since they are active against latent phases of the 
infection.107  During the second 4 to 7 month sterilizing phase, patients take INH and RIF  
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Figure 2.1:  First-Line Tuberculosis Treatment 
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to eliminate remaining bacilli.113  Second-line agents (Figure 2.2), including ethionamide, 
para-aminosalicyclic acid, cycloserine, capreomycin, and kanamycin, are generally 
utilized in cases of resistance, retreatment, or intolerance to first-line drugs.1  While these 
drugs are active against TB bacilli in vitro, they usually are less tolerated having higher 
incidences of adverse side effect, and are less effacacious requiring longer therapy for 
cure rates.1       
 
Isoniazid 
 
 Isoniazid is an orally active synthetic antibacterial agent that was discovered in 
the mid 1900s to be an effective anti-tuberculosis drug.  INH’s bactericidal effects are 
exerted only against the actively growing organisms.107  INH is known to disrupt cell 
wall biosynthesis by binding to one of the condensing enzymes (Inh A) in the fatty acid 
biosynthesis pathway.114, 115  It is a prodrug that is activated by catalase-peroxidase 
enzyme (katG) to for the activated radical acyl anion.  This form react with NADH to 
form a complex that binds tightly to InhA inhibiting the synthesis of critical mycolic 
acids of the mycobacterial cell wall.114  Resistance to INH is generally associated with 
mutations that inactivate the katG gene.116, 117            
  
Rifampin 
 
 Rifampin is an orally active, highly effective semi-synthetic antibiotic, derived 
from Streptomyces mediterranei.37  It is bactericidal against all populations of 
mycobacteria.107  Rifampin inhibits the β-subunit of RNA polymerase of the 
mycobacterium thus preventing transcription of DNA to RNA and the subsequent 
translation of proteins.  Resistance develops when a mutation occurs in the gene 
responsible for the β-subunit of the RNA polymerase (rpoB gene)118 resulting in inability 
of the antibiotic to readily bind to the RNA polymerase.  The introduction of rifampin to 
the standard regimen significantly reduced TB treatment by half (18 to 9 months).107   
 
Pyrazinamide 
 
 Pyrazinamide is an oral synthetic pyrazine analog of nicotinamide.  It is 
bactericidal on actively replicating bacteria.  Its activity is pH dependent with good in 
vivo activity at pH 5.5 but nearly inactive at neutral pH.1  Like INH pyrazinamide is a 
prodrug that uses pyrazinamidase to convert it to its active form, pyrazinoic acid, which 
inhibits fatty acid biosynthesis.119  Pyrazinamide is beneficial in that it is active against 
semi-dormant bacilli resulting in acidic environments that are not affected by other 
drugs.1  It is often used during the first 2 months of chemotherapy to reduce the total 
overall length of therapy.  The introduction of PZA reduced treatment from 9 months to 6 
months.107  The major serious side effect is the potential for hepatotoxicity.1 
 
Ethambutol 
 
 Ethambutol is a bacteriostatic agent that inhibits arabinogalactan biosynthesis, a 
key component of the mycobacterial cell wall.120, 121  It disrupts cell wall biosynthesis  
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Figure 2.2:  Second-Line Tuberculosis Treatment 
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allowing better entry of other drugs to rapidly growing tubercule bacilli producing better 
killing by those agents.  Ethambutol resistance involves a gene over expression and 
mutations of arabinosyl transferase which is controlled by the embB gene.122, 123 
 
Streptomycin 
  
 Streptomycin belongs to the aminoglycoside family of antibiotics.  It was the first 
aminoglycoside to enter the market in 1944.1  It is a bacteriostatic agent used in the 
treatment of drug resistant TB.107  Streptomycin stops bacterial growth by inhibiting 
protein synthesis.  Streptomycin is the only first-line agent that is given intramuscularly, 
which is associated with significant pain and is therefore not favored by patients.107 
 
 
Need for New Therapeutic Agents 
 
In the last 35 years there have been no new drugs to replace the current first-line 
agents.  Even though these chemotherapeutic agents are effective, there are still problems 
in treating tuberculosis including poor patient compliance and multiple-drug resistance.107  
As mentioned previously, the current treatment regimen usually lasts 6-9 months due to 
the time it takes to kill the latent and slow-growing bacteria.  A daily regiment of 4 drugs 
over this time period can lead to patience non compliance which in turn can lead to the 
development of resistance against the first-line agents.  Drug-resistant TB is a public 
health issue in many developing countries, as treatment is longer and requires more 
expensive drugs.111  The emergence of multi-drug resistant TB (MDR-TB) occurs when 
drug-susceptible tuberculosis is improperly or incompletely treated.  According to WHO, 
MDR-TB is defined as resistance to the two most effective first line TB drugs: rifampin 
and isoniazid.111  When a person is resistant to any fluoroquinolone, and at least one of 
three second-line drugs (capreomycin, kanamycin, and amikacin), in addition to MDR-
TB they are said to have extensively drug-resistant TB (XDR-TB).111  A person is usually 
infected with drug-resistant TB by:  (1) acquiring resistance by not taking the prescribed 
regimen appropriately or (2) being infected by an individual who is infected with a 
resistant strain of TB.109  Due to the problems with resistance and prolonged therapy, 
there is an urgent need to develop new, potent, fast acting anti-tuberculosis drugs with 
low toxicity. 
 
 
Targeting the Mycobacterium Cell Wall 
 
 
Introduction 
 
 One validated target for anti-mycobacterial agents is the cell wall, as many of the 
current drugs used to treat TB target the cell wall.124, 125  All mycobacteria share a 
characteristic cell wall, thicker than in many other bacteria, which is hydrophobic, waxy, 
and rich in mycolic acids.42  The mycolic acids are important constituents of the 
mycobacterial cell wall in that they provide a permeability barrier at the cell’s surface.  
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The mycolic acids are fastened to the arabinogalactan layer which is subsequently 
tethered to the peptidoglycan layer (Figure 2.3).42  This complex cell wall structure of M. 
tuberculosis is believed to be associated with virulence, innate drug resistance, and 
persistence.126  The mycobacterial cell wall is unique to mycobacteria in that neither the 
cell wall nor the enzymes and chemical intermediates in its formation have analogues in 
humans making it an ideal target for drug development.127    
 
 
Rhamnose Biosynthesis 
 
 In mycobacteria, L-rhamnose is essential to the structural integrity of the cell wall 
since it connects the peptidoglycan to the arabinogalactan layer.128, 129  To date, neither 
rhamnose nor the genes responsible for its synthesis have been identified in humans 
making its biosynthesis a great target for drug design.128  L- rhamnose is incorporated in 
the bacterial polysaccharides from a common precursor, deoxythymidine diphosphate-L-
rhamnose (dTDP-L-rhamnose). This precursor is synthesized from glucose-1-phosphate 
and deoxythymidine triphosphate (dTTP) via a pathway (Figure 2.5) that consists of four 
distinct enzymes:  (1) Glucose-1-phosphate thymidyltransferase (RmlA), which couples 
the glucose-1-phosphate moiety to deoxythymidine triphosphate;  (2) dTDP-D-glucose 
4,6-dehydratase (RmlB), which oxidizes the 4’ hydroxyl and dehydrates the 6’ hydroxyl; 
(3) dTDP-6-deoxy-D-xylo-4-hexulose 3,5-epimerase (RmlC), which inverts the 3’ and 5’ 
hydroxyls; and (4) dTDP-6-deoxy-L-xylo-4-hexulose reductase (RmlD), which reduces 
the 4’ ketone.128  Because it is structurally unique, highly substrate-specific, and does not 
require a cofactor, RmlC is considered to be the most promising drug target in the 
pathway.128, 130, 131  We chose RmlC as our target for drug design. 
 
 
Discovery of IC4760 
 
Several hit molecules were discovered by one of our collaborators, Dr. Michael 
McNeil at Colorado State University via high throughput screening of 35,000 compounds 
(Nanosyn, Tucson, AZ) for inhibitors of RmlB, RmlC, and RmlD simultaneously.127  
Active compounds were ordered and re-assayed individually against the three enzymes.  
Many of the active compounds were grouped into three chemical motifs:  rhodanines, 
pyrazolones, and quinoline carboxylics.  Two of the most potent inhibitors from the assay 
contained the pyrazolone scaffold.  Using one of the active pyrazolone compounds 
(Figure 2.5), a 2D similarity search was performed on the NCI depository to build a 
structre-activity relationship around this scaffold.  In this screen IC4760 (Figure 2.6) was 
discovered as an inhibitor of RmlC (40% @ 10 µg/mL, MIC > 50 µg/mL).  This 
compound was less active than the first inhibitor, but had higher solubility and therefore 
was a better candidate for co-crystallograpy or crystal soaking experiments.  Our other 
collaborator, Dr. James Naismith at the University of St. Andrew’s, was able to obtain a 
co-crystal structure of IC4760 with RmlC giving very important structural insight 
allowing us to perform rounds of structure-based drug design.   
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Figure 2.3:  Mycobacterial Cell Wall  
 
 
 
 
Figure 2.4:  Rhamnose Biosynthetic Pathway 
 
Permission to modify from:  Giraud M.F. and Naismith J.H., The rhamnose pathway.  
Curr Opin Struc Biol 2000, 10, 687-96.128 
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Figure 2.5:  Original Pyrazalone Inhibitor 9861 from Screen 
 
 
 
 
 
Figure 2.6:  RmlC Inhibitor IC4760 
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Generating a Pharmacophore Model 
 
 Two key co-crystal structures of enzyme-substrate and enzyme-IC4760 
complexes were used to gain knowledge of the binding into the active site of the RmlC 
enzyme.  The first co-crystal structure was of the product analog of RmlC, dTDP-
rhamnose, bound to the enzyme’s active site (Figure 2.7).132  This structure provided 
insight to the positions of the sugar and nucleotide binding pockets. The thymidine ring 
was held in place between two aromatic side chains (Tyr and Phe) by π-stacking 
interactions.  There was also a hydrogen bond interaction between one of the carbonyl 
oxygens of the thymine and the amino group of an asparagine residue.  The rhamnose 
ring was bound deep in the pocket interacting with histidine and lysine residues that are 
thought to be important for the enzyme’s function.130  The third important interaction 
involved the charge-charge interaction between the di-phosphate of dTDP-rhamnose and 
two arginine residues in the RmlC active site.  The second co-crystal structure was of the 
inhibitor IC4760 bound to the enzyme’s active site (Figure 2.8).132 This structure only 
included about two thirds of the molecule as the other parts could not be visualized 
within the electron density map.  This structure confirmed that the inhibitor binds to the 
active site with the pyrazolone ring occupying the thymidine binding site and the 
sulfonate group interacting with the region that normally interacts with the phosphate 
group.  These structures were very important in the development of the pharmacophore 
model.  Figure 2.9132 shows the overlay of the two crystal structures:  dTDP-rhamnose in 
green and inhibitor IC4760 in color.  Three key structural features were important to the 
design of potential inhibitors:  (1) an aromatic ring to bind to the nucleoside binding site; 
(2) a polar functional group that binds to the charged region made up of arginine 
residues; and (3) a cyclic or acyclic functional group that makes important amino 
interactions as seen with the rhamnose ring of the substrate.  The use of these key 
structural features led us to the design, synthesis, and evaluation of bi-aryl sulfonamide 
libraries as potential inhibitors of Mycobacterium tuberculosis cell wall biosynthesis.         
 
 
Virtual Screening Techniques in the Discovery of Novel RmlC Inhibitors 
 
 Previous work performed in our group involved the discovery of thiazolidinones 
as inhibitors of dTDP-rhamnose synthesis using a virtual screening approach.  Kerim 
Babaoglu et al., described the synthesis of 4-thiazolidinones, a bioisosteric replacement 
for the diphosphate, as inhibitors of RmlC.133  These compounds were discovered by first 
generating a virtual library of compounds based on commercially available starting 
materials, then filtering them in silico by docking experiments to provide a more 
prioritized list of compounds for synthesis.  From this study, several inhibitors of RmlC 
were discovered having < 50% inhibition @ 20µM (Figure 2.10).  None of the inhibitors 
showed significant whole cell antimicrobial activity (MIC ≥ 25 µg/mL), however the 
study provided insight into the successful use of structure-guided library design as a tool 
for drug discovery.       
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Figure 2.7:  Crystal Structure of dTDP-Rhamnose in RmlC Active Site 
 
Permission to modify from:  Babaoglu, K., Use of modern structure-based drug design 
techniques in the discovery and development of novel antimicrobial candidates, Ph.D. 
dissertation, University of Tennessee Health Science Center, 2004.132  
 
 
 
 
 
Figure 2.8:  Crystal Structure of Inhibitor IC4760 in RmlC Active Site 
 
Permission to modify from:  Babaoglu, K., Use of modern structure-based drug design 
techniques in the discovery and development of novel antimicrobial candidates, Ph.D. 
dissertation, University of Tennessee Health Science Center, 2004.132
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Figure 2.9:  Pharmacophore Model 
 
Permission to reprint from:  Babaoglu, K., Use of modern structure-based drug design 
techniques in the discovery and development of novel antimicrobial candidates, Ph.D. 
dissertation, University of Tennessee Health Science Center, 2004.132 
 
 
 
 
Figure 2.10:  Thiazolidinone Scaffold for Inhibitors of RmlC 
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First Generation Sulfonamide Libraries  
 
 Similar techniques were used in the discovery of potential sulfonamide inhibitors 
of RmlC as anti-tuberculosis agents.  Based on the given pharmacophore model, bi-aryl 
sulfonamide libraries were designed (Figure 2.11).  This library would include a 
heterocyclic ring mimicking the thymine ring, a sulfonamide moiety mimicking the 
phosphate group, and an amino side chain mimicking the rhamose sugar.  A virtual 
library of 1274 sulfonamides was created in silico using Combilibmaker134, a module of  
the Tripos software package.  One hundred and eighty two primary amines135 and 7 bi-
aryl sulfonylchlorides136from commercial vendors were visually inspected for the best 
pharmacophore match. These compounds were then docked into the RmlC active site 
using FlexX.137, 138  Next, the compounds were ranked by consensus scoring 
(CSCORE)134, and the top scoring compounds were visually examined to assure the 
pharmacophore pattern matched.  Nineteen of top scoring compounds were selected for 
synthesis.  Twelve of them were successfully synthesized and assayed.  
 
 
Synthesis 
 
Bi-aryl sulfonamides 2.3a-l were synthesized in parallel on a Radley’s Carousel 
Synthesizer.  Various bi-aryl sulfonyl chlorides 2.1 were reacted with corresponding 
primary amines 2.2 in DCM with catalytic amounts of polymer-supported dimethylamino 
pyridine (PS-DMAP) to afford the desired sulfonamides in low to moderate yields 
(Scheme 2.1).     
 
 
Results and Discussion 
 
The synthesized bi-aryl sulfonamides were tested for inhibition of the 
Mycobacterium tuberculosis RmlC (Table 2.1).  Only two of the compounds tested 
showed inhibitory activity: 2.3c (25% @ 100 µM) and 2.3g (45% @ 100 µM).  Both 
compounds had an aromatic ring that could make π-stacking interactions with the known 
pharmacophoric residues of the nucleoside binding pocket.  The rings also contained 
hydrogen bond acceptor groups similar to that seen with the thymidine ring of dTDP-
rhamnose.  The sulfonamide group is a bioisostere for the phosphate moiety that could 
make charge-charge interactions with active site arginine residues.  Both compounds also 
contained a carboxylic acid moiety that could form hydrogen bond interactions with the 
lysine and histidine residues in the sugar pocket.  The compounds were also tested for 
their antimicrobial activity against M. tuberculosis.  Activity was generally weak with no 
compound having an MIC < 50 µg/mL.  The lack of anti-tuberuculosis activity is not 
suprising given the relative weak enzyme inhibition and potential poor penetration in the 
M. tuberculosis cell wall.  In conclusion, inhibitors of M. tuberculosis RmlC were 
discovered.  However, on the analysis of the starting materials, we believe there was a 
lack of suitable structural diversity of the commercially available bi-aryl sulfonyl 
chorides that match the pharmacophore thymidine moiety.  With that, we moved to 
develop more complex bi-aryl sulfonamides to explore the nucleoside binding pocket. 
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Figure 2.11:  Target Sulfonamide Libarary 
 
 
 
Scheme 2.1:  First Generation Sulfonamide Library 
 
 
 
Reagents and Conditions:  (a) PS-DMAP, DCM, rt, 16h. 
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Table 2.1:  Activity of First Generation Sulfonamide Library 
 
 
 
a %Inhibition of M. tuberculosis RmlC @ 100µM inhibitor.  b Whole-cell Minimum 
Inhibitory Concentration of M. tuberculosis. c na = no activity.  d nt = not tested. 
Compound % Inhibitiona MIC (µg/mL)b 
2.3a 
 
nac 200 
2.3b 
 
na 100 
2.3c 
 
25 >200 
2.3d 
 
ntd 200 
2.3e  nt 200 
2.3f  na 50 
2.3g 
 
45 100 
2.3h 
 
na 50 
2.3i 
 
na >200 
2.3j 
 
na 200 
2.3k 
 
na 100 
2.3l 
 
na 100 
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Second Generation Bi-Aryl Sulfonamide Library   
 
In an attempt to address the low commercial availability of bi-aryl 
sulfonylchlorides as thymidine mimics, as well as further explore the rhamnose sugar 
pocket, we synthesized a series of new bi-aryl sulfonamides using different chemistries.  
Using a retrosynthetic analysis approach (Figure 2.12), we decided to use palladium-
mediated Suzuki cross-coupling to group various aryl halides with heterocyclic boronic 
acids that were similar to the thymine moiety, to introduce more diversity.  We also chose 
more primary amines that we considered would favor interactions seen with the rhamnose 
sugar moiety.  The second generation bi-aryl sulfonamides were synthesized using high 
throughput synthesis.   
 
 
Palladium-Mediated Suzuki Cross Coupling 
 
Palladium-mediated Suzuki cross-coupling of aryl halides and aryl boronic acids 
is an extremely important method for the synthesis of biaryls.139-141  Many reagents are 
required for cross-coupling:  palladium source, ligand, aryl/alkyl halide, boronic acid, 
base, and heat.  Boronic acids are generally non-toxic and thermally, air, and moisture 
stable which gives it the advantage over other cross-coupling processes.140  There are 
many protocols for Suzuki cross-coupling in the literature of which the choice depends 
on the structure of the reactants.  As previously mentioned, polymer-supported reagents 
for solution phase synthesis has become an increasingly utilized tool for the preparation 
of molecules.139, 142  The number one reason for their use is the ease of purification by 
filtration.  These reagents are attractive since excess amounts can be used to enhance 
chemoselectivity and drive reactions to completion.143  Polymer-supported palladium 
catalysts have been introduced as opposed to using a soluble catalyst because they offer 
significant benefits:  (1) they can be easily removed at the end of the reaction by 
filtration; (2) the products obtained typically contain much lower levels of residual 
phosphine oxide and palladium which can be extremely toxic as opposed to the soluble 
catalysts; and (3) they are air-stable and can be handled under ambient conditions.139,142, 
143  
 
 
Microwave Assisted Organic Synthesis 
 
Microwave chemistry has been around since mid-1980’s, in which domestic 
microwaves were used, which has been proven to be unsafe.144  However, development 
of efficient new technology has allowed microwave chemistry to gain more acceptance 
and popularity.  The use of microwaves for carrying out reactions in the laboratory 
provides advantages for synthesis: (1) reduces reaction times; (2) gives cleaner reaction 
due to fewer side reactions; and (3) requires only minimal quantities of solvent.145, 146  
Virtually all thermally driven reactions can be accelerated by microwave heating.144  
Microwaves increase reaction rates by providing the momentum to overcome the 
transition state barrier and complete the reaction more quickly than conventional 
heating.144  Unlike conventional heating, microwave heating is uniform.  Suzuki coupling 
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Figure 2.12:  Retrosynthetic Analysis for Second Generation Sulfonamide Library 
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using conventional heating methods is often sluggish and, in some cases, can take a 
number of days to go to completion.  This limitation can be overcome using microwave 
heating, enabling reaction times to be reduced to just a few minutes.139, 147   
 
 
Method Development 
 
Four methods were evaluated to prepare for the parallel synthesis of the target bi-
aryl sulfonamide library (Table 2.2).  The four methods evaluated the use of a polymer- 
supported catalyst versus its soluble counterpart, as well as, the use of microwave 
technology versus convential heating methods.   
 
Synthesis 
 
Three bi-aryl sulfonamides 2.8aa,ab,ba were synthesized for chemistry 
optimization.  The starting materials were chosen to cover the diversity of compounds 
that would be used for library synthesis.  The bromoaryl sulfonamide intermediates 
2.6a,b were synthesized by reacting 4-bromobenzene sulfonylchloride 2.5 with primary 
amines 2.4a,b in DCM and diisopropylethylamine (DIPEA) for 16h (Scheme 2.2).  After 
purification, the sulfonamide intermediates 2.6a,b were coupled with aryl boronic acids 
2.7a,b using four methods as outlined in Table 2.2.  After the reaction was complete, the 
mixtures were filtered and concentrated.  The crude mixtures were then tested for purity 
via RP-HPLC (Table 2.3). 
 
Results and Discussion  
     
 From the four methods used, all compounds showed purity >73% with most being 
above 90%.  Based on the purity results, there wasn’t much difference in the use of the 
soluble catalyst versus the polymer-supported catalyst.  However, the polymer-supported 
catalyst had advantages in that (1) it was easier to weigh out; (2) the nature of the catalyst 
allowed it to be handled in an air atmosphere; and (3) the work-up of the reaction is 
easier by just filtration of the polymer support.  In the use of microwave technology over 
conventional heating methods, generally the microwave produced compounds with 
higher purity ranges (mostly >90% verus 83-92% with conventional methods).  The 
microwave had significant advantages over conventional heating methods in that:  (1) 
reaction times were decreased from 16h to 10 min; (2) less space for the heating 
apparatuses were used; and (3) temperatures could be exceeded far beyond that of the oil 
bath for sluggish reactions.  In conclusion, four methods were performed to synthesize 
more complex bi-aryl sulfonamides which produced compounds with purity ranging from 
73-96%.  Method III, using soluble Pd(PPh3)4 in the microwave,  proved to be the best 
method for synthesizing  our complex bi-aryl sulfonamides with purity ranging from 90-
96%.  Though Method III produced the best results, Method IV was easier and quicker 
providing a more efficient method that required less post synthesis purification for 
parallel synthesis.  Therefore, Method IV, using PS-Pd(PPh3)4 and microwave 
technology, was the chosen method for synthesis of the target bi-aryl sulfonamide library. 
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Table 2.2:  Reaction Conditions for Chemistry Optimization 
 
Method Catalyst Reaction Conditions 
I Pd(PPh3)4 
Oil bath, 80ºC, 
16h 
II PS-Pd(PPh3)4 
Oil bath, 80ºC, 
16h 
III Pd(PPh3)4 
Microwave, 
160ºC, 10 min 
IV PS-Pd(PPh3)4 
Microwave, 
160ºC, 10 min 
 
 
 
Scheme 2.2:  Compounds for Chemistry Optimization 
 
 
 
Reagents and Conditions:  (a) DIPEA, DCM, rt, 16h; (b) Na2CO3, DME:EtOH: H2O, 
Methods I-IV (Table 2.2).  
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Table 2.3:  % Purity of Compounds for Method Development 
 
Compound Method I Method II Method III Method IV 
2.8aa  88 83 94 94 
2.8ab  93 89 90 73 
2.8ba 
 
83 92 96 95 
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Synthesis  
 
Bromoaryl sulfonamide intermediates 2.6a-k were synthesized in parallel on a 
Radley’s Carousel Synthesizer.  4-bromobenzene sulfonylchloride 2.5 was reacted with 
respective primary amines 2.4a-k in DCM and diisopropylethylamine (DIPEA) for 16h to 
afford the desired sulfonamide intermediates in good yields (Scheme 2.3).  After 
purification, the sulfonamide intermediates 2.6a-k were reacted with various aryl boronic 
acids 2.7a-i  in the presence of sodium carbonate, polymer-supported tetrakis 
triphenylphosphine palladium (PS- Pd(Ph3)4) and a mixture of dimethoxyethane, ethanol, 
and water (DME:EtOH:H2O) (Scheme 2.4).139, 142  The reaction was performed under 
argon and allowed to react under the following microwave conditions:  100W, 150°C, 
100psi, 10 min.  The mixtures were filtered and purified via RP-HPLC to afford the 
desired bi-aryl sulfonamides 2.8 in moderate yields.  
 
 
Results and Discussion    
 
 The synthesized second generation bi-aryl sulfonamides were tested for inhibition 
of the M. tuberculosis RmlC (Table 2.4).  Compounds 2.8fe (23% @ 50µM), 2.8gb (27% 
@ 50µM) and 2.8jg (28% @ 50µM) proved to be the most active in the library.  To gain 
information on the binding mode of these inhibitors, docking experiments were 
performed.  Using 2.8jg as a representative, the inhibitor 2.8jg binds similar to the 
substrate analog dTDP-rhamnose. A view of the best docking solution for inhibitor 2.8jg 
is superimposed on dTDP-rhamnose (green) in the active site of RmlC (Figure 2.13). In 
the nucleoside binding pocket, the aromatic ring of the inhibitor does not align for π-
stacking as seen with the inhibitor 4760, however, it does undergo hydrogen bonding 
with the asparagine residue.  The sulfonamide portion of the inhibitor binds to the 
charged pocket as seen with the di-phosphate moiety of dTDP-rhamnose and the 
sulfonate group of the inhibitor 4760.  Also, the amino group resides in the sugar binding 
pocket to undergo hydrogen bonding with the His residues.  In conclusion, a new bi-aryl 
sulfonamide inhibitor of RmlC with weak whole-cell activity was discovered.   We 
sought to explore more diversity of the nucleoside and sugar pockets in which we were 
successful.  However, we did not fully explore the diversity as selection of the starting 
materials was limited.  At the time during library development, the amines chosen were 
based on those that were available in the laboratory; the boronic acids chosen were based 
on visual inspection of a pharmacophoric match; and based on the ease of synthesis, only 
one sulfonyl chloride was chosen, which was based on the IC4760 scaffold for which our 
libraries were shaped.  We further planned to expand diversity in the thymidine binding 
pocket and the sugar pocket using a structure guided library approach to maximize 
interactions in the active site and potentially yield more desirable leads. 
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Scheme 2.3:  Synthesis of Sulfonamide Intermediates 
 
 
 
Reagents and Conditions:  (a) DIPEA, DCM, rt, 16h. 
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Scheme 2.4:  Synthesis of Bi-Aryl Sulfonamides via Suzuki Coupling 
 
 
 
Reagents and Conditions:  (a) PS-Pd(PPh3)4, Na2CO3, DME/H2O/EtOH, MW, 160°C, 10 
min, 100 psi. 
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Table 2.4:  Activity of Second Generation Bi-Aryl Sulfonamide Library 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound % Inhibitiona MIC (µg/mL)b 
2.8ab 
 
7 100 
2.8ac 
 
8 100 
2.8ae 
 
4 100 
2.8ag 
 
14 50 
2.8ai 
 
16 50 
2.8bb 
 
14 25c 
2.8cb 
 
4 25c 
2.8eg 
 
18 100 
2.8fe 
 
23 100 
2.8gb  27 25
c 
2.8ge  19 25
c 
2.8gi 
 
0 50c 
2.8hb 
 
0 200c 
2.8he  13 100
c 
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Table 2.4:  Continued 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a %Inhibition of M. tuberculosis RmlC @ 50 µM inhibitor.  b Whole-cell Minimum 
Inhibitory Concentration of M. tuberculosis c Showed obscure growth to bacteria. 
Compound % Inhibitiona MIC (µg/mL)b 
2.8ib 
 
0 100c 
2.8ie 
 
3 100c 
2.8ii 
 
0 100c 
2.8jf 
 
18 100 
2.8jg 
 
29 50 
2.8ji 
 
9 100 
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Figure 2.13:  Docking Solution of 2.8jg 
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Overall Conclusions 
 
 In the development of anti-tuberculosis drugs, bi-aryl sulfonamides have been 
successfully synthesized as potential inhibitors of rhamnose biosynthesis using a structure 
guided library approach.  From this study, several inhibitors of Mycobacterium 
tuberculosis RmlC were discovered with compounds 2.3c, 2.3g, and 2.8jg showing 
promise as leads for future library development.  These compounds showed favorable 
interactions as seen by our hit compound for which our libraries have been designed.  
Future work involves obtaining co-crystal structures of these compounds with RmlC 
which will help shape the design and synthesis of future libraries.  
 
 
Experimental Section 
 
 
Chemistry 
 
All reagents and anhydrous solvents were purchased from Sigma-Aldrich. All the 
reagent-grade solvents used for chromatography were purchased from Fisher Scientific 
 (Suwanee, GA) and flash column chromatography silica cartridges were obtained from 
Biotage Inc. (Lake Forest, VA).  A Biotage FLASH column chromatography system was 
used to purify some of the reaction mixtures.  Other compounds were purified via 
preparative RP-HPLC on a Gibson HPLC system.  RP-HPLC 1 methods were conducted 
using a Phenomenex Luna 5µ C-18 column (150 x 21.2 mm) at ambient temperature, and 
a flow rate of 4.0 mL/min.  HPLC1: Gradient: solvent A (0.1% TFA in water) and 
solvent B (acetonitrile): 0-2.00 min 20% B, 2.00-17.00 min 20-100% B (linear gradient), 
17.00-19.00 min 100% B, UV detection at 254 nm.  All 1H spectra were recorded on a 
Varian INOVA-500 spectrometer.  Chemical shifts (δ) are reported in ppm relative to the 
residual solvent peak or internal standard (tetramethylsilane), and coupling constants (J) 
are reported in hertz (Hz).  Mass spectra were recorded on a Bruker Esquire LCMS using 
ESI. The yields quoted are unoptimized.  The purity of the final compounds was tested 
via preparative RP-HPLC on a Hewlet Packet (HP1100series) HPLC system.  RP-HPLC 
2 methods were conducted using an Alltech Platinum EPS 5µ C-18 column (150 x 4.6 
mm) at ambient temperature, and a flow rate of 1.0 mL/min.  HPLC2:  Gradient:  solvent 
A (0.1% TFA in water) and solvent B (acetonitrile):  0-2.00 min 0%B, 2.00-17.00 min 0-
100%B (linear gradient), 17.00-19.00 100%B, UV detection at 254nm.     
 
General procedure for the synthesis of first generation biaryl sulfonamides (2.3a-l).  
To a carousel tube, 3ml of pyridine was added.  Next, PS-DMAP (1.4 eq, 0.7 mmol) was 
added to each tube.  Various sulfonylchlorides (1.0 eq, 0.5 mmol) were added followed 
by respective amines (1.0 eq, 0.5 mmol) to the tube.  The mixture was allowed to stir at 
room temperature overnight.  The mixture was filtered and washed with chloroform.  The 
filtrate and washings were combined and concentrated in vacuo.  Flash column 
purification (0-100%) Petroleum Ether/Ethyl Acetate) yielded the corresponding 
sulfonamides.   
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N-(2,5-dimethoxy-benzyl)-3-(2-methyl-pyrimidin-4-yl)-benzenesulfonamide (2.3a).  
Using the above procedure, 3-(2-methyl-pyrimidin-4-yl)-benzenesulfonyl chloride (0.5 
mmol), 2,5-dimethoxy-benzylamine (0.5 mmol), PS-DMAP (0.7 mmol), and pyridine (3 
mL) were used to synthesize 2.3a as a light yellow solid (21%).  1HNMR (500MHz, 
CDCl3):  δ 2.89 (s, 3H), 3.64 (s, 3H), 3.69 (s, 3H), 4.24 (d, 2H, J = 6.5 Hz), 5.58 (t, 1H, J 
= 6.0 Hz), 6.57 (m, 2H), 6.65 (s, 1H), 7.51 (d, 1H, J = 5.5 Hz), 7.56 (t, 1H, J = 8.0 Hz), 
7.92 (d, 1H, J = 8.0 Hz), 8.45 (s, 1H), 8.75 (d, 1H, J = 5.0 Hz).  MS(ESI):  m/z = 422.3 
(M+Na)+ .  HPLC2: tR 3.0 min, Purity 90%.  
 
N-(2-fluoro-3-trifluoromethyl-benzyl)-3-(2-methyl-pyrimidin-4-yl)-
benzenesulfonamide (2.3b).  Using the above procedure, 3-(2-methyl-pyrimidin-4-yl)-
benzenesulfonyl chloride (0.5 mmol), 2-fluoro-3-trifluoromethyl-benzylamine (0.5 
mmol), PS-DMAP (0.7 mmol), and pyridine (3 mL) were used to synthesize 2.3b as a 
light yellow solid (3%).  1HNMR (500MHz, CDCl3):  δ 2.74 (s, 3H), 4.27 (d, 2H, J = 5.5 
Hz), 5.07 (t, 1H, J = 6.0 Hz), 7.05 (t, 1H, J = 8.0 Hz), 7.36 (t, 1 H, J = 7.0 Hz),  7.43 (d, 
1H, J = 5.5 Hz), 7.47 (t, 1H, J = 7.5 Hz) 7.53 (t, 1H, J = 8.0 Hz), 7.85 (d, 1H, J = 8.0 Hz) 
8.18 (d, 1H, J = 7.5 Hz), 8.43 (s, 1H), 8.66 (d, 1H, J = 5.5 Hz).  MS(ESI):  m/z = 448.3 
(M+Na)+ .  HPLC2: tR 5.1 min, Purity > 99%.   
 
2-[3-(2-methyl-pyrimidin-4-yl)-benzenesulfonylamino]-3-phenyl-propionic acid 
methyl ester (2.3c).  Using the above procedure, 3-(2-methyl-pyrimidin-4-yl)-
benzenesulfonyl chloride (0.5 mmol), 2-amino-3-phenyl-propionic acid methyl ester (0.5 
mmol), PS-DMAP (0.7 mmol), and pyridine (3 mL) were used to synthesize 2.3c as a 
light yellow solid (33%).  1HNMR (500MHz, CDCl3):  δ 2.82 (s, 3H), 3.06 (dd, 2H, J = 
6.0, 6.5 Hz), 3.50 (s, 3H), 4.30 (m, 1H), 4.43 (t, 1H, J = 6.0 Hz), 7.08 (d, 2H, J = 7.0 Hz), 
7.20 (m, 3H), 7.53 (d, 1H, J = 5.5 Hz) 7.59 (t, 1H, J = 8.0 Hz), 7.86 (d, 1H, J = 8.0 Hz), 
8.31 (d, 1H, J = 7.5 Hz), 8.46 (s, 1H), 8.73 (d, 1H, J = 5.0 Hz).  MS(ESI):  m/z = 434.2 
(M+Na)+ .  HPLC2: tR 3.3 min, Purity 88%.   
 
4-{[3-(2-methyl-pyrimidin-4-yl)-benzenesulfonylamino]-methyl}-benzoic acid 
methyl ester (2.3d).  Using the above procedure, 3-(2-methyl-pyrimidin-4-yl)-
benzenesulfonyl chloride (0.5 mmol), 4-aminomethyl-benzoic acid methyl ester (0.5 
mmol), PS-DMAP (0.7 mmol), and pyridine (3 mL) were used to synthesize 2.3d as a 
light yellow solid (3%).  1HNMR (500MHz, CDCl3):  δ 2.94 (s, 3H), 3.94 (s, 3H), 4.34 
(d, 2H, J = 5.5 Hz), 5.11 (t, 1H, J = 6.0 Hz), 7.33 (d, 2H, J = 8.5 Hz), 7.70 (d, 2H, J = 8.0 
Hz) 7.92 (d, 2H, J = 8.0 Hz), 8.04 (d, 1H, J = 7.5 Hz) 8.35 (d, 1H, J = 7.5 Hz), 8.57 (s, 
1H), 8.87 (bs, 1H).  MS(ESI):  m/z = 398.3 (M+H)+ .  HPLC2: tR 3.2 min, Purity > 99%.   
 
N-(5-tert-Butyl-[1,3,4]thiadiazol-2-yl)-3-(2-methyl-pyrimidin-4-yl)-
benzenesulfonamide (2.3e).  Using the above procedure, 3-(2-methyl-pyrimidin-4-yl)-
benzenesulfonyl chloride (0.5 mmol), 5-tert-butyl-[1,3,4]thiadiazol-2-ylamine (0.5 
mmol), PS-DMAP (0.7 mmol), and pyridine (3 mL) were used to synthesize 2.3e as a 
light yellow solid (26%).  1HNMR (500MHz, CDCl3):  δ 1.16 (s, 9H), 2.83 (s, 3H), 7.59 
(d, 1H, J = 5.5 Hz), 7.74 (t, 1H, J = 7.5 Hz), 8.17 (d, 1H, J = 8.0 Hz) 8.48 (d, 1H, J = 8.0 
Hz), 8.72 (s, 1H), 8.77 (d, 1H, J = 5.5 Hz).  MS(ESI):  m/z = 390.2 (M+H)+.   
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3-(2-methyl-pyrimidin-4-yl)-N-(3-trifluoromethylsulfanyl-phenyl)-
benzenesulfonamide (2.3f).  Using the above procedure, 3-(2-methyl-pyrimidin-4-yl)-
benzenesulfonyl chloride (0.5 mmol), 3-trifluoromethylsulfanyl-phenylamine (0.5 mmol), 
PS-DMAP (0.7 mmol), and pyridine (3 mL) were used to synthesize 2.3f as a light 
yellow solid (11%).  1HNMR (500MHz, CDCl3):  δ 2.10 (s, 3H), 7.33 (s, 1H), 7.38 (m, 
3H)  7.64 (t, 1H, J = 8.0 Hz), 7.91 (d, 1H, J = 7.5 Hz) 8.34 (d, 1H, J = 8.0 Hz), 8.56 (s, 
1H), 8.76 (d, 1H, J = 5.5 Hz).  MS(ESI):  m/z = 448.8 (M+Na)+.  HPLC2: tR 3.0 min, 
Purity 95%.   
 
3-[4-(3-chloro-2-cyano-phenoxy)-benzenesulfonylamino]-2-methyl-benzoic acid 
methyl ester (2.3g).  Using the above procedure, 4-(3-chloro-2-cyano-phenoxy)-
benzenesulfonyl chloride (0.5 mmol), 3-amino-2-methyl-benzoic acid methyl ester (0.5 
mmol), PS-DMAP (0.7 mmol), and pyridine (3 mL) were used to synthesize 2.3g as a 
light yellow solid (43%).  1HNMR (500MHz, CDCl3):  δ 2.23 (s, 3H), 3.86 (s, 3H), 6.86 
(d, 1H, J = 7.0 Hz), 7.09 (d, 2H, J = 9.0 Hz), 7.20 (t, 1H, J = 8.5 Hz), 7.31 (d, 1H, J = 8.0 
Hz), 7.43 (d, 1H, J = 8.0 Hz), 7.50 (t, 1H, J = 8.0 Hz), 7.68 (d, 1H, J = 8.0 Hz), 7.74 (d, 
2H, J = 9.0 Hz).   MS(ESI):  m/z = 479.3 (M+Na)+.  HPLC2: tR 3.1 min, Purity 93%.  
 
N-[2-(4-ethyl-phenyl)-ethyl]-3-(2-methyl-pyrimidin-4-yl)-benzenesulfonamide (2.3h).  
Using the above procedure, 3-(2-methyl-pyrimidin-4-yl)-benzenesulfonyl chloride (0.5 
mmol), 2-(4-ethyl-phenyl)-ethylamine (0.5 mmol), PS-DMAP (0.7 mmol), and pyridine 
(3 mL) were used to synthesize 2.3h as a light yellow solid (14%).  1HNMR (500MHz, 
CDCl3):  δ 1.24 (t, 3H, J = 7.5 Hz), 2.63 (q, 2H, J = 7.5 Hz), 2.80 (t, 2H, J = 7.0 Hz), 2.86 
(s, 3H), 3.32 (q, 2H, J = 6.5 Hz), 4.74 (t, 1H, J = 6.0 Hz), 7.04 (d, 2H, J = 8.0 Hz), 7.12 
(d, 2H, J = 8.0 Hz), 7.59 (d, 1H, J = 5.0 Hz), 7.69 (t, 1H, J = 7.5 Hz), 7.98 (d, 1H, J = 8.0 
Hz) 8.36 (d, 1H, J = 8.0 Hz), 8.58 (s, 1H), 8.77 (d, 1H, J = 5.5 Hz).  MS(ESI):  m/z = 
404.4 (M+Na)+.  HPLC2: tR 3.4 min, Purity 95%. 
 
4-{2-[3-(2-methyl-pyrimidin-4-yl)-benzenesulfonylamino]-ethyl}-benzoic acid (2.3i).  
Using the above procedure, 3-(2-methyl-pyrimidin-4-yl)-benzenesulfonyl chloride (0.5 
mmol), 4-(2-amino-ethyl)-benzoic acid (0.5 mmol), PS-DMAP (0.7 mmol), and pyridine 
(3 mL) were used to synthesize 2.3i as a light yellow solid (22%).  1HNMR (500MHz, 
CDCl3):  δ 2.78 (s, 3H), 2.82 (t, 2H, J = 7.0 Hz), 3.25 (d, 2H, J = 7.5 Hz), 7.20 (d, 2H, J = 
8.0 Hz), 7.69 (t, 1H, J = 8.0 Hz), 7.81 (t, 3H, J = 8.0 Hz), 7.96 (d, 1H, J = 8.0 Hz) 8.36 
(d, 1H, J = 8.0 Hz), 8.55 (s, 1H), 8.75 (d, 1H, J = 5.5 Hz).  MS(ESI):  m/z = 398.3 
(M+H)+. 
 
N-(2-hydroxy-1-methyl-2,2-diphenyl-ethyl)-3-(5-methyl-[1,3,4]oxadiazol-2-yl)-
benzenesulfonamide (2.3j).  Using the above procedure, 3-(5-methyl-[1,3,4]oxadiazol-2-
yl)-benzenesulfonyl chloride (0.5 mmol), 2-amino-1,1-diphenyl-propan-1-ol (0.5 mmol), 
PS-DMAP (0.7 mmol), and pyridine (3 mL) were used to synthesize 2.3j as a light 
yellow solid (17%).  1HNMR (500MHz, CDCl3):  δ 1.14 (d, 3H, J = 6.5 Hz), 2.63 (s, 3H), 
4.48 (m, 1H), 6.91 (t, 1H, J = 7.5 Hz), 7.00 (t, 2H, J = 8.0 Hz), 7.17 (t, 1H, J = 7.5 Hz), 
7.27 ( t, 2H, J = 8.0 Hz), 7.34 (d, 2H, J = 7.0 Hz), 7.39 (d, 2H, J = 7.5 Hz), 7.49 (t, 1H, J 
= 8.0 Hz), 7.75 (d, 1H, J = 8.0 Hz), 8.13 (d, 1H, J= 7.5 Hz), 8.21 (s, 1H).  MS(ESI):  m/z 
= 448.0 (M-H)-.  HPLC2: tR 2.9 min, Purity > 99%.  
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N-(2-hydroxy-1-methyl-2,2-diphenyl-ethyl)-3-(2-methyl-pyrimidin-4-yl)-
benzenesulfonamide (2.3k).  Using the above procedure, 3-(2-methyl-pyrimidin-4-yl)-
benzenesulfonyl chloride (0.5 mmol), 2-amino-1,1-diphenyl-propan-1-ol (0.5 mmol), PS-
DMAP (0.7 mmol), and pyridine (3 mL) were used to synthesize 2.3k as a light yellow 
solid (13%).  1HNMR (500MHz, CDCl3):  δ 1.19 (d, 3H, J = 6.5 Hz), 2.82 (s, 3H), 4.51 
(m, 1H), 5.14 (d, 1H = J= 8.5 Hz), 6.95 (t, 1H, J = 7.0 Hz), 7.05 (t, 2H, J = 7.0 Hz), 7.20 
(t, 1H, J = 7.0 Hz), 7.29 ( t, 2H, J = 7.0 Hz), 7.33 (d, 2H, J = 7.0 Hz), 7.40 (d, 2H, J = 7.0 
Hz), 7.47 (d, 1H, J = 5.0 Hz), 7.51 (t, 1H, J = 8.0 Hz), 7.73 (d, 1H, J = 8.0 Hz) 8.27 (d, 
1H, J = 8.0 Hz), 8.32 (s, 1H), 8.67 (d, 1H, J = 5.0 Hz).  MS(ESI):  m/z = 458.0 (M-H)-.  
HPLC2: tR 3.1 min, Purity 80%. 
 
4-(3-chloro-2-cyano-phenoxy)-N-[2-hydroxy-1-(4-hydroxy-benzyl)-ethyl]-
benzenesulfonamide (2.3l).  Using the above procedure, 4-(3-chloro-2-cyano-phenoxy)-
benzenesulfonyl chloride (0.5 mmol), 4-(2-amino-3-hydroxy-propyl)-phenol (0.5 mmol), 
PS-DMAP (0.7 mmol), and pyridine (3 mL) were used to synthesize 2.3l as a light yellow 
solid (15%).  1HNMR (500MHz, CDCl3):  δ  2.45 (dd, 1H, J = 8.0, 8.0 Hz), 2.83 (dd, 1H, 
J = 5.5, 6.0 Hz), 3.32 (m, 1H), 3.46 (dd, 1H, J = 6.0, 6.0 Hz), 3.57 (dd, 1H, J = 5.0, 5.0 
Hz), 6.60 (d, 2H, J = 9.0 Hz), 6.99 (d, 2H, J = 8.5 Hz), 7.07 (d, 1H, J = 8.0 Hz), 7.10 (d, 
2H, J = 6.5 Hz), 7.46 (d, 1H, J = 8.5 Hz), 7.66 (t, 1H, J = 8.5 Hz), 7.68 (d, 2H, J = 8.5 
Hz).  MS(ESI):  m/z = 459.1 (M+H)+.  HPLC2: tR 2.8 min, Purity 93%.   
 
General procedure for the synthesis of bromo-benzene sulfonamide intermediates 
(2.6a-k).  To a carousel tube dichloromethane (DCM) (5 mL) was added.  Next, 4-
benzene sulfonyl chloride (1.0 eq) was added followed by di-isopropylethylamine 
(DIPEA) (3.0 eq).  Finally, appropriate primary amines (1.0 eq) were added drop-wise to 
the mixture.  The mixture was allowed to stir at room temperature overnight.  The 
mixtures were concentrated in vacuo.  Flash column purification (0-100% Petroleum 
Ether/ Ethyl Acetate) yielded the corresponding bromo-benzene sulfonamide 
intermediates.   
 
4-bromo-N-[2-(3,4-dimethoxy-phenyl)-ethyl]-benzenesulfonamide (2.6a).  Using the 
above procedure, 4-benzenesulfonylchloride (5.0 mmol), 3,4-dimethoxy phenethylamine 
(5.0 mmol), DIPEA (3.0 eq), and DCM (5mL) were used to synthesize 2.6a as a white 
solid (90%).  1HNMR (500MHz, CDCl3):  δ  2.71 (t, 2H, J = 7.0 Hz), 3.19 (q, 2H, J = 7.0 
Hz), 3.80 (s, 3H), 3.83 (s, 3H), 4.95 (t, 1H, J = 5.8 Hz), 6.58 ( s, 1H), 6.61 (d, 1H, J = 8.0 
Hz), 6.74 (d, 1H, J = 8.0 Hz), 7.60 (d, 2H, J = 8.5 Hz), 7.64 (d, 2H, J = 8.0 Hz).  
MS(ESI):  m/z = 422.2, 424.1 (M+Na)+.  HPLC2: tR 13.0 min, Purity > 99%.  
 
4-bromo-N-(1-hydroxymethyl-propyl)-benzenesulfonamide (2.6b).  Using the above 
procedure, 4-benzenesulfonylchloride (5.0 mmol), 2-amino-1-butanol (5.0 mmol), 
DIPEA (3.0 eq), and DCM (5mL) were used to synthesize 2.6b as a white semisolid 
(45%).  1HNMR (500MHz, MeOD):  δ  0.78 (t, 3H, J = 7.5 Hz), 1.42 (m, 1H), 1.52 (m, 
1H), 3.20 (m, 1H), 3.53 (m, 1H), 3.59 (m, 1H), 4.88 (d, NH, J = 8.5 Hz), 7.66 (d, 2H, J = 
9.0 Hz), 7.76 (d, 2H, J = 8.5 Hz).  MS(ESI):  m/z = 330.0, 332.0 (M+Na)+.  HPLC2: tR 
11.2 min, Purity > 99%. 
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4-bromo-N-pyridin-2-ylmethyl-benzenesulfonamide (2.6c).  Using the above 
procedure, 4-benzenesulfonylchloride (5.0 mmol), 2-Pyridinyl methylamine (5.0 mmol), 
DIPEA (3.0 eq), and DCM (5mL) were used to synthesize 2.6c as a light yellow solid 
(67%).  1HNMR (300MHz, DMSO):  δ 5.16 (s, 2H), 7.27 (d, 1H, J = 12.5 Hz), 7.71 (t, 
1H, J = 13.5 Hz), 7.78 (d, 1H, J = 13.0 Hz), 7.84 (bs, 4H), 8.40 (d, 1H, J = 8.5 Hz).  
MS(ESI):  m/z = 326.0 (M-H)-.  HPLC2: tR 14.5 min, Purity 95%. 
 
4-bromo-N-(3,4,5-trimethoxy-benzyl)-benzenesulfonamide (2.6d).  Using the above 
procedure, 4-benzenesulfonylchloride (5.0 mmol), 3,4,5-tremethozyl benzylamine (5.0 
mmol), DIPEA (3.0 eq), and DCM (5mL) were used to synthesize 2.6d as a light yellow 
solid (92%).  1HNMR (500MHz, CDCl3):  δ  3.77 (s, 6H), 3.80 (s, 3H), 4.08 (d, 2H, J = 
6.0 Hz), 4.98 (bs, 1H), 6.35 (s, 2H), 7.65 (d, 2H, J = 8.5 Hz), 7.72 (d, 2H, J = 8.5 Hz).  
MS(ESI):  m/z = 440.1 (M+Na)+.  HPLC2: tR 12.5 min, Purity 97%. 
 
4-bromo-N-(2-methoxymethyl-pyrrolidin-1-yl)-benzenesulfonamide (2.6e).  Using 
the above procedure, 4-benzenesulfonylchloride (5.0 mmol), 2-Methoxymethyl-
pyrrolidin-1-ylamine (5.0 mmol), DIPEA (3.0 eq), and DCM (5mL) were used to 
synthesize 2.6e as a light yellow solid (67%).  1HNMR (500MHz, CDCl3):  δ 1.49 (1H, 
m), 1.66 (m, 2H), 1.84 (m, 1H), 2.55 (q, 1H, J = 10 Hz), 2.86 (m, 1H), 2.94 (m, 1H), 3.13 
(dd, 1H, J = 6.5, 10.0 Hz), 3.18 (s, 3H), 3.23 (dd, 1H, J = 5.0, 10.0 Hz), 7.66 (d, 2H, J = 
9.0 Hz), 7.83 (d, 2H, J = 9.0 Hz).  MS(ESI):  m/z = 349.1, 351.1 (M+H)+.  HPLC2: tR 
12.4 min, Purity 73%. 
 
4-bromo-N-(2-piperidin-1-yl-ethyl)-benzenesulfonamide (2.6f).  Using the above 
procedure, 4-benzenesulfonylchloride (5.0 mmol), 2-Piperidinyl ethylamine (5.0 mmol), 
DIPEA (3.0 eq), and DCM (5mL) were used to synthesize 2.6f as a light yellow solid 
(60%).  1HNMR (500MHz, CDCl3):  δ 1.39 (bs, 2H), 1.47 (m, 4H), 2.24 (bs, 4H), 2.34 (t, 
2H, J = 6.0 Hz), 2.97 (t, 2H, J = 6.0 Hz), 7.66 (d, 2H, J = 8.5 Hz), 7.75 (d, 2H, J = 8.5 
Hz).  MS(ESI):  m/z = 348.8 (M+H)+.  HPLC2: tR 11.0 min, Purity 80%. 
 
4-bromo-N-furan-2-ylmethyl-benzenesulfonamide (2.6g).  Using the above procedure, 
4-benzenesulfonylchloride (5.0 mmol), furfuranylamine (5.0 mmol), DIPEA (3.0 eq), and 
DCM (5mL) were used to synthesize 2.6g as a white solid (93%).  1HNMR (500MHz, 
CDCl3):  δ  4.20 (d, 2H, J = 6.0 Hz), 5.08 (t, 1H, J = 6.0 Hz), 6.09 ( d, 1H, J = 3.5 Hz), 
6.21 (t, 1H, J = 3.0 Hz), 7.21 (d, 1H, J = 2.0 Hz), 7.59 (d, 2H, J = 9.0 Hz), 7.66 (d, 2H, J 
= 8.5 Hz).  MS(ESI):  m/z = 337.1, 339.1 (M+Na)+.  HPLC2: tR 12.5 min, Purity > 99%. 
 
4-bromo-N-[3-(2-oxo-pyrrolidin-1-yl)-propyl]-benzenesulfonamide (2.6h).  Using the 
above procedure, 4-benzenesulfonylchloride (5.0 mmol), 1-(3-Amino-propyl)-pyrrolidin-
2-one (5.0 mmol), DIPEA (3.0 eq), and DCM (5mL) were used to synthesize 2.6h as a 
white solid (78%).  1HNMR (500MHz, CDCl3):  δ 1.70 (m, 2H), 2.01 (m, 2H), 2.35 (t, 
2H, J = 8.0 Hz), 2.87 (q, 2H, J = 7.0 Hz), 3.33 (m, 4H), 6.33 (t, 2H, J = 8.0 Hz), 7.74 (d, 
2H, J = 8.5 Hz).  MS(ESI):  m/z = 383.5 (M+Na)+.  HPLC2: tR 11.8 min, Purity > 99%. 
 
4-bromo-N-(6-methoxy-pyrimidin-4-yl)-benzenesulfonamide (2.6i).  Using the above 
procedure, 4-benzenesulfonylchloride (5.0 mmol), 6-methoxy-4-pyrimidine (5.0 mmol), 
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DIPEA (3.0 eq), and DCM (5mL) were used to synthesize 2.6i as a light yellow solid 
(83%).  1HNMR (500MHz, CDCl3):  δ  3.97 (s, 3H), 6.51 (s, 1H), 7.64 (d, 2H, J = 9.0 
Hz), 7.78 (d, 2H, J = 8.5 Hz), 8.59 (s, 1H).  MS(ESI):  m/z = 365.0, 367.0 (M+Na)+. 
HPLC2: tR 11.5 min, Purity > 99%. 
 
N-benzothiazol-6-yl-4-bromo-benzenesulfonamide (2.6j).  Using the above procedure, 
4-benzenesulfonylchloride (5.0 mmol), benzothiazol-6-ylamine (5.0 mmol), DIPEA (3.0 
eq), and DCM (5mL) were used to synthesize 2.6j as a light yellow solid (69%).  1HNMR 
(500MHz, DMSO):  δ  7.25 (dd, 1H, J = 2.0, 8.5 Hz), 7.50 (t, 1H, J = 8.5 Hz), 7.75 (d, 
1H, J = 7.5 Hz),  7.83 (d, 1H, J = 7.5 Hz), 7.90 (d, 1H, J = 2.0 Hz), 7.92 (d, 1H, J = 2.0 
Hz), 7.98 (t, 1H, J = 9.0 Hz), 9.29 (s, 1H).  MS(ESI):  m/z = 368.4 (M-H)-.  HPLC2: tR 
19.3 min, Purity > 99%. 
 
2-(4-bromo-benzenesulfonylamino)-3-phenyl-propionic acid methyl ester (2.6k).  
Using the above procedure, 4-benzenesulfonylchloride (5.0 mmol), 2-amino-3-phenyl-
propionic acid methyl ester (5.0 mmol), DIPEA (3.0 eq), and DCM (5mL) were used to 
synthesize 2.6k as a white solid (44%).  1HNMR (500MHz, CDCl3):  δ  2.99 (dd, 1H, J = 
6.5, 14.0 Hz), 3.07 (dd, 1H, J = 5.5, 14.0 Hz), 3.56 (s, 3H), 4.19 (m, 1H), 5.39 (d, 1H, J = 
9.0 Hz),  7.06 (m, 2H), 7.24 (m, 3H), 7.54 (d, 2H, J = 8.5 Hz), 7.56 (d, 2H, J = 8.5 Hz).  
MS(ESI):  m/z = 420.2 (M+Na)+.  HPLC2: tR 13.4 min, Purity 81%. 
 
General procedure for the synthesis of second generation bi-aryl libraries (2.8).  In a 
10 mL microwave tube with a stir bar were added sulfonamide intermediate (1.0 eq), aryl 
boronic acid (1.2 eq), sodium carbonate (3.0 eq), polymer supported tetrakis-
triphenylphosphine palladium catalyst (PS- Pd(Ph3)4, 10% mol eq).  While stirring, the 
flask was evacuated and then refilled under argon (repeated 2 times).  Next, the solvent 
[1:1:1 DME: EtOH: H2O, 5ml] was added.  The flask was again evacuated and refilled 
under argon.  The microwave tube was then inserted into the microwave synthesis 
instrument.  Reaction conditions:  100W, 150°C, 100psi, 10 min.  After 10 min the 
mixture was cooled to room temperature.  The mixture was then filtered and 
concentrated.  All compounds were purified via preparative HPLC (20-100%, H20 with 
0.5% TFA:ACN). 
 
3'-fluoro-4'-methoxy-biphenyl-4-sulfonic acid [2-(3,4-dimethoxy-phenyl)-ethyl]-
amide (2.8ab).  Using the above general procedure, 4-bromo-N-[2-(3,4-dimethoxy-
phenyl)-ethyl]-benzenesulfonamide (0.25mmol), (3-fluoro-4-methoxyphenylboronic acid 
(0.30 mmol), sodium carbonate (0.75 mmol), PS- Pd(Ph3)4 (0.025 mmol) and 
DME:EtOH:H2O (5 mL) were used to synthesize 2.8ab as a white solid (73%).  1HNMR 
(500MHz, CDCl3):  δ  2.62 (t, 2H, J = 7.5 Hz), 2.98 (t, 2H, J = 7.5 Hz), 3.68 (s, 3H), 3.69 
(s, 3H), 3.90 (s, 3H), 6.65 (d, 1H, J = 8.0 Hz), 6.74 (s, 1H), 6.81 (d, 1H, J = 8.0 Hz), 7.29 
(t, 1H, J = 9.5 Hz), 7.57 (d, 1H, J = 8.5 Hz), 7.67 (d, 1H, J = 15.0 Hz), 7.79 (d, 2H, J = 
8.5 Hz), 7.85 (d, 2H, J = 8.5 Hz).  MS(ESI):  m/z = 446.1 (M+H)+.  HPLC2: tR 13.8 min, 
Purity > 99%. 
 
4'-[2-(3,4-dimethoxy-phenyl)-ethylsulfamoyl]-biphenyl-4-carboxylic acid (2.8ac).  
Using the above general procedure, 4-bromo-N-[2-(3,4-dimethoxy-phenyl)-ethyl]-
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benzenesulfonamide (0.25mmol), 4-carboxylphenylboronic acid (0.30 mmol), sodium 
carbonate (0.75 mmol), PS- Pd(Ph3)4 (0.025 mmol) and DME:EtOH:H2O (5 mL) were 
used to synthesize 2.8ac as a light yellow solid (65%).  1HNMR (500MHz, CDCl3):  δ  
2.75 (t, 2H, J = 6.5 Hz), 3.23 (t, 2H, J = 6.5 Hz), 3.81 (s, 3H), 3.84 (s, 3H), 6.62 (s, 1H), 
6.66 (d, 1H, J = 8.5 Hz), 6.78 (d, 1H, J = 8.0 Hz), 7.68 (d, 2H, J = 8.0 Hz), 7.73 (d, 2H, J 
= 8.5 Hz), 7.87 (d, 2H, J = 8.0 Hz), 8.16 (d, 2H, J = 8.0 Hz).  MS(ESI):  m/z = 442.1 
(M+H)+.  HPLC2: tR 12.7 min, Purity > 99%. 
 
4-benzo[1,3]dioxol-5-yl-N-[2-(3,4-dimethoxy-phenyl)-ethyl]-benzenesulfonamide 
(2.8ae).  Using the above general procedure, 4-bromo-N-[2-(3,4-dimethoxy-phenyl)-
ethyl]-benzenesulfonamide (0.25mmol), 1,3-benxodioxol-5-ylboronic acid (0.30 mmol), 
sodium carbonate (0.75 mmol), PS- Pd(Ph3)4 (0.025 mmol) and DME:EtOH:H2O (5 mL) 
were used to synthesize 2.8ae as a white solid (82%).  1HNMR (500MHz, CDCl3):  δ  
2.70 (t, 2H, J = 7.0 Hz), 3.14 (t, 2H, J = 7.0 Hz), 3.76 (s, 3H), 3.77 (s, 3H), 6.03 (s, 2H), 
6.68 (d, 1H, J = 8.5 Hz) 6.72 (s, 1H), 6.82 (d, 1H, J = 8.5 Hz), 6.94 (d, 1H, J = 7.5 Hz), 
7.20 (d, 1H, J = 7.5 Hz), 7.21(s,1H),  7.70 (d, 2H, J = 8.5 Hz), 7.79 (d, 2H, J = 8.5 Hz).  
MS(ESI):  m/z = 442.1 (M+H)+.  HPLC2: tR 13.7 min, Purity 82%. 
 
N-[2-(3,4-dimethoxy-phenyl)-ethyl]-4-(3,5-dimethyl-isoxazol-4-yl)-
benzenesulfonamide (2.8af).  Using the above general procedure, 4-bromo-N-[2-(3,4-
dimethoxy-phenyl)-ethyl]-benzenesulfonamide (0.25mmol), 3,5-dimethyl-4-
isoxazolylboronic acid (0.30 mmol), sodium carbonate (0.75 mmol), PS- Pd(Ph3)4 (0.025 
mmol) and DME:EtOH:H2O (5 mL) were used to synthesize 2.8af as a white solid 
(75%).  1HNMR (500MHz, CDCl3):  δ  2.31 (s, 3H), 2.48 (s, 3H), 2.72 (t, 2H, J = 7.0 
Hz), 3.16 (t, 2H, J = 7.0 Hz), 3.79 (s, 3H), 3.80 (s, 3H), 6.71 (d, 1H, J = 8.0 Hz), 6.78(s, 
1H), 6.85 (d, 1H, J = 8.0 Hz), 7.55 (d, 2H, J = 8.5 Hz), 7.90 (d, 2H, J = 8.5 Hz).  
MS(ESI):  m/z = 417.2 (M+H)+.  HPLC2: tR 12.8 min, Purity > 99%. 
 
4-(2,4-dihydroxy-pyrimidin-5-yl)-N-[2-(3,4-dimethoxy-phenyl)-ethyl]-
benzenesulfonamide (2.8ag).  Using the above general procedure, 4-bromo-N-[2-(3,4-
dimethoxy-phenyl)-ethyl]-benzenesulfonamide (0.25mmol), 2,4-dioxoheahyropyrimidin-
5-yl boronic acid (0.30 mmol), sodium carbonate (0.75 mmol), PS- Pd(Ph3)4 (0.025 
mmol) and DME:EtOH:H2O (5 mL) were used to synthesize 2.8ag as a white solid 
(57%).  1HNMR (500MHz, CDCl3):  δ  2.69 (t, 2H, J = 7.5 Hz), 3.16 (t, 2H, J = 7.0 Hz), 
3.77 (s, 3H), 3.80 (s, 3H), 6.68 (d, 1H, J = 8.5 Hz), 6.70 (s, 1H), 6.83 (d, 1H, J = 8.0 Hz), 
7.71 (d, 2H, J = 8.5 Hz), 7.76 (d, 2H, J = 8.5 Hz), 7.76 (s, 1H).  MS(ESI):  m/z = 432.3 
(M+H)+.  HPLC2: tR 10.6 min, Purity > 99%. 
 
N-[2-(3,4-dimethoxy-phenyl)-ethyl]-4-(5-formyl-furan-2-yl)-benzenesulfonamide 
(2.8ah).  Using the above general procedure, 4-bromo-N-[2-(3,4-dimethoxy-phenyl)-
ethyl]-benzenesulfonamide (0.25mmol), 5-formyl-2-furylboronic acid (0.30 mmol), 
sodium carbonate (0.75 mmol), PS- Pd(Ph3)4 (0.025 mmol) and DME:EtOH:H2O (5 mL) 
were used to synthesize 2.8ah as a light yellow solid (52%).  1HNMR (500MHz, CDCl3):  
δ  2.71 (t, 2H, J = 7.0 Hz), 3.16 (t, 2H, J = 7.0 Hz), 3.77 (s, 6H), 6.69 (d, 1H, J = 9.5 Hz), 
6.74 (s, 1H), 6.83 (d, 1H, J = 8.0 Hz), 7.51 (d, 1H, J = 7.5 Hz), 7.71 (d, 1H, J = 8.0 Hz), 
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7.78 (d, 2H, J = 8.5 Hz), 7.85 (d, 2H, J = 8.5 Hz).  MS(ESI):  m/z = 438.1 (M+Na)+.  
HPLC2: tR 13.8 min, Purity > 99%. 
 
2'-formyl-4'-methoxy-biphenyl-4-sulfonic acid [2-(3,4-dimethoxy-phenyl)-ethyl]-
amide (2.8ai).  Using the above general procedure, 4-bromo-N-[2-(3,4-dimethoxy-
phenyl)-ethyl]-benzenesulfonamide (0.25mmol), 2-formyl-4-methoxyphenylboronic acid 
(0.30 mmol), sodium carbonate (0.75 mmol), PS- Pd(Ph3)4 (0.025 mmol) and 
DME:EtOH:H2O (5 mL) were used to synthesize 2.8ai as a white solid (63%).  1HNMR 
(500MHz, CDCl3):  δ  2.79 (t, 2H, J = 6.5 Hz), 3.29 (q, 2H, J = 6.5 Hz), 3.84 (s, 3H), 
3.85 (s, 3H), 3.93 (s, 3H), 4.67 (t, 1H, J = 6.0 Hz), 6.66 (s, 1H), 6.68 (d, 1H, J = 8.0 Hz), 
6.80 (d, 1H, J = 8.0 Hz), 7.25 (d, 1H, J = 8.0 Hz), 7.38 (d, 1H, J = 8.5 Hz), 7.47 (d, 2H, J 
= 8.0 Hz), 7.54 (s, 1H), 7.90 (d, 2H, J = 8.5 Hz), 9.92 (s, 1H).  MS(ESI):  m/z = 478.1 
(M+Na)+, 454.0 (M-H)-.  HPLC2: tR 13.5 min, Purity > 99%. 
 
3'-fluoro-4'-methoxy-biphenyl-4-sulfonic acid (1-hydroxymethyl-propyl)-amide 
(2.8bb).  Using the above general procedure, 4-bromo-N-(1-hydroxymethyl-propyl)-
benzenesulfonamide (0.25mmol), 3-fluoro-4-methoxyphenylboronic acid(0.30 mmol), 
sodium carbonate (0.75 mmol), PS- Pd(Ph3)4 (0.025 mmol) and DME:EtOH:H2O (5 mL) 
were used to synthesize 2.8bb as a white solid (72%).  1HNMR (300MHz, DMSO):  δ  
0.66 (t, 3H, J = 7.5 Hz), 1.22 (m, 1H), 1.55 (m, 1H), 2.99 (m, 1H), 3.14 (dd, 1H, J = 7.0, 
10.0 Hz), 3.27 (dd, 1H, J = 4.5, 11.0 Hz), 3.89 (s, 3H), 7.28 (t, 1H, J = 9.0 Hz), 7.58 (d, 
1H, J = 9.0 Hz), 7.68 (d, 1H, J = 13.0 Hz), 7.83 (d, 2H, J = 9.0 Hz), 7.87 (d, 2H, J = 9.0 
Hz).  MS(ESI):  m/z = 376.3 (M+Na)+.  HPLC2: tR 12.6 min, Purity 95%.   
 
4'-(1-hydroxymethyl-propylsulfamoyl)-biphenyl-4-carboxylic acid (2.8bc).  Using the 
above general procedure, 4-bromo-N-(1-hydroxymethyl-propyl)-benzenesulfonamide 
(0.25mmol), 4-carboxylphenylboronic acid (0.30 mmol), sodium carbonate (0.75 mmol), 
PS- Pd(Ph3)4 (0.025 mmol) and DME:EtOH:H2O (5 mL) were used to synthesize 2.8bc 
as a white solid (72%).  1HNMR (300MHz, DMSO):  δ  0.66 (t, 3H, J = 7.0 Hz), 1.24 (m, 
1H), 1.51 (m, 1H), 2.96 (m, 1H), 3.16 (dd, 1H, J = 3.0, 7.0 Hz), 3.27 (dd, 1H, J = 5.0, 
10.5 Hz), 7.66 (d, 2H, J = 8.0 Hz), 7.86 (bs, 4H), 7.99 (d, 2H, J = 8.0 Hz).  MS(ESI):  
m/z = 350.2 (M+H)+.  HPLC2: tR 11.2 min, Purity 87%.   
 
5-[4-(1-hydroxymethyl-propylsulfamoyl)-phenyl]-thiophene-2-carboxylic acid 
(2.8bd).  Using the above general procedure, 4-bromo-N-(1-hydroxymethyl-propyl)-
benzenesulfonamide (0.25mmol), 5-(dihydroxylboryl)-2-thiophenecarboxylic acid 
 (0.30 mmol), sodium carbonate (0.75 mmol), PS- Pd(Ph3)4 (0.025 mmol) and 
DME:EtOH:H2O (5 mL) were used to synthesize 2.8bd as a white solid (89%).  1HNMR 
(500MHz, MeOD):  δ  0.78 (t, 3H, J = 7.5 Hz), 1.35 (m, 1H), 1.64 (m, 1H), 3.20 (m, 1H), 
3.37 (dd, 1H, J = 6.0, 15.0 Hz), 3.59 (dd, 1H, J = 4.5, 11.0 Hz), 7.61 (d, 2H, J = 3.5 Hz), 
7.80 (d, 2H, J = 4.0 Hz), 7.91 (d, 2H, J = 9.0 Hz), 7.95 (d, 2H, J = 8.5 Hz).  MS(ESI):  
m/z = 356.1 (M+H)+.  HPLC2: tR 11.1 min, Purity > 99%.   
 
4-benzo[1,3]dioxol-5-yl-N-(1-hydroxymethyl-propyl)-benzenesulfonamide (2.8be).  
Using the above general procedure, 4-bromo-N-(1-hydroxymethyl-propyl)-
benzenesulfonamide (0.25mmol), 1,3-benxodioxol-5-ylboronic acid (0.30 mmol), sodium 
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carbonate (0.75 mmol), PS- Pd(Ph3)4 (0.025 mmol) and DME:EtOH:H2O (5 mL) were 
used to synthesize 2.8be as a white solid (62%).  1HNMR (300MHz, DMSO):  δ  0.66 (t, 
3H, J = 7.0 Hz), 1.22 (m, 1H), 1.53 (m, 1H), 2.97 (m, 1H), 3.14 (dd, 1H, J = 7.5, 9.0 Hz), 
3.25 (dd, 1H, J = 8.0, 12.0 Hz), 6.06 (s, 2H), 7.04 (d, 1H, J = 8.0 Hz), 7.25 (d, 1H, J = 8.0 
Hz), 7.35 (s, 1H), 7.82 (bs, 4H).  MS(ESI):  m/z = 372.1 (M+Na)+.  HPLC2: tR 12.4 min, 
Purity 92%.   
 
4-(3,5-dimethyl-isoxazol-4-yl)-N-(1-hydroxymethyl-propyl)-benzenesulfonamide 
(2.8bf).  Using the above general procedure, 4-bromo-N-(1-hydroxymethyl-propyl)-
benzenesulfonamide (0.25mmol), 3,5-dimethyl-4-isoxazolylboronic acid (0.30 mmol), 
sodium carbonate (0.75 mmol), PS- Pd(Ph3)4 (0.025 mmol) and DME:EtOH:H2O (5 mL) 
were used to synthesize 2.8bf as a white solid (69%).  1HNMR (500MHz, MeOD):  δ  
0.77 (t, 3H, J = 7.5 Hz), 1.35 (m, 1H), 1.64 (m, 1H), 2.30 (s, 3H), 2.46 (s, 3H), 3.16 (m, 
1H), 3.39 (dd, 1H, J = 6.0, 11.0 Hz), 3.47 (dd, 1H, J = 4.5, 15.0 Hz), 7.57 (d, 2H, J = 8.5 
Hz), 8.00 (d, 2H, J = 8.5 Hz).  MS(ESI):  m/z = 325.0 (M+H)+.  HPLC2: tR 11.1 min, 
Purity > 99%.   
 
4-(2,4-dihydroxy-pyrimidin-5-yl)-N-(1-hydroxymethyl-propyl)-benzenesulfonamide 
(2.8bg).  Using the above general procedure, 4-bromo-N-(1-hydroxymethyl-propyl)-
benzenesulfonamide (0.25mmol), 2,4-dihydroxypyrimidine-5-boronic acid (0.30 mmol), 
sodium carbonate (0.75 mmol), PS- Pd(Ph3)4 (0.025 mmol) and DME:EtOH:H2O (5 mL) 
were used to synthesize 2.8bg as a white solid (66%).  1HNMR (500MHz, MeOD):  δ  
0.78 (t, 3H, J = 7.5 Hz), 1.34 (m, 1H), 1.63 (m, 1H), 3.13 (m, 1H), 3.35 (dd, 1H, J = 6.5, 
11.0 Hz), 3.45 (dd, 1H, J = 4.5, 12.0 Hz), 7.74 (s, 1H), 7.78 (d, 2H, J = 8.5 Hz), 7.89 (d, 
2H, J = 9.0 Hz).  MS(ESI):  m/z = 362.1 (M+Na)+.  HPLC2: tR 8.5 min, Purity > 99%.   
 
2'-formyl-4'-methoxy-biphenyl-4-sulfonic acid (1-hydroxymethyl-propyl)-amide 
(2.8bi).  Using the above general procedure, 4-bromo-N-(1-hydroxymethyl-propyl)-
benzenesulfonamide (0.25mmol), 2-formyl-4-methoxyphenylboronic acid (0.30 mmol), 
sodium carbonate (0.75 mmol), PS- Pd(Ph3)4 (0.025 mmol) and DME:EtOH:H2O (5 mL) 
were used to synthesize 2.8bi as a white solid (63%).  1HNMR (300MHz, DMSO):  δ  
0.77 (t, 3H, J = 7.5 Hz), 1.35 (m, 1H), 1.64 (m, 1H), 3.18 (m, 1H), 3.39 (dd, 1H, J = 6.0, 
11.0 Hz), 3.48 (dd, 1H, J = 5.0, 11.0 Hz), 3.91 (s, 3H), 7.33 (t, 1H, J = 3.0 Hz), 7.44 (s, 
1H), 7.51 (d, 1H, J = 3.0 Hz), 7.57 (d, 2H, J = 9.0 Hz), 7.99 (d, 2H, J = 8.5 Hz), 9.95 (s, 
1H).  MS(ESI):  m/z = 386.2 (M+Na)+.  HPLC2: tR 12.2 min, Purity 92%.   
 
3'-fluoro-4'-methoxy-biphenyl-4-sulfonic acid (pyridin-2-ylmethyl)-amide (2.8cb).  
Using the above general procedure, 4-bromo-N-pyridin-2-ylmethyl-benzenesulfonamide 
(0.25mmol), 3-fluoro-4-methoxyphenylboronic acid  (0.30 mmol), sodium carbonate 
(0.75 mmol), PS- Pd(Ph3)4 (0.025 mmol) and DME:EtOH:H2O (5 mL) were used to 
synthesize 2.8cb as a white solid (72%).  1HNMR (500MHz, CDCl3):  δ 3.88 (s, 3H), 
4.10 (s, 2H), 7.22 (t, 1H, J = 8.5 Hz), 7.30 (t, 1H, J = 15.0 Hz), 7.38 (d, 1H, J = 13.0 Hz), 
7.56 (d, 1H, J = 14.5 Hz), 7.70 (t, 1H, J = 14.0 Hz), 7.72 (d, 1H, J = 12.0Hz), 7.82 (bs, 
4H), 8.42 (d, 1H, J = 7.0 Hz).  MS(ESI):  m/z = 395.3 (M+Na)+.  HPLC2: tR 12.2 min, 
Purity 96%.   
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4-benzo[1,3]dioxol-5-yl-N-pyridin-2-ylmethyl-benzenesulfonamide (2.8ce).  Using the 
above general procedure, 4-bromo-N-pyridin-2-ylmethyl-benzenesulfonamide 
(0.25mmol), 1,3-benxodioxol-5-ylboronic acid (0.30 mmol), sodium carbonate (0.75 
mmol), PS- Pd(Ph3)4 (0.025 mmol) and DME:EtOH:H2O (5 mL) were used to synthesize 
2.8ce as a white solid (84%).  1HNMR (500MHz, CDCl3):  δ 6.10 (s, 2H), 7.05 (d, 1H, J 
= 8.0 Hz), 7.23 (d, 2H, J = 5.0 Hz), 7.34 (s, 1H), 7.37 (d, 1H, J = 7.5 Hz), 7.72 (t, 1H, J = 
7.5 Hz), 7.78 (d, 2H, J = 8.5 Hz), 7.81 (d, 2H, J = 9.0 Hz), 8.44 (d, 1H, J = 5.0 Hz).  
MS(ESI):  m/z = 391.1 (M+Na)+.  HPLC2: tR 12.0 min, Purity 84%.      
 
3'-fluoro-4'-methoxy-biphenyl-4-sulfonic acid 3,4,5-trimethoxy-benzylamide (2.8db).  
Using the above general procedure, 4-bromo-N-(3,4,5-trimethoxy-benzyl)-
benzenesulfonamide (0.25mmol), 3-fluoro-4-methoxyphenylboronic acid 
 (0.30 mmol), sodium carbonate (0.75 mmol), PS- Pd(Ph3)4 (0.025 mmol) and 
DME:EtOH:H2O (5 mL) were used to synthesize 2.8db as a white solid (96%).  1HNMR 
(500MHz, CDCl3):  δ  3.53 (s, 3H), 3.67 (s, 6H), 3.90 (s, 3H), 4.00 (s, 2H), 6.49 (s, 2H), 
7.29 (t, 1H, J = 8.5Hz),7.54 (d, 1H, J = 8.5Hz),  7.64 (d, 1H, J = 13.0Hz), 7.78 (d, 2H, J 
= 9.0Hz), 7.81 (d, 2H, J =9.0Hz).  MS(ESI):  m/z = 484.1 (M+Na)+.  HPLC2: tR 13.5 
min, Purity 97%.   
 
4'-(3,4,5-trimethoxy-benzylsulfamoyl)-biphenyl-4-carboxylic acid (2.8dc).  Using the 
above general procedure, 4-bromo-N-(3,4,5-trimethoxy-benzyl)-benzenesulfonamide 
(0.25mmol), 4-carboxylphenylboronic acid (0.30 mmol), sodium carbonate (0.75 mmol), 
PS- Pd(Ph3)4 (0.025 mmol) and DME:EtOH:H2O (5 mL) were used to synthesize 2.8dc 
as a white solid (78%).  1HNMR (500MHz, CDCl3):  δ  3.51 (s, 3H), 3.67 (s, 6H), 4.01 (s, 
2H), 6.50 (s, 2H), 7.64 (d, 2H, J = 8.0 Hz), 7.83(bs, 4H),  8.00 (d, 2H, J = 7.5 Hz).  
MS(ESI):  m/z = 456.0 (M-H)-.  HPLC2: tR 12.4 min, Purity 93%.   
 
5-[4-(3,4,5-trimethoxy-benzylsulfamoyl)-phenyl]-thiophene-2-carboxylic acid 
(2.8dd).  Using the above general procedure, 4-bromo-N-(3,4,5-trimethoxy-benzyl)-
benzenesulfonamide (0.25mmol), 5-(dihydroxylboryl)-2-thiophenecarboxylic acid 
 (0.30 mmol), sodium carbonate (0.75 mmol), PS- Pd(Ph3)4 (0.025 mmol) and 
DME:EtOH:H2O (5 mL) were used to synthesize 2.8dd as a white solid (48%).  1HNMR 
(500MHz, CDCl3):  δ  3.65 (s, 3H), 3.75 (s, 6H), 4.13 (s, 2H), 6.47 (s, 2H), 7.55 (d, 1H, J 
= 4.0 Hz), 7.71 (d, 1H, J = 4.0 Hz), 7.82 (bs, 4H).  MS(ESI):  m/z = 486.1 (M+Na)+.  
HPLC2: tR 12.3 min, Purity > 99%.  
 
4-benzo[1,3]dioxol-5-yl-N-(3,4,5-trimethoxy-benzyl)-benzenesulfonamide (2.8de).  
Using the above general procedure, 4-bromo-N-(3,4,5-trimethoxy-benzyl)-
benzenesulfonamide (0.25mmol), 1,3-benxodioxol-5-ylboronic acid (0.30 mmol), sodium 
carbonate (0.75 mmol), PS- Pd(Ph3)4 (0.025 mmol) and DME:EtOH:H2O (5 mL) were 
used to synthesize 2.8de as a white solid (68%).  1HNMR (500MHz, CDCl3):  δ  3.54 (s, 
3H), 3.67 (s, 6H), 4.00 (s, 2H), 6.10 (s, 2H), 6.49 (s, 2H), 7.05 (d, 1H, J = 8.0 Hz), 7.22 
(d, 1H, J = 8.0 Hz), 7.31(s, 1H), 7.77 (bs, 4H).  MS(ESI):  m/z = 480.5 (M+Na)+.  
HPLC2: tR 13.4 min, Purity > 99%.   
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4-(3,5-dimethyl-isoxazol-4-yl)-N-(3,4,5-trimethoxy-benzyl)-benzenesulfonamide 
(2.8df).  Using the above general procedure, 4-bromo-N-(3,4,5-trimethoxy-benzyl)-
benzenesulfonamide (0.25mmol), 3,5-dimethyl-4-isoxazolylboronic acid (0.30 mmol), 
sodium carbonate (0.75 mmol), PS- Pd(Ph3)4 (0.025 mmol) and DME:EtOH:H2O (5 mL) 
were used to synthesize 2.8df as a white solid (41%).  1HNMR (500MHz, CDCl3):  δ  
2.30 (s, 3H), 2.46 (s, 3H), 3.68 (s, 3H), 3.76 (s, 6H), 4.16 (s, 2H), 6.51 (s, 2H), 7.47 (d, 
2H, J = 8.5 Hz), 7.86 (d, 2H, J = 8.5 Hz).  MS(ESI):  m/z = 430.9 (M-H)-.  HPLC2: tR 
11.6 min, Purity 87%.  
  
4-(2,4-dihydroxy-pyrimidin-5-yl)-N-(3,4,5-trimethoxy-benzyl)-benzenesulfonamide 
(2.8dg).  Using the above general procedure, 4-bromo-N-(3,4,5-trimethoxy-benzyl)-
benzenesulfonamide (0.25mmol), 2,4-dihydroxypyrimidine-5-boronic acid (0.30 mmol), 
sodium carbonate (0.75 mmol), PS- Pd(Ph3)4 (0.025 mmol) and DME:EtOH:H2O (5 mL) 
were used to synthesize 2.8dg as a white solid (75%).  1HNMR (500MHz, CDCl3):  δ  
3.71 (s, 3H), 3.76 (s, 6H), 4.08 (s, 2H), 6.49 (s, 2H), 7.53 (t, 2H, J = 7.5 Hz), 7.59 (t, 1H, 
J = 7.5 Hz), 7.82 (d, 2H, J = 8.0 Hz).  MS(ESI):  m/z = 446.0 (M-H)-.  HPLC2: tR 11.6 
min, Purity 88%.   
 
4-(5-formyl-furan-2-yl)-N-(3,4,5-trimethoxy-benzyl)-benzenesulfonamide (2.8dh).  
Using the above general procedure, 4-bromo-N-(3,4,5-trimethoxy-benzyl)-
benzenesulfonamide (0.25mmol), 5-formyl-2-furylboronic acid (0.30 mmol), sodium 
carbonate (0.75 mmol), PS- Pd(Ph3)4 (0.025 mmol) and DME:EtOH:H2O (5 mL) were 
used to synthesize 2.8dh as a light yellow solid (39%).  1HNMR (500MHz, CDCl3):  δ  
3.64 (s, 3H), 3.76 (s, 6H), 4.14 (s, 2H), 6.48 (s, 2H), 6.96 (d, 1H, J = 3.0 Hz), 7.25 (d, 1H, 
J = 4.0 Hz), 7.86 (d, 2H, J = 8.5 Hz), 7.98 (d, 2H, J = 8.5 Hz).  MS(ESI):  m/z = 454.6 
(M+Na)+.  HPLC2: tR 12.2 min, Purity 80%.    
 
2'-formyl-4'-methoxy-biphenyl-4-sulfonic acid 3,4,5-trimethoxy-benzylamide (2.8di).  
Using the above general procedure, 4-bromo-N-(3,4,5-trimethoxy-benzyl)-
benzenesulfonamide (0.25mmol), 2-formyl-4-methoxyphenylboronic acid (0.30 mmol), 
sodium carbonate (0.75 mmol), PS- Pd(Ph3)4 (0.025 mmol) and DME:EtOH:H2O (5 mL) 
were used to synthesize 2.8di as a white solid (90%).  1HNMR (500MHz, CDCl3):  δ  
3.78 (s, 9H), 3.93 (s, 3H), 4.15 (s, 2H), 6.45 (s, 2H), 7.24 (d, 1H, J = 8.5 Hz),7.36 (d, 1H, 
J = 8.5 Hz), 7.48 (d, 2H, J = 8.5 Hz), 7.54 (s, 1H), 7.94 (d, 2H, J = 8.0 Hz), 9.91 (s, 1H).  
MS(ESI):  m/z = 494.6 (M+Na)+.  HPLC2: tR 13.2 min, Purity > 99%.  
 
3'-fluoro-4'-methoxy-biphenyl-4-sulfonamide (2.8eb).  Using the above general 
procedure, 4-bromo-N-(2-methoxymethyl-pyrrolidin-1-yl)-benzenesulfonamide 
(0.25mmol), 3-fluoro-4-methoxyphenylboronic acid  (0.30 mmol), sodium carbonate 
(0.75 mmol), PS- Pd(Ph3)4 (0.025 mmol) and DME:EtOH:H2O (5 mL) were used to 
synthesize 2.8eb as a white solid (79%).  1HNMR (500MHz, MeOD):  δ 3.94 (s, 3H), 
7.19 (t, 1H, J = 8.5 Hz), 7.42 (d, 1H, J = 3.5 Hz), 7.44 (s, 1H), 7.67 (d, 2H, J = 8.0 Hz), 
7.73 (d, 2H, J = 8.0 Hz).  MS(ESI):  m/z = 280.8 (M-H)-.  HPLC2: tR 11.8 min, Purity 
83%.     
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4'-sulfamoyl-biphenyl-4-carboxylic acid (2.8ec).  Using the above general procedure, -
bromo-N-(2-methoxymethyl-pyrrolidin-1-yl)-benzenesulfonamide (0.25mmol), 5-
(dihydroxylboryl)-2-thiophenecarboxylic acid (0.30 mmol), sodium carbonate (0.75 
mmol), PS- Pd(Ph3)4 (0.025 mmol) and DME:EtOH:H2O (5 mL) were used to synthesize 
2.8ec as a white solid (74%).  1HNMR (500MHz, CDCl3):  δ  7.66 (d, 2H, J = 8.5 Hz), 
7.74 (d, 2H, J = 8.5 Hz), 7.77 (d, 2H, J = 8.5 Hz), 8.05 (d, 2H, J = 8.5 Hz).  MS(ESI):  
m/z = 277.0 (M+H)+.  HPLC2: tR 10.2 min, Purity 85%. 
 
5-(4-sulfamoyl-phenyl)-thiophene-2-carboxylic acid (2.8ed).  Using the above general 
procedure, bromo-N-(2-methoxymethyl-pyrrolidin-1-yl)-benzenesulfonamide 
(0.25mmol), 5-(dihydroxylboryl)-2-thiophenecarboxylic acid (0.30 mmol), sodium 
carbonate (0.75 mmol), PS- Pd(Ph3)4 (0.025 mmol) and DME:EtOH:H2O (5 mL) were 
used to synthesize 2.8ed as a white solid (24%).  1HNMR (500MHz, MeOD):  δ  7.31 (d, 
1H, J = 8.5 Hz), 7.51 (d, 1H, J = 8.5 Hz), 7.61 (d, 2H, J = 8.5 Hz), 7.75 (d, 2H, J = 8.5 
Hz).  MS(ESI):  m/z = 284.1 (M+H)+.  HPLC2: tR 8.3 min, Purity 80%.    
 
4-benzo[1,3]dioxol-5-yl-benzenesulfonamide (2.8ee).  Using the above general 
procedure, bromo-N-(2-methoxymethyl-pyrrolidin-1-yl)-benzenesulfonamide 
(0.25mmol), 1,3-benxodioxol-5-ylboronic acid (0.30 mmol), sodium carbonate (0.75 
mmol), PS- Pd(Ph3)4 (0.025 mmol) and DME:EtOH:H2O (5 mL) were used to synthesize 
2.8ee as a white solid (63%).  1HNMR (500MHz, MeOD):  δ 6.02 (s, 2H), 6.92 (d, 1H, J 
= 9.0 Hz), 7.16 (d, 1H, J = 5.5 Hz), 7.63 (d, 2H, J = 8.5 Hz), 7.77 (s, 1H), 7.88 (d, 2H, J 
= 8.5 Hz).  MS(ESI):  m/z = 276.9 (M-H)-.  HPLC2: tR 12.0 min, Purity 92%.      
 
4-(2,4-dihydroxy-pyrimidin-5-yl)-benzenesulfonamide (2.8eg).  Using the above 
general procedure, bromo-N-(2-methoxymethyl-pyrrolidin-1-yl)-benzenesulfonamide 
(0.25mmol), 2,4-dihydroxypyrimidine-5-boronic acid (0.30 mmol), sodium carbonate 
(0.75 mmol), PS- Pd(Ph3)4 (0.025 mmol) and DME:EtOH:H2O (5 mL) were used to 
synthesize 2.8eg as a white solid (61%).  1HNMR (500MHz, MeOD):  δ  6.22 (s, 1H), 
6.28 (d, 2H, J = 8.5 Hz), 6.33 (d, 2H, J = 8.5Hz).  MS(ESI):  m/z = 266.2 (M-H)-.  
HPLC2: tR 10.1 min, Purity > 99%.   
 
4-(5-formyl-furan-2-yl)-N-(2-methoxymethyl-pyrrolidin-1-yl)-benzenesulfonamide 
(2.8eh).  Using the above general procedure, 4-bromo-N-(2-methoxymethyl-pyrrolidin-1-
yl)-benzenesulfonamide (0.25mmol), 5-formyl-2-furylboronic acid (0.30 mmol), sodium 
carbonate (0.75 mmol), PS- Pd(Ph3)4 (0.025 mmol) and DME:EtOH:H2O (5 mL) were 
used to synthesize 2.8eh as a light yellow solid (24%).  1HNMR (500MHz, MeOD):  δ  
1.60 (m, 2H), 1.87 (m, 2H),  3.27 (m, 1H), 3.38 (s, 3H), 3.43 (m, 2H), 3.60 (dd, 1H, J = 
4.0, 9.0 Hz), 3.79 (m, 1H), 7.28 (d, 1H, J = 6.0 Hz), 7.56 (d, 1H, J = 5.5 Hz), 7.97 (d, 2H, 
J = 8.0 Hz), 8.11 (d, 2H, J = 8.5 Hz), 9.67 (s, 1H).  MS(ESI):  m/z = 363.3 (M-H)-.  
HPLC2: tR 12.7 min, Purity > 99%. 
 
2'-formyl-4'-methoxy-biphenyl-4-sulfonic acid (2-methoxymethyl-pyrrolidin-1-yl)-
amide (2.9ei).  Using the above general procedure, 4-bromo-N-(2-methoxymethyl-
pyrrolidin-1-yl)-benzenesulfonamide (0.25mmol), 2-formyl-4-methoxyphenylboronic 
acid (0.30 mmol), sodium carbonate (0.75 mmol), PS- Pd(Ph3)4 (0.025 mmol) and 
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DME:EtOH:H2O (5 mL) were used to synthesize 2.8bi as a white solid (92%).  1HNMR 
(500MHz, MeOD):  δ  1.60 (m, 2H), 1.86 (m, 2H),  3.27 (m, 1H), 3.39 (s, 3H), 3.43 (m, 
2H), 3.60 (dd, 1H, J = 4.0, 9.0 Hz), 3.79 (m, 1H), 3.88 (s, 3H),  6.97 (d, 1H, J = 8.0 Hz), 
7.19 (d, 1H, J = 8.0 Hz), 7.24 (d, 1H, J = 8.0 Hz), 7.61 (d, 2H, J = 8.5 Hz), 7.491 (d, 2H, 
J = 8.0 Hz).  .MS(ESI):  m/z = 403.2 (M-H)-.  HPLC2: tR 12.7 min, Purity > 99%. 
 
3'-fluoro-4'-methoxy-biphenyl-4-sulfonic acid (2-piperidin-1-yl-ethyl)-amide (2.8fb).  
Using the above general procedure, 4-bromo-N-(2-piperidin-1-yl-ethyl)-
benzenesulfonamide (0.25mmol), 3-fluoro-4-methoxyphenylboronic acid(0.30 mmol), 
sodium carbonate (0.75 mmol), PS- Pd(Ph3)4 (0.025 mmol) and DME:EtOH:H2O (5 mL) 
were used to synthesize 2.8fb as a white solid (23%).  1HNMR (500MHz, MeOD):  δ  
1.57 (bt, 1H, J = 12.0 Hz), 1.85 (m, 3H), 1.98 (bd, 4H, J = 15.0 Hz), 3.01 (t, 2H, J = 12.0 
Hz), 3.27 (m, 4H), 3.62 (bd, 2H, J = 12.5 Hz), 3.96 (s, 3H), 7.25 (t, 1H, J = 8.5 Hz), 7.51 
(s, 1H), 7.53 (t, 1H, J = 3.5 Hz), 7.86 (d, 2H, J = 8.5 Hz), 7.95 (d, 2H, J = 8.5 Hz).  
MS(ESI):  m/z = 393.2 (M+H)+.  HPLC2: tR 12.7 min, Purity > 99%.   
 
4'-(2-piperidin-1-yl-ethylsulfamoyl)-biphenyl-4-carboxylic acid (2.8fc).  Using the 
above general procedure, 4-bromo-N-(2-piperidin-1-yl-ethyl)-benzenesulfonamide 
(0.25mmol), 4-carboxylphenylboronic acid (0.30 mmol), sodium carbonate (0.75 mmol), 
PS- Pd(Ph3)4 (0.025 mmol) and DME:EtOH:H2O (5 mL) were used to synthesize 2.8fc as 
a white solid (67%).  1HNMR (500MHz, MeOD):  δ  1.57 (bt, 1H, J = 13.5 Hz), 1.86 (m, 
3H), 1.99 (bd, 4H, J = 14.5 Hz), 3.02 (t, 2H, J = 14.5 Hz), 3.28 (bs, 4H), 3.63 (bd, 2H, J = 
12.0 Hz), 7.84 (d, 2H, J = 8.0 Hz), 7.96 (d, 2H, J = 8.5 Hz), 8.02 (d, 2H, J = 8.5 Hz), 8.18 
(d, 2H, J = 8.5 Hz).  MS(ESI):  m/z = 389.1 (M+H)+.  HPLC2: tR 11.3 min, Purity > 99%.   
 
4-benzo[1,3]dioxol-5-yl-N-(2-piperidin-1-yl-ethyl)-benzenesulfonamide (2.8fe).  
Using the above general procedure, 4-bromo-N-(2-piperidin-1-yl-ethyl)-
benzenesulfonamide (0.25mmol), 1,3-benxodioxol-5-ylboronic acid (0.30 mmol), sodium 
carbonate (0.75 mmol), PS- Pd(Ph3)4 (0.025 mmol) and DME:EtOH:H2O (5 mL) were 
used to synthesize 2.8fe as a white solid (34%).  1HNMR (500MHz, MeOD):  δ  1.57 (bt, 
1H, J = 13.5 Hz), 1.85 (m, 3H), 1.98 (bd, 4H, J = 14.5 Hz), 3.01 (t, 2H, J = 12.5 Hz), 3.27 
(m, 4H), 3.61 (bd, 2H, J = 11.5 Hz), 6.05 (s, 2H), 6.97 (d, 1H, J = 8.5 Hz), 7.22 (m, 2H, 
7.81 (d, 2H, J = 8.5 Hz), 7.93 (d, 2H, J = 8.5 Hz).  MS(ESI):  m/z = 389.1 (M+H)+.  
HPLC2: tR 12.7 min, Purity 89%.   
 
4-(3,5-dimethyl-isoxazol-4-yl)-N-(2-piperidin-1-yl-ethyl)-benzenesulfonamide (2.8ff).  
Using the above general procedure, 4-bromo-N-(2-piperidin-1-yl-ethyl)-
benzenesulfonamide (0.25mmol), 3,5-dimethyl-4-isoxazolylboronic acid (0.30 mmol), 
sodium carbonate (0.75 mmol), PS- Pd(Ph3)4 (0.025 mmol) and DME:EtOH:H2O (5 mL) 
were used to synthesize 2.8ff as a light yellow solid (66%).  1HNMR (500MHz, MeOD):  
δ  1.57 (bt, 1H, J = 12.5 Hz), 1.86 (m, 3H), 1.99 (bd, 4H, J = 15.0 Hz), 2.31 (s, 3H), 2.48 
(s, 3H), 3.02 (t, 2H, J = 12.5 Hz), 3.29 (bs, 4H), 3.63 (bd, 2H, J = 11.0 Hz), 7.64 (d, 2H, J 
= 8.5 Hz), 8.01 (d, 2H, J = 8.5 Hz).  MS(ESI):  m/z = 364.1 (M+H)+.  HPLC2: tR 11.3 
min, Purity 91%.   
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4-(2,4-dihydroxy-pyrimidin-5-yl)-N-(2-piperidin-1-yl-ethyl)-benzenesulfonamide 
(2.8fg).  Using the above general procedure, 4-bromo-N-(2-piperidin-1-yl-ethyl)-
benzenesulfonamide (0.25mmol), 2,4-dihydroxypyrimidine-5-boronic acid (0.30 mmol), 
sodium carbonate (0.75 mmol), PS- Pd(Ph3)4 (0.025 mmol) and DME:EtOH:H2O (5 mL) 
were used to synthesize 2.8fg as a light yellow solid (74%).  1HNMR (500MHz, MeOD):  
δ  1.57 (bt, 1H, J = 11.5 Hz), 1.85 (m, 3H), 1.98 (bd, 4H, J = 16.0 Hz), 3.01 (t, 2H, J = 
12.5 Hz), 3.25 (m, 4H), 3.61 (bd, 2H, J = 11.5 Hz), 7.76 (s, 1H), 7.83 (d, 2H, J = 8.5 Hz), 
7.91 (d, 2H, J = 9.0 Hz).  MS(ESI):  m/z = 379.1 (M+H)+.  HPLC2: tR 8.9 min, Purity > 
99%.   
 
4-(5-formyl-furan-2-yl)-N-(2-piperidin-1-yl-ethyl)-benzenesulfonamide (2.8fh).  
Using the above general procedure, 4-bromo-N-(2-piperidin-1-yl-ethyl)-
benzenesulfonamide (0.25mmol), 5-formyl-2-furylboronic acid (0.30 mmol), sodium 
carbonate (0.75 mmol), PS- Pd(Ph3)4 (0.025 mmol) and DME:EtOH:H2O (5 mL) were 
used to synthesize 2.8fh as a light yellow solid (69%).  1HNMR (500MHz, MeOD):  δ  
1.57 (bt, 1H, J = 12.0 Hz), 1.85 (m, 3H), 1.98 (bd, 4H, J = 17.5 Hz), 3.01 (t, 2H, J = 12.0 
Hz), 3.26 (bs, 4H), 3.62 (bd, 2H, J = 12.0 Hz), 6.59 (d, 1H, J = 4.0 Hz), 7.06 (d, 1H, J = 
3.0 Hz), 7.93 (d, 2H, J = 8.5 Hz), 7.96 (d, 2H, J = 8.5 Hz).  MS(ESI):  m/z = 363.1 
(M+H)+.  HPLC2: tR 12.2 min, Purity > 99%.   
 
2'-formyl-4'-methoxy-biphenyl-4-sulfonic acid (2-piperidin-1-yl-ethyl)-amide (2.8fi).  
Using the above general procedure, 4-bromo-N-(2-piperidin-1-yl-ethyl)-
benzenesulfonamide (0.25mmol), 2-formyl-4-methoxyphenylboronic acid (0.30 mmol), 
sodium carbonate (0.75 mmol), PS- Pd(Ph3)4 (0.025 mmol) and DME:EtOH:H2O (5 mL) 
were used to synthesize 2.8fi as a white solid (31%).  1HNMR (500MHz, MeOD):  δ  
1.58 (bt, 1H, J = 11.5 Hz), 1.86 (m, 3H), 1.99 (bd, 4H, J = 16.0 Hz), 3.02 (t, 2H, J = 13.5 
Hz), 3.30 (bs, 4H), 3.63 (bd, 2H, J = 11.5 Hz), 3.94 (s, 3H), 7.35 (d, 1H, J = 8.5 Hz), 7.47 
(d, 1H, J = 8.5 Hz), 7.56 (s, 1H) 7.66 (d, 2H, J = 8.5 Hz), 8.01 (d, 2H, J = 8.5 Hz), 9.92 
(s, 1H).  MS(ESI):  m/z = 403.2 (M+H)+.  HPLC2: tR 12.4 min, Purity 95%.   
 
3'-fluoro-4'-methoxy-biphenyl-4-sulfonic acid (furan-2-ylmethyl)-amide (2.8gb).  
Using the above general procedure, 4-bromo-N-furan-2-ylmethyl-benzenesulfonamide 
(0.25mmol), 3-fluoro-4-methoxyphenylboronic acid(0.30 mmol), sodium carbonate (0.75 
mmol), PS- Pd(Ph3)4 (0.025 mmol) and DME:EtOH:H2O (5 mL) were used to synthesize 
2.8gb as a white solid (98%).  1HNMR (500MHz, DMSO):  δ  3.91 (s, 3H), 4.20 (s, 2H), 
6.18 (s, 1H), 6.31 (t, 1H, J = 2.5 Hz), 7.30 (t, 1H, J = 8.5 Hz), 7.49, (s, 1H), 7.57 (d, 1H, J 
= 9.0 Hz), 7.67 (d, 1H, J = 13.0 Hz), 7.79 (d, 2H, J = 8.5 Hz), 7.84 (d, 2H, J = 8.5 Hz).  
MS(ESI):  m/z = 384.3 (M+Na)+.  HPLC2: tR 13.5 min, Purity 98%.   
 
4'-[(furan-2-ylmethyl)-sulfamoyl]-biphenyl-4-carboxylic acid (2.8gc).  Using the 
above general procedure, 4-bromo-N-furan-2-ylmethyl-benzenesulfonamide (0.25mmol), 
(0.30 mmol), sodium carbonate (0.75 mmol), PS- Pd(Ph3)4 (0.025 mmol) and 
DME:EtOH:H2O (5 mL) were used to synthesize 2.8gc as a white solid (91%).  1HNMR 
(300MHz, MeOD):  δ  4.16 (s, 2H), 6.12 (s, 1H), 6.22 (s, 1H), 7.28 (s, 1H), 7.83 (t, 4H, J 
= 13.5 Hz), 7.91 (d, 2H, J = 14.5 Hz), 8.15 (d, 2H, J = 14.0Hz).  MS(ESI):  m/z = 381.1 
(M+Na)+.  HPLC2: tR 12.3 min, Purity > 99%.   
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5-{4-[(furan-2-ylmethyl)-sulfamoyl]-phenyl}-thiophene-2-carboxylic acid (2.8gd).  
Using the above general procedure, 4-bromo-N-furan-2-ylmethyl-benzenesulfonamide 
(0.25mmol), 5-(dihydroxylboryl)-2-thiophenecarboxylic acid (0.30 mmol), sodium 
carbonate (0.75 mmol), PS- Pd(Ph3)4 (0.025 mmol) and DME:EtOH:H2O (5 mL) were 
used to synthesize 2.8gd as a light yellow solid (34%).  1HNMR (300MHz, MeOD):  δ  
4.15 (s, 2H), 6.11 (s, 1H), 6.21 (s, 1H), 7.27 (s, 1H), 7.57 (d, 1H, J = 6.5 Hz), 7.78 (d, 1H, 
J = 6.5 Hz), 7.84 (bs, 4H).  MS(ESI):  m/z = 386.0 (M+Na)+.  HPLC2: tR 12.3 min, Purity 
94%.   
 
4-benzo[1,3]dioxol-5-yl-N-furan-2-ylmethyl-benzenesulfonamide (2.8ge).  Using the 
above general procedure, 4-bromo-N-furan-2-ylmethyl-benzenesulfonamide (0.25mmol), 
1,3-benxodioxol-5-ylboronic acid (0.30 mmol), sodium carbonate (0.75 mmol), PS- 
Pd(Ph3)4 (0.025 mmol) and DME:EtOH:H2O (5 mL) were used to synthesize 2.8ge as a 
white solid (92%).  1HNMR (500MHz, DMSO):  δ  4.02 (s, 2H), 6.10 (s, 2H), 6.19 (d, 
1H, J = 3.5 Hz), 6.31 (t, 1H, J = 2.5 Hz), 7.05, (d, 1H, J = 8.5 Hz), 7.24 (d, 1H, J = 8.5 
Hz), 7.35 (d, 1H, J = 2.0 Hz), 7.50 (s, 1H), 7.89 (bs, 4H).  MS(ESI):  m/z = 380.1 
(M+Na)+.  HPLC2: tR 13.4 min, Purity 96%.   
 
4-(2,4-dihydroxy-pyrimidin-5-yl)-N-furan-2-ylmethyl-benzenesulfonamide (2.8gg).  
Using the above general procedure, 4-bromo-N-furan-2-ylmethyl-benzenesulfonamide 
(0.25mmol), 2,4-dihydroxypyrimidine-5-boronic acid (0.30 mmol), sodium carbonate 
(0.75 mmol), PS- Pd(Ph3)4 (0.025 mmol) and DME:EtOH:H2O (5 mL) were used to 
synthesize 2.8gg as a white solid (93%).  1HNMR (500MHz, MeOD):  δ  4.18 (s, 2H), 
6.13 (d, 1H, J = 3.0 Hz), 6.24 (t, 1H, J = 3.0 Hz), 7.31 (s, 1H), 7.73 (d, 3H, J = 9.0 Hz), 
7.82 (d, 2H, J = 8.5 Hz).  MS(ESI):  m/z = 370.0 (M+Na)+.  HPLC2: tR 9.8 min, Purity > 
99%.   
 
4-(5-formyl-furan-2-yl)-N-furan-2-ylmethyl-benzenesulfonamide (2.8gh).  Using the 
above general procedure, 4-bromo-N-furan-2-ylmethyl-benzenesulfonamide (0.25mmol), 
5-formyl-2-furylboronic acid (0.30 mmol), sodium carbonate (0.75 mmol), PS- Pd(Ph3)4 
(0.025 mmol) and DME:EtOH:H2O (5 mL) were used to synthesize 2.8gh as a light 
yeallow solid (52%).  1HNMR (300MHz, MeOD):  δ  4.17 (s, 2H), 6.11 (d, 1H, J = 6.5 
Hz), 6.20 (t, 1H, J = 4.5 Hz), 7.26 (d, 2H, J = 6.5 Hz), 7.56, (d, 1H, J = 6.5 Hz), 7.89 (d, 
2H, J = 11.5 Hz), 8.01 (d, 2H, J = 14.5 Hz).  MS(ESI):  m/z = 332.0 (M+H)+.  HPLC2: tR 
13.0 min, Purity 86%.   
 
2'-formyl-4'-methoxy-biphenyl-4-sulfonic acid (furan-2-ylmethyl)-amide (2.8gi).  
Using the above general procedure, 4-bromo-N-furan-2-ylmethyl-benzenesulfonamide 
(0.25mmol), 2-formyl-4-methoxyphenylboronic acid (0.30 mmol), sodium carbonate 
(0.75 mmol), PS- Pd(Ph3)4 (0.025 mmol) and DME:EtOH:H2O (5 mL) were used to 
synthesize 2.8gi as a white solid (92%).  1HNMR (500MHz, MeOD):  δ  3.94 (s, 3H), 
4.21 (s, 2H), 6.11 (d, 1H, J = 3.0 Hz), 6.22 (t, 1H, J = 2.5 Hz), 7.30 (s, 1H), 7.33 (d, 1H, J 
= 8.5 Hz), 7.45, (d, 1H, J = 8.5 Hz), 7.52 (d, 2H, J = 8.5 Hz), 7.54 (d, 1H, J = 3.0 Hz), 
7.89 (d, 2H, J = 8.5 Hz), 9.88 (s, 1H).  MS(ESI):  m/z = 394.4 (M+Na)+.  HPLC2: tR 13.1 
min, Purity 96%.   
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3'-fluoro-4'-methoxy-biphenyl-4-sulfonic acid [3-(2-oxo-pyrrolidin-1-yl)-propyl]-
amide (2.8hb).  Using the above general procedure, 4-bromo-N-[3-(2-oxo-pyrrolidin-1-
yl)-propyl]-benzenesulfonamide (0.25mmol), 3-fluoro-4-methoxyphenylboronic acid 
(0.30 mmol), sodium carbonate (0.75 mmol), PS- Pd(Ph3)4 (0.025 mmol) and 
DME:EtOH:H2O (5 mL) were used to synthesize 2.8hb as a white solid (84%).  1HNMR 
(500MHz, DMSO):  δ  1.57 (m, 2H), 1.86 (m,2H), 2.16 (t, 2H, J = 8.0 Hz), 2.72 (t, 2H, J 
= 7.0 Hz), 3.14 (m, 2H), 3.23 (t, 2H, J = 7.0 Hz), 3.90 ( s, 3H), 7.30 (d, 1H, J = 9.0 Hz), 
7.58 (d, 1H, J = 8.5 Hz), 7.68 (d, 1H, J = 12.0 Hz), 7.82 (d, 2H, J = 6.0 Hz), 7.89 (d, 2H, 
J = 4.5 Hz).  MS(ESI):  m/z = 429.6 (M+Na)+.  HPLC2: tR 13.0 min, Purity 93%.   
 
4'-[3-(2-oxo-pyrrolidin-1-yl)-propylsulfamoyl]-biphenyl-4-carboxylic acid (2.8hc).  
Using the above general procedure, 4-bromo-N-[3-(2-oxo-pyrrolidin-1-yl)-propyl]-
benzenesulfonamide (0.25mmol), 4-carboxylphenylboronic acid (0.30 mmol), sodium 
carbonate (0.75 mmol), PS- Pd(Ph3)4 (0.025 mmol) and DME:EtOH:H2O (5 mL) were 
used to synthesize 2.8hc as a white solid (72%).  1HNMR (500MHz, MeOD):  δ  1.74 (m, 
2H), 2.03 (m, 2H), 2.36 (t, 2H, J = 8.0 Hz), 2.91 (t, 2H, J = 7.0 Hz), 3.33 (m, 2H), 3.43 (t, 
2H, J = 7.5 Hz), 7.83 (d, 2H, J = 6.0 Hz), 7.92 (d, 2H, J = 4.0 Hz), 7.98 (d, 2H, J = 4.0 
Hz), 8.17 (d, 2H, J = 4.0 Hz).  MS(ESI):  m/z = 403.5 (M+H)+.  HPLC2: tR 11.6 min, 
Purity 85%.   
 
4-benzo[1,3]dioxol-5-yl-N-[3-(2-oxo-pyrrolidin-1-yl)-propyl]-benzenesulfonamide 
(2.8he).  Using the above general procedure, 4-bromo-N-[3-(2-oxo-pyrrolidin-1-yl)-
propyl]-benzenesulfonamide (0.25mmol), 1,3-benxodioxol-5-ylboronic acid (0.30 mmol), 
sodium carbonate (0.75 mmol), PS- Pd(Ph3)4 (0.025 mmol) and DME:EtOH:H2O (5 mL) 
were used to synthesize 2.8he as a light yellow solid (97%).  1HNMR (500MHz, DMSO):  
δ  1.57 (m, 2H), 1.85 (m, 2H), 2.16 (t, 2H, J = 8.0 Hz), 2.71 (t, 2H, J = 7.0 Hz), 3.13 (m, 
2H), 3.23 (t, 2H, J = 7.0 Hz), 6.09 ( s, 2H), 7.04 (d, 1H, J = 8.0 Hz), 7.24 (d, 1H, J = 8.0 
Hz), 7.35 (s, 1H), 7.80 (d, 2H, J = 9.0 Hz), 7.84 (d, 2H, J = 9.0 Hz).  MS(ESI):  m/z = 
425.6 (M+Na)+.  HPLC2: tR 12.8 min, Purity 97%.   
 
4-(3,5-dimethyl-isoxazol-4-yl)-N-[3-(2-oxo-pyrrolidin-1-yl)-propyl]-
benzenesulfonamide (2.8hf).  Using the above general procedure, 4-bromo-N-[3-(2-oxo-
pyrrolidin-1-yl)-propyl]-benzenesulfonamide (0.25mmol), 3,5-dimethyl-4-
isoxazolylboronic acid (0.30 mmol), sodium carbonate (0.75 mmol), PS- Pd(Ph3)4 (0.025 
mmol) and DME:EtOH:H2O (5 mL) were used to synthesize 2.8hf as a light yellow solid 
(53%).  1HNMR (500MHz, MeOD):  δ  1.75 (m, 2H), 2.04 (m, 2H), 2.31(s, 3H), 2.37 (t, 
2H, J = 8.0 Hz), 2.48 (s, 3H), 2.91 (t, 2H, J = 7.0 Hz), 3.33 (m, 2H), 3.45 (t, 2H, J = 7.0 
Hz), 7.60 (d, 2H, J = 8.5 Hz), 7.96 (d, 2H, J = 8.5 Hz).  MS(ESI):  m/z = 378.1 (M+H)+.  
HPLC2: tR 11.7 min, Purity 82%.   
 
4-(2,4-dihydroxy-pyrimidin-5-yl)-N-[3-(2-oxo-pyrrolidin-1-yl)-propyl]-
benzenesulfonamide (2.8hg).  Using the above general procedure, 4-bromo-N-[3-(2-
oxo-pyrrolidin-1-yl)-propyl]-benzenesulfonamide (0.25mmol), 2,4-dihydroxypyrimidine-
5-boronic acid (0.30 mmol), sodium carbonate (0.75 mmol), PS- Pd(Ph3)4 (0.025 mmol) 
and DME:EtOH:H2O (5 mL) were used to synthesize 2.8hg as a white solid (72%).  
1HNMR (500MHz, MeOD):  δ  1.71 (m, 2H), 2.03 (m, 2H), 2.36 (t, 2H, J = 8.0 Hz), 2.87 
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(t, 2H, J = 7.0 Hz), 3.30 (m, 2H), 3.42 (t, 2H, J = 7.0 Hz), 7.75 (s, 1H), 7.79 (d, 2H, J = 
9.0 Hz), 7.86 (d, 2H, J = 8.5 Hz).  MS(ESI):  m/z = 393.1 (M+H)+.  HPLC2: tR 9.2 min, 
Purity > 99%.   
 
2'-formyl-4'-methoxy-biphenyl-4-sulfonic acid [3-(2-oxo-pyrrolidin-1-yl)-propyl]-
amide (2.8hi).  Using the above general procedure, 4-bromo-N-[3-(2-oxo-pyrrolidin-1-
yl)-propyl]-benzenesulfonamide (0.25mmol), 2-formyl-4-methoxyphenylboronic acid 
(0.30 mmol), sodium carbonate (0.75 mmol), PS- Pd(Ph3)4 (0.025 mmol) and 
DME:EtOH:H2O (5 mL) were used to synthesize 2.8hi as a yellow solid (35%).  1HNMR 
(500MHz, MeOD):  δ  1.74 (m, 2H), 2.04 (m, 2H), 2.37 (t, 2H, J = 8.0 Hz), 2.94 (t, 2H, J 
= 6.5 Hz), 3.32 (m, 2H), 3.45 (t, 2H, J = 7.0 Hz), 3.94 (s, 3H), 7.33 (d, 1H, J = 8.5 Hz), 
7.47 (d, 1H, J = 8.5 Hz), 7.55 (d, 1H, J = 3.0 Hz), 7.61 (d, 2H, J = 8.5 Hz), 7.97 (d, 2H, J 
= 8.0 Hz), 9.91 (s, 1H).  MS(ESI):  m/z = 417.3 (M+H)+.  HPLC2: tR 12.6 min, Purity > 
81%.     
 
3'-fluoro-4'-methoxy-biphenyl-4-sulfonic acid (6-methoxy-pyrimidin-4-yl)-amide 
(2.8ib).  Using the above general procedure, 4-bromo-N-(6-methoxy-pyrimidin-4-yl)-
benzenesulfonamide (0.25mmol), 3-fluoro-4-methoxyphenylboronic acid(0.30 mmol), 
sodium carbonate (0.75 mmol), PS- Pd(Ph3)4 (0.025 mmol) and DME:EtOH:H2O (5 mL) 
were used to synthesize 2.8ib as a white solid (88%).  1HNMR (300MHz, DMSO):  δ  
3.68 (s, 3H), 3.88 (s, 3H), 5.92 (s, 1H), 7.25 (t, 1H, J = 9.0 Hz), 7.49 (d, 1H, J = 8.5 Hz), 
7.58 (d, 1H, J = 13.0 Hz), 7.67 (d, 2H, J = 4.0 Hz), 7.76 (d, 2H, J = 5.0 Hz), 8.04 (s, 1H).  
MS(ESI):  m/z = 387.9 (M-H)-.  HPLC2: tR 12.9 min, Purity > 99%.   
 
4'-(6-methoxy-pyrimidin-4-ylsulfamoyl)-biphenyl-4-carboxylic acid (2.8ic).  Using 
the above general procedure, 4-bromo-N-(6-methoxy-pyrimidin-4-yl)-
benzenesulfonamide (0.25mmol), 4-carboxylphenylboronic acid (0.30 mmol), sodium 
carbonate (0.75 mmol), PS- Pd(Ph3)4 (0.025 mmol) and DME:EtOH:H2O (5 mL) were 
used to synthesize 2.8ic as a white solid (78%).  1HNMR (300MHz, DMSO):  δ  3.68 (s, 
3H), 5.93 (s, 1H), 7.60 (d, 2H, J = 8.0 Hz), 7.69 (d, 2H, J = 8.5 Hz), 7.79 (d, 2H, J = 8.0 
Hz), 7.95 (d, 2H, J = 8.0 Hz), 8.04 (s, 1H).  MS(ESI):  m/z = 386.1 (M+H)+.  HPLC2: tR 
11.5 min, Purity 90%.   
 
4-benzo[1,3]dioxol-5-yl-N-(6-methoxy-pyrimidin-4-yl)-benzenesulfonamide (2.8ie).  
Using the above general procedure, 4-bromo-N-(6-methoxy-pyrimidin-4-yl)-
benzenesulfonamide (0.25mmol), 1,3-benxodioxol-5-ylboronic acid (0.30 mmol), sodium 
carbonate (0.75 mmol), PS- Pd(Ph3)4 (0.025 mmol) and DME:EtOH:H2O (5 mL) were 
used to synthesize 2.8ie as a white solid (81%).  1HNMR (300MHz, DMSO):  δ  3.68 (s, 
3H), 5.93 (s, 1H), 6.06 (s, 2H), 6.99 (d, 1H, J = 8.0 Hz), 7.17 (d, 1H, J = 8.0 Hz), 7.27 (s, 
1H), 7.62 (d, 2H, J = 8.5 Hz), 7.75 (d, 2H, J = 8.5 Hz), 8.04 (s, 1H).  MS(ESI):  m/z = 
384.0 (M-H)-.  HPLC2: tR 12.7 min, Purity > 99%.   
 
4-(3,4-dimethyl-isoxazol-5-yl)-N-(6-methoxy-pyrimidin-4-yl)-benzenesulfonamide 
(2.9if).  Using the above general procedure, 4-bromo-N-(6-methoxy-pyrimidin-4-yl)-
benzenesulfonamide (0.25mmol), 3,5-dimethyl-4-isoxazolylboronic acid (0.30 mmol), 
sodium carbonate (0.75 mmol), PS- Pd(Ph3)4 (0.025 mmol) and DME:EtOH:H2O (5 mL) 
 71  
were used to synthesize 2.8if as a light yellow solid (47%).  1HNMR (500MHz, CDCl3):  
δ  2.29 (s, 3H), 2.44 (s, 3H), 4.00 (s, 3H), 6.64 (s, 1H), 7.41 (d, 2H, J = 8.5 Hz), 8.01 (d, 
2H, J = 8.0 Hz), 8.56 (s, 1H).  MS(ESI):  m/z = 361.1 (M+H)+.  HPLC2: tR 11.4 min, 
Purity 83%.   
 
4-(3,4-dimethyl-isoxazol-5-yl)-N-(6-methoxy-pyrimidin-4-yl)-benzenesulfonamide 
(2.8ig).  Using the above general procedure, 4-bromo-N-(6-methoxy-pyrimidin-4-yl)-
benzenesulfonamide (0.25mmol), 2,4-dihydroxypyrimidine-5-boronic acid (0.30 mmol), 
sodium carbonate (0.75 mmol), PS- Pd(Ph3)4 (0.025 mmol) and DME:EtOH:H2O (5 mL) 
were used to synthesize 2.8ig as a white solid (71%).  1HNMR (500MHz, CDCl3):  δ  
3.93 (s, 3H), 6.48 (s, 1H), 7.59 (d, 2H, J = 8.0 Hz),  7.65 (s, 1H), 8.00 (d, 2H, J = 7.0 Hz), 
8.33 (s, 1H).  MS(ESI):  m/z = 376.0 (M+H)+.  HPLC2: tR 10.1 min, Purity 87%.   
 
4-(5-formyl-furan-2-yl)-N-(6-methoxy-pyrimidin-4-yl)-benzenesulfonamide (2.8ih).  
Using the above general procedure, 4-bromo-N-(6-methoxy-pyrimidin-4-yl)-
benzenesulfonamide (0.25mmol), 5-formyl-2-furylboronic acid (0.30 mmol), sodium 
carbonate (0.75 mmol), PS- Pd(Ph3)4 (0.025 mmol) and DME:EtOH:H2O (5 mL) were 
used to synthesize 2.8ih as a light yellow solid (57%).  1HNMR (500MHz, CDCl3):  δ  
3.93 (s, 3H), 6.47 (s, 1H), 7.57 (d, 1H, J = 7.5 Hz), 7.58 (d, 2H, J = 8.0 Hz), 7.65  (d, 1H, 
J = 7.0 Hz), 8.00 (d, 2H, J = 7.5 Hz), 8.33 (s, 1H).  MS(ESI):  m/z = 360.0 (M+H)+.  
HPLC2: tR 10.1 min, Purity 80%.   
 
2'-formyl-4'-methoxy-biphenyl-4-sulfonic acid (6-methoxy-pyrimidin-4-yl)-amide 
(2.8ii).  Using the above general procedure, 4-bromo-N-(6-methoxy-pyrimidin-4-yl)-
benzenesulfonamide (0.25mmol), 2-formyl-4-methoxyphenylboronic acid (0.30 mmol), 
sodium carbonate (0.75 mmol), PS- Pd(Ph3)4 (0.025 mmol) and DME:EtOH:H2O (5 mL) 
were used to synthesize 2.8ii as a white solid (75%).  1HNMR (300MHz, DMSO):  δ  
3.69 (s, 3H), 3.87 (s, 3H), 5.96 (s, 1H), 7.31 – 7.489 (m, 3H), 7.40 (d, 2H, J = 7.5 Hz), 
7.83 (d, 2H, J = 8.0 Hz), 8.04 (s, 1H), 9.83 (s, 1H).  MS(ESI):  m/z = 398.0 (M-H)-.  
HPLC2: tR 12.3 min, Purity > 99%.   
 
3'-fluoro-4'-methoxy-biphenyl-4-sulfonic acid benzothiazol-6-ylamide (2.8jb).  Using 
the above general procedure, N-(2-hydroxy-1-methyl-2,2-diphenyl-ethyl)-3-(5-methyl-
[1,3,4]oxadiazol-2-yl)-benzenesulfonamide (0.25mmol), 3-fluoro-4-
methoxyphenylboronic acid (0.30 mmol), sodium carbonate (0.75 mmol), PS- Pd(Ph3)4 
(0.025 mmol) and DME:EtOH:H2O (5 mL) were used to synthesize 2.8jb as a yellow 
solid (65%).  1HNMR (500MHz, MeOD):  δ  3.92 (s, 3H), 7.15 (t, 1H, J = 9.0 Hz), 7.23-
7.27 (m, 2H), 7.30 (dd, 1H, J = 2.0, 8.5 Hz), 7.54 (t, 1H, J = 8.0 Hz), 7.72 (d, 1H, J = 7.5 
Hz),  7.88 (d, 1H, J = 8.0 Hz), 7.88-7.90 (m, 2H), 7.94 (d, 1H, J = 9.0 Hz), 9.17 (s, 1H).  
MS(ESI):  m/z = 415.1 (M+H)+.  HPLC2: tR 13.6 min, Purity > 99%.   
 
4'-(benzothiazol-6-ylsulfamoyl)-biphenyl-4-carboxylic acid (2.8jc).  Using the above 
general procedure, N-(2-hydroxy-1-methyl-2,2-diphenyl-ethyl)-3-(5-methyl-
[1,3,4]oxadiazol-2-yl)-benzenesulfonamide (0.25mmol), 4-carboxylphenylboronic acid 
(0.30 mmol), sodium carbonate (0.75 mmol), PS- Pd(Ph3)4 (0.025 mmol) and 
DME:EtOH:H2O (5 mL) were used to synthesize 2.8jc as a yellow solid (48%).  1HNMR 
 72  
(500MHz, MeOD):  δ  7.31 (dd, 1H, J = 2.0, 8.5 Hz), 7.49 (t, 1H, J = 8.0 Hz), 7.60 (d, 
2H, J = 8.0 Hz), 7.81 (d, 1H, J = 7.5 Hz), 7.89 (d, 1H, J = 8.0 Hz), 7.91 (d, 1H, J = 2.0 
Hz), 7.95 (d, 1H, J = 9.0 Hz), 7.99 (t, 1H, J = 2.0 Hz), 8.09 (d, 2H, J = 8.5), 9.17 (s, 1H).  
MS(ESI):  m/z = 411.1 (M+H)+.  HPLC2: tR 12.4 min, Purity 89%.   
 
5-[4-(benzothiazol-6-ylsulfamoyl)-phenyl]-thiophene-2-carboxylic acid (2.8jd).  
Using the above general procedure, N-(2-hydroxy-1-methyl-2,2-diphenyl-ethyl)-3-(5-
methyl-[1,3,4]oxadiazol-2-yl)-benzenesulfonamide (0.25mmol), 5-(dihydroxylboryl)-2-
thiophenecarboxylic acid (0.30 mmol), sodium carbonate (0.75 mmol), PS- Pd(Ph3)4 
(0.025 mmol) and DME:EtOH:H2O (5 mL) were used to synthesize 2.8jd as a yellow 
solid (49%).  1HNMR (500MHz, MeOD):  δ  7.29 (dd, 1H, J = 2.0, 8.5 Hz), 7.49 (t, 2H, J 
= 7.5 Hz), 7.57 (d, 1H, J = 7.5 Hz), 7.79 (d, 2H, J = 8.5 Hz), 7.84 (d, 1H, J = 8.5 Hz), 
7.91 (d, 1H, J = 2.0 Hz), 9.15 (s, 1H).  MS(ESI):  m/z = 417.0 (M+H)+.  HPLC2: tR 11.7 
min, Purity 88%.   
 
4-benzo[1,3]dioxol-5-yl-N-benzothiazol-6-yl-benzenesulfonamide (2.8je).  Using the 
above general procedure, N-(2-hydroxy-1-methyl-2,2-diphenyl-ethyl)-3-(5-methyl-
[1,3,4]oxadiazol-2-yl)-benzenesulfonamide (0.25mmol), 1,3-benxodioxol-5-ylboronic 
acid (0.30 mmol), sodium carbonate (0.75 mmol), PS- Pd(Ph3)4 (0.025 mmol) and 
DME:EtOH:H2O (5 mL) were used to synthesize 2.8je as a yellow solid (67%). 1HNMR 
(500MHz, MeOD):  δ  6.01 (s, 2H), 6. 95 (d, 1H, J = 8.5 Hz), 7.30 (dd, 1H, J = 2.0, 8.5 
Hz), 7.52 (t, 1H, J = 8.0 Hz), 7.70 (d, 1H, J = 7.5 Hz), 7.74 (d, 2H, J = 7.5 Hz), 7.85 (d, 
1H, J = 2.0 Hz), 7.89 (d, 1H, J = 2.0 Hz), 7.94 (d, 1H, J = 8.5 Hz), 9.17 (s, 1H).  
MS(ESI):  m/z = 411.1 (M+H)+.  HPLC2: tR 13.4 min, Purity > 99%.   
 
N-benzothiazol-6-yl-4-(3,4-dimethyl-isoxazol-5-yl)-benzenesulfonamide (2.8jf).  
Using the above general procedure, N-(2-hydroxy-1-methyl-2,2-diphenyl-ethyl)-3-(5-
methyl-[1,3,4]oxadiazol-2-yl)-benzenesulfonamide (0.25mmol), 3,5-dimethyl-4-
isoxazolylboronic acid (0.30 mmol), sodium carbonate (0.75 mmol), PS- Pd(Ph3)4 (0.025 
mmol) and DME:EtOH:H2O (5 mL) were used to synthesize 2.8jf as a yellow solid 
(84%).  1HNMR (500MHz, MeOD):  δ  2.02 (s, 3H), 2.19 (s, 3H), 7.30 (dd, 1H, J = 2.0, 
8.5 Hz), 7.56 (d, 1H, J = 8.0 Hz), 7.64 (t, 1H, J = 7.5 Hz),  7.87 (d, 1H, J = 7.5 Hz), 7.91 
(d, 1H, J = 2.0 Hz), 7.94 (d, 1H, J = 9.0 Hz), 9.29 (s, 1H).  MS(ESI):  m/z = 386.0 
(M+H)+.  HPLC2: tR 12.5 min, Purity 94%.   
 
N-benzothiazol-6-yl-4-(2,4-dihydroxy-pyrimidin-5-yl)-benzenesulfonamide (2.8jg).  
Using the above general procedure, N-(2-hydroxy-1-methyl-2,2-diphenyl-ethyl)-3-(5-
methyl-[1,3,4]oxadiazol-2-yl)-benzenesulfonamide (0.25mmol), 2,4-
dihydroxypyrimidine-5-boronic acid (0.30 mmol), sodium carbonate (0.75 mmol), PS- 
Pd(Ph3)4 (0.025 mmol) and DME:EtOH:H2O (5 mL) were used to synthesize 2.8jg as a 
light yellow solid (58%).  1HNMR (500MHz, MeOD):  δ  7.31 (dd, 1H, J = 2.0, 9.0 Hz), 
7.48 (t, 1H, J = 7.5 Hz), 7.59 (s, 1H), 7.69 (d, 1H, J = 7.5 Hz),  7.73 (d, 1H, J = 8.0 Hz), 
7.87 (d, 1H, J = 2.5 Hz), 7.91 (d, 1H, J = 8.5 Hz), 8.10 (t, 1H, J = 2.0 Hz), 9.15 (s, 1H).  
MS(ESI):  m/z = 401.0 (M+H)+.  HPLC2: tR 10.4 min, Purity > 99%.   
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N-benzothiazol-6-yl-4-(5-formyl-furan-2-yl)-benzenesulfonamide (2.8jh).  Using the 
above general procedure, N-(2-hydroxy-1-methyl-2,2-diphenyl-ethyl)-3-(5-methyl-
[1,3,4]oxadiazol-2-yl)-benzenesulfonamide (0.25mmol), 5-formyl-2-furylboronic acid 
(0.30 mmol), sodium carbonate (0.75 mmol), PS- Pd(Ph3)4 (0.025 mmol) and 
DME:EtOH:H2O (5 mL) were used to synthesize 2.8jh as a yellow solid (64%).  1HNMR 
(500MHz, MeOD):  δ  7.27 (dd, 1H, J = 2.0, 9.0 Hz), 7.49 (t, 2H, J = 8.0 Hz), 7.57 (t, 1H, 
J = 7.0 Hz), 7.79 (d, 1H, J = 8.5 Hz), 7.84 (d, 2H, J = 2.0 Hz), 7.91 (d, 1H, J = 8.5 Hz), 
9.15 (s, 1H).  MS(ESI):  m/z = 384.6 (M-H)-.  HPLC2: tR 11.7 min, Purity > 99%.   
 
2-(3'-fluoro-4'-methoxy-biphenyl-4-sulfonylamino)-3-phenyl-propionic acid (2.8kb).  
Using the above general procedure, 2-(4-bromo-benzenesulfonylamino)-3-phenyl-
propionic acid methyl ester (0.25mmol), 3-fluoro-4-methoxyphenylboronic acid 
 (0.30 mmol), sodium carbonate (0.75 mmol), PS- Pd(Ph3)4 (0.025 mmol) and 
DME:EtOH:H2O (5 mL) were used to synthesize 2.8kb as a light yellow solid (77%).  
1HNMR (500MHz, MeOD):  δ  2.90 (dd, 1H, J = 4.0, 13.0 Hz), 3.06 (dd, 1H, J = 5.5, 
13.0 Hz), 3.90 (s, 3H), 4.10 (m, 1H), 7.15 (m, 5H), 7.28 (t, 1H, J = 9.0 Hz), 7.56 (d, 1H, J 
= 9.0 Hz), 7.66 (d, 1H, J = 13.0 Hz), 7.75 (d, 2H, J = 8.5 Hz), 7.82 (d, 2H, J = 8.5 Hz).  
MS(ESI):  m/z = 427.9 (M-H)-.  HPLC2: tR 13.3 min, Purity > 99%.   
 
4'-(1-carboxy-2-phenyl-ethylsulfamoyl)-biphenyl-4-carboxylic acid (2.8kc).  Using 
the above general procedure, 2-(4-bromo-benzenesulfonylamino)-3-phenyl-propionic 
acid methyl ester (0.25mmol), 4-carboxylphenylboronic acid (0.30 mmol), sodium 
carbonate (0.75 mmol), PS- Pd(Ph3)4 (0.025 mmol) and DME:EtOH:H2O (5 mL) were 
used to synthesize 2.8kc as a white solid (70%).  1HNMR (500MHz, MeOD):  δ  2.93 (d, 
1H, J = 11.0 Hz), 3.05 (d, 1H, J = 12.0 Hz), 4.10 (m, 1H), 7.18 (m, 5H), 7.66 (d, 2H, J = 
7.0 Hz), 7.80 (bs,4H), 8.00 (d, 2H, J = 6.5 Hz).  MS(ESI):  m/z = 423.9 (M-H)-.  HPLC2: 
tR 12.2 min, Purity 93%.   
 
5-[4-(1-carboxy-2-phenyl-ethylsulfamoyl)-phenyl]-thiophene-2-carboxylic acid 
(2.8kd).  Using the above general procedure, 2-(4-bromo-benzenesulfonylamino)-3-
phenyl-propionic acid methyl ester (0.25mmol), 5-(dihydroxylboryl)-2-
thiophenecarboxylic acid (0.30 mmol), sodium carbonate (0.75 mmol), PS- Pd(Ph3)4 
(0.025 mmol) and DME:EtOH:H2O (5 mL) were used to synthesize 2.8kd as a yellow 
solid (55%).  1HNMR (500MHz, MeOD):  δ  2.88 (dd, 1H, J = 8.5, 14.0 Hz), 3.10 (dd, 
1H, J = 5.5, 14.0 Hz), 4.10 (m, 1H), 7.18 (m, 5H), 7.53 (d, 1H, J = 9.0 Hz), 7.57 (d, 1H, J 
= 9.0), 7.71 (d, 2H, J = 8.5 Hz), 7.77 (d, 2H, J = 6.5 Hz).  MS(ESI):  m/z = 432.1 
(M+H)+.  HPLC2: tR 12.7 min, Purity 80%.   
 
2-(4-benzo[1,3]dioxol-5-yl-benzenesulfonylamino)-3-phenyl-propionic acid (2.8ke).  
Using the above general procedure, 2-(4-bromo-benzenesulfonylamino)-3-phenyl-
propionic acid methyl ester (0.25mmol), 1,3-benxodioxol-5-ylboronic acid (0.30 mmol), 
sodium carbonate (0.75 mmol), PS- Pd(Ph3)4 (0.025 mmol) and DME:EtOH:H2O (5 mL) 
were used to synthesize 2.8ke as a light yellow solid (65%)  1HNMR (500MHz, MeOD):  
δ  2.92 (d, 1H, J = 13.0 Hz), 3.06 (d, 1H, J = 11.5 Hz), 4.10 (m, 1H), 6.09 (s, 2H), 7.13 
(d, 1H, J = 8.5 Hz), 7.17 (m, 5H), 7.23 (d, 1H, J = 8.5 Hz), 7.33 (s, 1H), 7.74 (bs,4H).  
MS(ESI):  m/z = 423.9 (M-H)-.  HPLC2: tR 13.2 min, Purity 91%.   
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2-[4-(3,4-dimethyl-isoxazol-5-yl)-benzenesulfonylamino]-3-phenyl-propionic acid 
(2.8kf).  Using the above general procedure, 2-(4-bromo-benzenesulfonylamino)-3-
phenyl-propionic acid methyl ester (0.25mmol), 3,5-dimethyl-4-isoxazolylboronic acid 
(0.30 mmol), sodium carbonate (0.75 mmol), PS- Pd(Ph3)4 (0.025 mmol) and 
DME:EtOH:H2O (5 mL) were used to synthesize 2.8kf as a yellow solid (74%).  1HNMR 
(500MHz, MeOD):  δ  2.34 (s, 3H), 2.36 (s, 3H), 2.84 (dd, 1H, J = 9.0, 14.0 Hz), 3.09 
(dd, 1H, J = 5.0, 14.0 Hz), 4.06 (m, 1H), 7.17 (m, 5H), 7.53 (d, 2H, J = 4.5 Hz), 7.57 (d, 
2H, J = 9.0 Hz).  MS(ESI):  m/z = 401.1 (M+H)+.  HPLC2: tR 12.2 min, Purity 83%.   
 
2-[4-(2,4-dihydroxy-pyrimidin-5-yl)-benzenesulfonylamino]-3-phenyl-propionic acid 
(2.8kg).  Using the above general procedure, 2-(4-bromo-benzenesulfonylamino)-3-
phenyl-propionic acid methyl ester (0.25mmol), 2,4-dioxoheahyropyrimidin-5-yl boronic 
acid (0.30 mmol), sodium carbonate (0.75 mmol), PS- Pd(Ph3)4 (0.025 mmol) and 
DME:EtOH:H2O (5 mL) were used to synthesize 2.8kg as a white solid (84%).  1HNMR 
(500MHz, MeOD):  δ  2.88 (dd, 1H, J = 8.5, 14.0 Hz), 3.08 (dd, 1H, J = 6.0, 13.5 Hz), 
4.07 (m, 1H), 7.18 (m, 5H), 7.64 (d, 2H, J = 9.0 Hz), 7.68 (d, 2H, J = 9.0 Hz), 7.70 (s, 
1H).  MS(ESI):  m/z = 416.1 (M+H)+.  HPLC2: tR 10.2 min, Purity > 99%.   
 
2-[4-(5-formyl-furan-2-yl)-benzenesulfonylamino]-3-phenyl-propionic acid (2.8kh).  
Using the above general procedure, 2-(4-bromo-benzenesulfonylamino)-3-phenyl-
propionic acid methyl ester (0.25mmol), 5-formyl-2-furylboronic acid (0.30 mmol), 
sodium carbonate (0.75 mmol), PS- Pd(Ph3)4 (0.025 mmol) and DME:EtOH:H2O (5 mL) 
were used to synthesize 2.8kh as a light yellow solid (78%).  1HNMR (500MHz, MeOD):  
δ  2.89 (dd, 1H, J = 8.5, 14.0 Hz), 3.10 (dd, 1H, J = 5.0, 13.5 Hz), 4.10 (m, 1H), 7.18 (m, 
5H), 7.53 (d, 1H, J = 8.5 Hz), 7.57 (d, 1H, J = 9.0 Hz), 7.71 (d, 2H, J = 8.5 Hz), 7.77 (d, 
2H, J = 8.5 Hz).  MS(ESI):  m/z = 400.1 (M+H)+.  HPLC2: tR 12.7 min, Purity 86%.  
HPLC(254nm) 86%, rt = 12.717. 
 
2-(2'-formyl-4'-methoxy-biphenyl-4-sulfonylamino)-3-phenyl-propionic acid (2.8ki).  
Using the above general procedure, 2-(4-bromo-benzenesulfonylamino)-3-phenyl-
propionic acid methyl ester (0.25mmol), 2-formyl-4-methoxyphenylboronic acid (0.30 
mmol), sodium carbonate (0.75 mmol), PS- Pd(Ph3)4 (0.025 mmol) and DME:EtOH:H2O 
(5 mL) were used to synthesize 2.8ki as a white solid (86%).  1HNMR (500MHz, 
MeOD):  δ  2.89 (dd, 1H, J = 9.0, 13.5 Hz), 3.11 (dd, 1H, J = 5.5, 13.5 Hz), 3.94 (s, 3H), 
4.11 (m, 1H), 7.21 (m, 6H), 7.33 (d, 1H, J = 8.5 Hz), 7.43 (d, 1H, J = 9.5 Hz), 7.75 (d, 
2H, J = 8.5 Hz), 7.82 (d, 2H, J = 8.5 Hz).  MS(ESI):  m/z = 440.1 (M+H)+.  HPLC2: tR 
13.0 min, Purity > 99%. 
 
 
MIC Determinations  
 
MIC values of the bi-aryl sulfonamides against M. tuberculosis H37Rv were 
determined by the micro broth dilution method according to NCCLS guidelines.  A broth 
culture of M. tuberculosis was grown in Middlebrook 7H9 medium with 10% ADC 
supplement to an OD600 of 0.4-0.6.  The culture was diluted with 7H9 medium to an 
OD600 of 0.01, and 100 µL of these cells was then added to a microtiter plate containing 
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serial dilutions of the nitrofuranyl amides for a final volume of 200 µL.  The plates were 
incubated at 37 °C for 7 days. The MIC90 was determined by visual inspection for wells 
with greater than 90% inhibition of growth. 
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CHAPTER 3:  NOVEL INHIBITORS OF PHOSPHOLIPID BIOSYNTHESIS IN 
GRAM-POSITIVE BACTERIA 
 
 
Introduction  
 
The widespread occurrence of resistance to current antibiotics by gram-positive 
bacteria, including methicillin resistant Staphylococcus aureus (MRSA), vancomycin 
resistant Enterococcus (VRE) and macrolide resistant Streptococcus pneumoniae, 
exemplifies the urgent need for the development of new antimicrobials to combat the 
growing menace of complicated infections.53  The sequencing of bacterial genomes has 
identified many new drug targets with the promise of introducing novel classes of drugs 
with different modes of action to overcome the problems associated with current 
therapies while avoiding cross-resistance.148  Among these attractive targets are the 
unique enzymes involved in the biosynthesis of lipids in bacteria.88, 149, 150  Accordingly, 
this chapter involves the design of inhibitors of bacterial phospholipid biosynthesis.    
 
 
Phospholipid Biosynthesis 
 
 Phospholipids are abundant and essential membrane components in all bacterial 
species.  They form the structural elements of the cell membrane, and disruption of their 
biosynthesis results in cell death.151  Phosphatidic acid is a key intermediate in the 
biosynthesis of bacterial membrane phospholipids, and is formed by the acylation of sn-
glycerol-3-phosphate (G3P).152  In E. coli, phosphatidic acid biosynthesis is initiated by 
the PlsB acyltransferase that transfers a fatty acid from acyl-acyl carrier protein (ACP) to 
the 1-position of G3P (Figure 3.1a).152  There are a number of PlsB homologs in animals 
that perform the same function; however, PlsB is not universally expressed in bacteria.153  
Specifically, it is not found in the clinically important Gram-positive bacteria, such as S. 
pneumonia and S. aureus.153  In some bacteria, such as Pseudomonas aeruginosa, the 
plsB gene is non-essential154 demonstrating the presence of an alternate pathway to the 
initiation of phosphatidic acid biosynthesis.       
 
 
Discovery of PlsX/PlsY 
 
Using S. pneumoniae as a representative, an alternate two-step pathway was 
recently discovered that is required for G3P acylation in Gram-positive pathogens (Figure 
3.1b).153 The first step is catalyzed by PlsX, a soluble phosphate:acyl-ACP 
acyltransferase, that produces an acylphosphate (acyl-PO4) intermediate.  The second step 
is catalyzed by PlsY, an integral transmembrane acyl-PO4:G3P acyltransferase that 
transfers the acyl group from acyl-PO4 to the 1-position of G3P.  The PlsX/PlsY pathway 
is the only route to membrane phospholipids in Firmicutes (Figure 3.2),153 which include 
the most clinically important Gram-positive bacteria, including Staphylococci, 
Streptococci, and Enterococci.155  Importantly, there are no mammalian homologs of the  
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Figure 3.1:  Phosphatidic Acid Formation.  (a) Pathway in E. coli. (b) Pathway in S. 
pneumoniae. 
 
 
 
 
 
Figure 3.2:  Distribution of pls Genes in Bacteria 
 
Permission to reprint from:  Lu, Y.J.; Zhang, Y.M.; Grimes K.D.; Qi, J.; Lee, R.E.; Rock 
C.O., Acyl-Phosphates Initiate Membrane Phospholipid Synthesis in Gram-Positive 
Pathogens. Molecular Cell 2006, 23, 765-72.153 
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PlsX/PlsY pathway making it an attractive target for drug discovery.153  PlsC, is 
universally expressed in bacteria and completes the synthesis of phosphatidic acid by 
transferring an acyl chain from acyl-ACP to the 2-position of 1-acyl-G3P (Figure 3.1).153   
 
 
Synthesis of Substrate 
  
 Research performed in this section began with the synthesis of monopalmitoyl 
phosphate, a biosynthetic intermediate used to validate the function of PlsX and PlsY 
(Scheme 3.1).153  Though it seemed as if the synthesis of this substrate would be 
straightforward, it proved to be quite challenging due to the product’s high lability and 
contrasting solubilities of the reagents.  The synthesis of monopalmitoyl phosphate was 
finally achieved using the method of Lehninger (Scheme 3.1).156 Silver phosphate was 
reacted with anhydrous phosphoric acid in diethyl ether to form the monosilver phosphate 
salt.  Next, palmitoyl chloride 3.1 in diethyl ether was added drop-wise to the resulting 
mixture generating the desired crude product.  The resulting mixture was concentrated 
then recrystalized in warm benzene yielding monopalmitoyl phosphate 3.2 as a white 
powder with a 24% yield.   
 
 
Design of Substrate Mimics   
 
Studies performed by our collaborators at St. Jude Children’s Research Hospital 
established that, in S. pneumoniae, two types of fatty acids were found at the first position 
of bacterial phospholipids:  palmitic acid and cis-vaccenic acid.153  This information 
initiated the design and synthesis of acylphosphate mimetics as inhibitors of this newly 
discovered pathway.  We focused on designing novel inhibitors of this pathway through 
the synthesis of stabilized homologs of the acyl-PO4 intermediate utilizing bioisosteric 
replacement strategies for the highly labile acyl-PO4 group.  We began with the synthesis 
of known bioisosteric replacement strategies for the labile phosophate moiety in the form 
of phosphonates and phosphoramides containing the palmitic and cis-vaccenic acid 
groups.  From analysis of the activity in this initial study, we learned that these 
compounds were good inhibitors of S. pneumoniae PlsY (SpPlsY).  With this success, we 
decided to design and synthesize an expanded set of potential substrate-based inhibitors 
which included a series of phosphonates, phosphoramides, difluoromethyl phosphonates, 
and reverse-amide phosphonates having both saturated and unsaturated acyl chains of 
various lengths, as well as the replacement of the acyl chain with various aromatic and 
nonaromatic ring systems to further probe this pathway.   
 
During our efforts to synthesize substrate mimics, we encountered the work of 
Aldrich et al., showing the design and the synthesis of non-ribosomal tRNA synthetase 
inhibitors, whose substrate was similar to the PlsY acylphosphate substrate.157-160  These 
inhibitors incorporated several bioisosteric replacement strategies for the labile phosphate 
moiety which included β-ketophosphonate, acylsulfamate, acylsulfamide, sulfamate, β-
ketosulfonamide, α, α-difluoro-β-ketosulfonamide, acyltriazole, and vinylsulfonamide 
linkages.  We chose to incorporate two of these bioisosteric replacements in our library of  
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Scheme 3.1:  Synthesis of Monopalmitoyl Phosphate 
 
 
Reagents and Conditions:  (a) Silver phosphate, Diethyl ether, rt, 1h. 
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substrate mimics (sulfamates and sulfamides).  We only sought to synthesize the 
palmitoyl and cis-vaccecinoyl or cis-oleoyl chains for our initial study, since from the 
previous studies we knew that these chains had the most significant activity.  This work 
evaluated the study of six acyl-PO4 bioisosteric head groups combined with a series of 
acyl chains (Figure 3.3) to develop a preliminary structure activity relationship (SAR) for 
PlsY inhibition and anti-bacterial activity 
 
 
Synthesis 
  
 Acylphosphonate derivatives were synthesized by reacting lithiated dimethyl 
methane phosphonate with the appropriate esters or acid chlorides 3.3 to yield the 
corresponding phosphonate esters in good yields 3.6a-h (Scheme 3.2).161  Diethyl α,α-
difluoromethyl phosphonate esters 3.7a,e,i,j were synthesized in an analogous manner 
from lithiated diethyl α,α-difluoromethyl phosphonate.162  All the phosphonate esters 
were cleaved with bromotrimethylsilane (TMSBr), to yield the desired phosphonic acids 
3.6a-h, 3.7a,e,i,j.  Acyl phosphoramides were prepared starting from the corresponding 
fatty acid potassium salts 3.8a-f.  Acylation of 3.8a-f with ethylchloroformate yielded the 
anyhydrides 3.7a-f, which were subsequently reacted with the lithium salt of diethyl 
phosphoramidate to give acylphosphoramide esters 3.10a-f.163  Then, TMSBr mediated 
cleavage of the phosphoramide esters yielded the target acylphosphoramides 3.11a-f 
(Scheme 3.3).  Reverse amide phosphonates were synthesized by coupling various 
amines 3.12a-d with diethylphosphonoacetic acid using 1-hydroxybenzotriazole (HOBt) 
and N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide (EDCI) to form the corresponding 
phosphonate esters 3.13a-d,164 which were then deprotected with TMSBr to generate the 
target phosphonates 3.14a-d (Scheme 3.4).   
 
The acylsulfamates and acylsulfamides were synthesized starting from the 
aminosulfonyl chloride 3.16, according to the protocol of Appel and Berger.165  
Aminosulfonyl chloride 3.16 was treated with various alcohols or propylamine to 
generate the intermediate sulfamates 3.17a-d166 or sulfamide 3.18a,b.167  The sulfamates 
and sulfamide were then acylated with selected acid chlorides in the presence of 
triethylamine and catalytic 4-(dimethylamino) pyridine (DMAP) to form the desired 
acylsulfamates 3.19a-d and acylsulfamide 3.20a,b (Scheme 3.5). 
 
 
Results and Discussion 
 
The synthesized acyl-PO4 bioisosteres were tested for inhibition of the S. 
pneumoniae PlsX and PlsY (SpPlsX/Y) (Table 3.1).  None of the compounds showed 
SpPlsX activity.  For this reason, we focused primarily on PlsY inhibition for 
development.  Compounds from all six of the bioisosteric head group series showed 
varying degrees of SpPlsY inhibition.  The most potent inhibitors in each class contained 
saturated or unsaturated alkyl chains of 12 carbons or more.  The weakest inhibitors 
included the shortest alkyl chains ranging from 4 to 11 or the equivalent.  These results 
suggested that shorter chained analogs are not able to mimic the same interactions as the  
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Figure 3.3:  Design of Substrate Mimics of Acylphosphate. 
 
 
 
Scheme 3.2:  Synthesis of Ketophosphonates and Acyl α,α-Difluromethyl 
Phosphonates 
 
 
 
Reagents and Conditions:   (a) Dimethyl methylphosphonate, BuLi, THF, -78°C, (b) 
Diethyl (difluoromethane) phosphonate, LDA, THF, -78°C, (c) TMSBr, DCM, then 
95%EtOH. 
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Scheme 3.3:  Synthesis of Acylphosphoramides 
 
 
 
Reagents and Conditions:  (a) Ethylcholoroformate, DCM; (b) Diethyl phosphoramidate, 
BuLi, THF, -78°C, (c) TMSBr, DCM, then 95%EtOH. 
 
 
 
Scheme 3.4:  Synthesis of Reverse Amide Phosphonates 
 
 
 
Reagents and Conditions:  (a) Diethylphosphonoacetic acid, HOBt, EDCI, DCM:DMF, 
rt, 16hrs; (b) TMSBr, DCM, then 95%EtOH. 
 
 
 
Scheme 3.5:  Synthesis of Acylsulfamates and Acylsulfamides 
 
 
 
Reagents and Conditions:  (a) HCO2H, neat; (b) R’OH, DMA; (c) R’NH2, neat, NaOH; (d) RCOCl, DMAP, NEt3, DCM:DMF. 
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Table 3.1:  Enzyme Activity of Acylphosphate Mimics 
 
 
 
a %Inhibition of S. pneumoiae PlsY @ 200μM inhibitor and 50μM acyl (16:0) phosphate.  
b IC50 were only determined on compounds for which there was greater than 50% 
inhibition at SpPlsY. c nd = not determined.     
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natural substrate.  Unsaturated C18 derivatives showed significant inhibitory activity, 
which is expected based on initial results observed on the fatty acids incorporated in the 
1-position of G3P.153  The most active compounds were acylphosphonate 3.6b (IC50 48 
µM, C18∆11), α,α-difluoromethyl phosphonates 3.7a (IC50 39 µM, C16) and 3.7i (IC50 20 
µM, C18∆9), and acylphosphoramide 3.11b (IC50 11 µM, C18∆11).  In contrast, the long 
chain reverse amide phosphonates 3.14a-c had moderate activity against SpPlsY.  The 
acylsulfamates 3.19a-c had good activity against SpPlsY (IC50 85 µM, 70 µM, and 60 
µM, respectively); however, acylsulfamide 3.20b was considerably less potent.  Kinetic 
analyses of the acyl-PO4 bioisosteres were performed which determined that these 
compounds act as competitive inhibitors of SpPlsY with respect to the acyl-PO4 (Figure 
3.4).  
  
The antimicrobial activity for the compound series was tested against a clinically-
relevant panel of bacteria consisting of S. pneumoniae, E. faecalis, Methicillin resistant S. 
aureus, B. subtilis, and B. anthracis (Table 3.2).  Activity was weak to moderate against 
all Gram-positive species tested except for the B. anthracis Sterne strain, which was 
potently inhibited by acylphosphonates 3.6a (MIC 1.56 µg/mL) and 3.6b (MIC 0.05 
µg/mL) and reverse amide phosphonates 3.14a (MIC 0.1 µg/mL), 3.14b (MIC 0.1 
µg/mL), and 3.14c (MIC 3.13 µg/mL).  Acylsulfamate 3.19c displayed considerable 
antibacterial activity against B. anthracis and B. subtilis (MIC 3.13 µg/mL, respectively) 
with some activity against S. pneumoniae (MIC 12.5 µg/mL).  The SAR of compounds 
exhibiting activity against B. anthracis generally correlated with inhibition data against 
the SpPlsY enzyme, and together revealed that the most active acylphosphonate and 
reverse amide phosphonate compounds had longer alkyl chains.  The acylphosphoramide 
and acyl α,α-difluormethyl phosphonate series were generally inactive, which may be 
attributed to a chemical instability and increased acidity of the phosphoramides and 
difluormethylphosphonates respectively, preventing entry into the cell.  None of the 
compounds tested exhibited antimicrobial activity against Gram-negative species, E. coli 
and P. aeruginosa (< 200 µg/mL).  Cytotoxicity against mammalian epithelial cells was 
also evaluated for the most active compounds (Table 3.2).  Compounds 3.6a, 3.6b, 3.14a 
and 3.14b only exhibited cytotoxicity at high concentrations, producing high selectivity 
indices (Cytoxicity IC50 /B. anthracis MIC) ranging from 2200-4850. 
 
The discovery of the potent antimicrobial activity against B. anthracis sparked 
further studies of the PlsX/PlsY pathway in this bacterium.  We initially questioned the 
nature of B. anthracis or the strain (Sterne) used versus the other Gram-positive bacteria 
in our panel.  Indeed, a potential explanation for species selectivity was the capsule 
deficient status of the attenuated B. anthracis Sterne strain, which might enable better 
penetration of the compounds into its cells.168  In contrast, poor penetration into the other 
Gram-positive species that likely carry competent capsules may explain the inactivity.  In 
order to explore this relationship we contacted Dr. Vicki Luna at the University of South 
Florida who has a significant background in B. anthracis and other bacillus species.169, 170  
Her lab was able to test our compounds against a panel of B. anthracis and closely related 
B. cereus strains (Tables 3.3 and 3.4).  Interestingly, acylphosphonates 3.6a,b and reverse 
amide phosphonates 3.14a-c showed potent anti-cereus activity across most of the strains 
tested.  Likewise, similar inhibitory activity for capsule-positive and deficient strains of 
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Figure 3.4:  Enzyme Kinetics Profile for 3.11b 
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Table 3.2:  Antimicrobial Activity of Acylphosphate Mimetics against a Panel of 
Gram-Positive Bacteria.  
 
 
aWhole-cell Minimum Inhibitory Concentration of the following species:  SP-
Streptococcus pneumoniae DAW30, EF-Enterococcus faecalis ATCC33186, MRSA-
Methicillin resistant Staphylococcus aureus ATCC33591, BS-Bacillus subtilis ATCC 
23857, and BA-Bacillus anthracis Sterne 34F2. b Doxycycline (IC50 = 212μg/mL) was used as a control.  Assays were performed using the Vero monkey kidney cell line (CCL-
81). c nd = not determined. 
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Table 3.3:  Antimicrobial Activity of Acylphosphate Mimics against a Panel of 
Bacillus cereus Strains 
 
 
a Whole-cell Minimum Inhibitory Concentration of varying strains of Bacillus cereus. 
b Capsule-deficient strain of B. cereus.     
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Table 3.4:  Antimicrobial Activity against a Panel of Bacillus anthracis Strains 
 
 
a Whole-cell Minimum Inhibitory Concentration in µg/ml of varying strains of Bacillus 
Anthracis.  Penicillin (MIC = 0.008-0.03 µg/ml) and Ciprofloxacin (MIC = 0.03-
0.06µg/ml) were used as controls.  b Capsule-deficient strain. 
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B. anthracis was seen with some strains showing low MICs confirming our initial results 
and showing that these compounds possess significant activity against clinically relevant 
B. anthracis strains.  However, these data demonstrated that the anti-anthracis activity 
seen was independent of the presence of the capsule. 
 
Our second idea questioned the uniqueness of the PlsX/PlsY pathway in B. 
anthracis.  This idea was supported by an analysis from our collaborators at St. Jude 
Children’s Research Hospital of the B. anthracis genome showing that it has three 
putative plsY genes.  This finding is unusual because most bacteria (> 99%) posses only a 
single plsY gene.  Several bacillus species harbor multiple PlsY isoforms.  B. 
licheniformis, B. thuringinesis, B. cereus, and B. clausii have two homologs, whereas B. 
subtilis has only a single PlsY.  To date, all three plsY homolgs from B. anthracis have 
been purified following cloning and expression.  A comparative analysis of the protein 
sequences of B. subtilis PlsY (BsPlsY) and the three BaPlsYs have been performed.  This 
indicated that BaPlsY1 and BaPlsY2 are similar to BsPlsY and other prototypical PlsYs 
with 62% and 53% sequence identity, respectively.  The BaPlsY3 is the most different.  It 
has 92% sequence similarity to the BcPlsY2 but these are not related to any other PlsY 
isoforms.  BcPlsY1 and BaPlsY1 are 97% identical which may explain the similarities in 
antimicrobial activity seen in the two species.  BaPlsY1 was tested for its acyltransferase 
activity using one of our potent inhibitors 3.9e comparing it to that of SpPlsY.  We have 
discovered that this enzyme is indeed an acyl-PO4:G3P acyltransferase showing BaPlsY1 
inhibitory activity.  Comparison of enzyme inhibition activity of SpPlsY and BaPlsY1 of 
our compound library is listed in Table 3.5.  There are considerable differences in activity 
for some compounds, but the acylsulfamates and acylsulfamamides have similar activity 
against the two PlsY enzymes.  There is ongoing work to determine if the other two plsY 
genes also encode glycerol-phosphate acyltransferases or some other acyltransferase 
activity.  Determining the specific roles of the three BaPlsY enzymes would give us 
insight in to which enzyme is essential to phospholipid biosynthesis as it would be the 
target for the design of selective inhibitors for future antimicrobial drug discovery. 
 
 
Conclusions 
 
Substrate mimics incorporating six acyl-PO4 bioisosteric head groups have been 
synthesized.  Based on the preliminary SAR, longer chain analogues matching the 
substrate were the most active in each series.  Kinetic profiles show that these compounds 
are acting competitively at PlsY.   Acylphosphonates 3.6a-b, reverse amide phosphonates 
3.14a-c, and acylsulfamate 3.19c show promise as early leads in the development of 
potential novel antimicrobial agents demonstrating good target enzyme inhibition, good 
antimicrobial activity against B. anthracis, and low cytotoxicity.  Even though these 
compounds showed significant activity against at SpPlsY, overall antimicrobial activity 
was generally weak or nonexistent with only a few compounds having MIC’s of 
12.5µg/mL (acylsulfamates 3.19a and 3.19c).  A possible explanation for this activity 
could be lack of cell penetration due to chemical instability or increased acidity of the 
compounds in the library.  Overall, we’ve discovered the first known inhibitors of the 
Gram-positive PlsX/PlsY pathway to phosphatidic acid.  
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Table 3.5:  Comparison of Inhibitory Activity for SpPlsY and BaPlsY1 
 
 
a %Inhibition of S. pneumoiae PlsY @ 200μM inhibitor and 50μM acyl (16:0) phosphate.  
b %Inhibition of B. anthracis PlsY @ 200μM inhibitor and 50μM acyl (16:0) phosphate.  
c nd = not determined. 
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Experimental Section 
 
 
Chemistry 
 
All reagents and anhydrous solvents were purchased from Sigma-Aldrich. All the 
reagent-grade solvents used for chromatography were purchased from Fisher Scientific  
 (Suwanee, GA) and flash column chromatography silica cartridges were obtained from 
Biotage Inc. (Lake Forest, VA). The reactions were monitored by thin-layer 
chromatography (TLC) on pre-coated Merck 60 F254 silica gel plates and visualized 
using UV light (254 nm) and Iodine staining. A Biotage FLASH column chromatography 
system was used to purify the reaction mixtures. All 1H and 13C NMR spectra were 
recorded on a Varian INOVA-500 spectrometer. Chemical shifts (δ) are reported in ppm 
relative to the residual solvent peak or internal standard (tetramethylsilane), and coupling 
constants (J) are reported in hertz (Hz). Mass spectra were recorded on a Bruker Esquire 
LCMS using ESI. The yields quoted are unoptimized.  Purity of the final products were 
analyzed by a Waters Acquity UPLC-PDA-ELSD-MS.  UPLC separations were 
performed using an Acquity UPLC 2.1 x 50 mm BEH C18 column (1.7 um, Waters) at 
50°C, and a 1.0 mL/min flow rate.  The PDA was set to acquire UV data from 210-400 
nm throughout the run.  UPLC1: Gradient: solvent A (10 mM ammonium acetate in 
water) and solvent B (10 mM ammonium acetate in acetonitrile): 0 - 0.2 min 10-30% B, 
0.20 – 1.40 min 30-95% B (linear gradient), 1.40-1.70 min 95% B, 1.70-1.75 min 10%B.  
UPLC2: Gradient: solvent A (10 mM ammonium acetate in water) and solvent B (10 mM 
ammonium acetate in acetonitrile): 0 - 0.2 min 10-30% B, 0.20 – 1.40 min 30-95% B 
(linear gradient), 1.40-2.70 min 95% B, 2.70-2.75 min 10%B. 
 
Synthesis of monopalmitoyl phosphate (3.2).  Silver phosphate (376 mg, 0.90 mmol) 
was added to anhydrous phosphoric acid (199 mg, 2.03 mmol) in diethyl ether (10 mL), 
and the mixture was stirred at room temperature for 16 hr.  Palmitoyl chloride (558 mg, 
2.03 mmol) was dissolved in diethyl ether (5 ml) and added dropwise to the resulting 
mixture.  After the addition was complete, the mixture was stirred for an additional hour. 
The resulting mixture was filtered, and the solid was washed with diethyl ether. The 
filtrate and washings were combined and concentrated in vacuo. Recrystallization of the 
resulting residue from warm benzene yielded monopalmitoyl phosphate as a white 
powder (24%). 1HNMR (MeOD, 300 MHz), δ 0.92 (t, 3H, J = 6.0 Hz), 1.31 (bs, 26 H), 
1.65 (m, 2H), 2.46 (t, 2H, J = 7.0 Hz). 13CNMR (MeOD, 300MHz), δ 12.5, 21.8, 23.6, 
28.6, 28.7, 28.8, 31.1, 34.0, 168.3. MS(ESI), m/z = 335 (M-H)-. 
 
General procedure for synthesis of acylphosphonate esters (3.4a-h).  A 1.6M solution 
of n-Butyl lithium (3.5 eq) in hexanes was added to THF at -78°C. After stirring for 
30min, dimethyl methanephosphonate (3.5 eq) was added drop-wise to the mixture over 
30 min generating the carbanion.  After the resulting suspension was stirred for an 
additional 30 min, various esters or acid chlorides (1.0 eq) in THF were added drop-wise 
over 30 min.  The resulting suspension was allowed to stir until the temperature rose to -
20°C.  The reaction mix was quenched with glacial acetic acid (3 mL) until mildly acidic 
(pH = 5).  The reaction mix was extracted with ethyl acetate.  The organic layer was 
 92  
washed with brine, dried over Na2SO4, and then concentrated in vacuo.  Flash column 
purification (0-100%, Petroleum Ether/Ethyl Acetate) yielded the corresponding 
acylphosphonate esters.  
 
Dimethyl 2-oxoheptadecylphosphonate (3.4a).  Using the above general procedure, n-
butyl lithium (32.0 mmol), dimethyl methanephosphonate (32.0 mmol), methylpalmitate 
(9.24 mmol) and THF (45 mL) were used to synthesize 3.4a as a white solid (89%), mp = 
47-49ºC.  TLC Rf = 0.5 (Ethyl Acetate).    1H NMR (CDCl3, 500MHz):  δ 0.90 (t, 3H, J = 
6.5 Hz), 1.27-1.33 (bs, 24H), 1.60 (m, 2H), 2.63 (t, 2H, J = 7.0 Hz), 3.11 (d, 2H, J = 23.0 
Hz), 3.80 (s, 3H), 3.82 (s, 3H).  MS(ESI), m/z = 385.9 [M+Na]+ , 361.3 [M-H]-.   
 
(Z)-dimethyl 2-oxononadec-12-enylphosphonate (3.4b).  Using the above general 
procedure, n-butyl lithium (3.5 mmol), dimethyl methanephosphonate (3.5 mmol), 
vaccenoyl chloride (1.0 mmol) and THF (15 mL) were used to synthesize 3.4b as a 
colorless waxy solid (77%).  TLC Rf = 0.5 (Ethyl Acetate).  1H NMR (CDCl3, 500MHz):  
δ 0.81 (t, 3H, J = 7.0 Hz), 1.24 (bs, 20H), 1.50 (m, 2H), 1.94 (q, 4H, J = 8.5 Hz), 2.53 (t, 
2H, J = 7.5 Hz), 3.01 (d, 2H, J = 22.5 Hz), 3.71 (s, 3H), 3.73 (s, 3H), 5.28 (m, 2H). 
MS(ESI), m/z =411.4 [M + Na]+, 387.1 [M-H]-.   
 
Dimethyl 2-oxononylphosphonate (3.4c).  Using the above general procedure, n-butyl 
lithium (32.0 mmol), dimethyl methanephosphonate (32.0 mmol), methyl octanoate (9.24 
mmol) and THF (40 mL) were used to synthesize 3.4c as a colorless oil (14%).  TLC Rf = 
0.5 (Ethyl Acetate).  1H NMR (CDCl3, 500MHz):  δ 0.89 (t, 3H, J = 7.0 Hz), 1.30 (bs, 
8H), 1.60 (m, 2H), 2.62 (t, 2H, J = 7.5 Hz), 3.11 (d, 2H, J = 23.0 Hz), 3.80 (m, 3H), 3.82 
(m, 3H).  MS(ESI), m/z =273.1 [M + Na]+.   
 
Dimethyl 2-oxopentylphosphonate (3.4d).  Using the above general procedure, n-butyl 
lithium (17.5 mmol), dimethyl methanephosphonate (17.5 mmol), methyl butyrate (5.0 
mmol) and THF (25 mL) were used to synthesize 3.4d as a colorless oil (76%).  TLC Rf = 
0.2 (Ethyl Acetate).  1H NMR (CDCl3, 500MHz):  δ 0.93 (t, 3H, J = 7.5 Hz), 1.62 (m, 
2H), 2.60 (t, 2H, J= 7.0 Hz), 3.08 (d, 2H, J = 22.5 Hz), 3.78 (s, 3H), 3.80 (s, 3H).  
MS(ESI), m/z =217.0 [M + Na]+  192.70 [M-H]-. 
 
Dimethyl 2-oxotridecylphosphonate (3.4e).  Using the above general procedure, n-butyl 
lithium (17.5 mmol), dimethyl methanephosphonate (17.5 mmol), methyl laurate (5.0 
mmol) and THF (25 mL) were used to synthesize 3.4e as a white solid (73%).  TLC Rf = 
0.4 (Ethyl Acetate).  1H NMR (CDCl3, 500MHz):  δ 0.88 (t, 3H, J = 7.0 Hz), 1.25 (bs, 
16H), 1.59 (m, 2H), 2.61 (t, 2H, J = 7.0 Hz), 3.08 (d, 2H, J = 22.5 Hz), 3.78 (s, 3H), 3.80 
(s, 3H).  MS(ESI), m/z = 329.3 [M+Na]+ , 305.0 [M-H]-.   
 
Dimethyl 6-cyclohexyl-2-oxohexylphosphonate (3.4f).  Using the above general 
procedure, n-butyl l lithium (17.5 mmol), dimethyl methanephosphonate (17.5 mmol), 
cyclohexanepentanoyl chloride (5.0 mmol) and THF (25 mL) were used to synthesize 
3.4f as a colorless oil (67%).  TLC Rf = 0.4 (Ethyl Acetate).  1H NMR (CDCl3, 500MHz):  
δ 0.85 (m, 2H), 1.11-1.32 (m, 6H), 1.53- 1.68 (m, 10H), 2.61 (t, 2H, J = 7.0 Hz), 3.08 (d, 
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2H, J = 23.0 Hz), 3.78 (s, 3H), 3.80 (s, 3H).  MS(ESI), m/z = 313.10 [M+Na]+ , 288.9 
[M-H]-.   
 
Dimethyl 2-oxo-6-phenylhexylphosphonate (3.4g).  Using the above general procedure, 
n-butyl lithium (17.5 mmol), dimethyl methanephosphonate (17.5 mmol), 5-
phenylpentanoyl chloride (5.0 mmol) and THF (25 mL) were used to synthesize 3.4g as a 
colorless oil (62%).  TLC Rf = 0.5 (Ethyl Acetate).  1H NMR (CDCl3, 500MHz):  δ 1.63 
(m, 4H), 2.63 (m, 4H), 3.07 (d, 2H, J = 22.5 Hz), 3.77(s, 3H), 3.79 (s, 3H), 7.16 (d, 2H, J 
= 8.0 Hz), 7.17 (t, 1H, J = 7.5 Hz), 7.27 (t, 2H, J = 8.0 Hz).  MS(ESI), m/z = 307.10 
[M+Na]+ , 282.90 [M-H]-.   
 
Dimethyl 2-oxo-12-phenoxydodecylphosphonate (3.4h).  Using the above general 
procedure, n-butyl lithium (17.5 mmol), dimethyl methanephosphonate (17.5 mmol), 11-
phenoxyundecanoyl chloride (5.0 mmol) and THF (25 mL) were used to synthesize 3.4h 
as a white solid (66%).  TLC Rf = 0.6 (Ethyl Acetate).  1H NMR (CDCl3, 500MHz):  δ 
1.28 (bs10H), 1.45 (m, 2H), 1.58 (m, 2H), 1.77 (m, 2H), 2.61 (t, 2H, J = 7.0 Hz), 3.08 (d, 
2H, J = 22.5 Hz), 3.78 (s, 3H), 3.80 (s, 3H), 3.95 (t, 2H, J = 6.5 Hz), 6.89 (d, 2H, J = 
8.0Hz), 6.92 (t, 1H, J = 7.5 Hz), 7.27 (t, 2H, J = 7.0 Hz).  MS(ESI), m/z = 407.30 
[M+Na]+ , 382.90 [M-H]-.   
 
General procedure for synthesis of acyl α,α-difluoromethyl phosphonate esters 
(3.5a,e,i,j).  A freshly prepared solution of LDA (2.0 eq) was added to THF (20 mL) at -
78°C. After stirring for 30 min, diethyl α,α-difluoromethyl phosphonate (2.0 eq) in THF 
(1 mL) was added drop-wise to the mixture over 10 min to generate the carbanion.  After 
the resulting suspension was stirred for an additional 45 min, various esters or acid 
chlorides (1.0 eq) in THF (5 mL) were added drop-wise over 10 min.  The resulting 
suspension was allowed to stir for 2.5h.  After the reaction was complete, it was 
quenched with glacial acetic acid (2 mL) followed by saturated ammonium chloride.  The 
mixture was allowed to warm to room temperature and extracted with chloroform.  The 
organic extracts were washed with brine, dried over Na2SO4, and then concentrated in 
vacuo.  Flash column purification (0-100%, Petroleum Ether/Ethyl Acetate) yielded the 
desired acyl α,α-difluoromethyl phosphonate esters. 
 
Diethyl 1,1-difluoro-2-oxoheptadecylphosphonic acid (3.5a).  Using the above general 
procedure, n-butyl lithium (4.25 mmol), diisopropylamine (4.25 mmol), diethyl α,α-
difluromethyl phosphonate (4.25 mmol), methylpalmitate (2.13 mmol) and THF (30 mL) 
were used to synthesize 3.5a as a colorless oil (55%).  TLC Rf = 0.5 (8:2, Pet 
Ether:EtOAc).  1H NMR (CDCl3, 500MHz):  δ 0.89 (t, 3H, J = 7.0 Hz), 1.25 (bs, 24H), 
1.39 (t, 6H, J = 7.0 Hz), 1.63 (m, 2H), 2.77 (t, 2H, J = 7.5 Hz), 4.31 (m, 4H).  MS(ESI), 
m/z = 449.4 [M+Na]+ , 425.1 [M-H]-. 
 
Diethyl 1,1-difluoro-2-oxotridecylphosphonic acid (3.5e):  Using the above general 
procedure, n-butyl lithium (6.0 mmol), diisopropylamine (6.0 mmol), diethyl α,α-
difluromethyl phosphonate (6.0 mmol), methyl laurate (2.0 mmol) and THF (30 mL) 
were used to synthesize 3.5e as a colorless oil (69%).  TLC Rf = 0.6 (8:2, Pet 
Ether:EtOAc).  1H NMR (CDCl3, 300MHz):  δ 0.90 (t, 3H, J = 6.8 Hz), 1.28 (bs, 16H), 
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1.41 (t, 6H, J = 6.0 Hz), 1.65 (m, 2H), 2.79 (t, 2H, J = 7.2 Hz), 4.33 (m, 4H).   MS(ESI), 
m/z =393.3 [M+Na]+.  
 
Diethyl (Z)-1,1-difluoro-2-oxononadec-10-enylphosphonic acid (3.5i).  Using the 
above general procedure, n-butyl lithium (6.0 mmol), diisopropylamine (6.0 mmol), 
diethyl α,α-difluromethyl phosphonate (6.0 mmol), methyl oleate (2.0 mmol) and THF 
(30 mL) were used to synthesize 3.5i as a colorless oil (78%).  TLC Rf = 0.5 (8:2, Pet 
Ether:EtOAc).  1H NMR (CDCl3, 500MHz):  δ 0.88 (t, 3H, J = 6.5 Hz), 1.29 (bd, 20H), 
1.39 (t, 6H, J = 7.0 Hz), 1.64 (m, 2H), 2.01 (q, 4H, J = 5.0 Hz), 2.77 (t, 2H, J = 7.0 Hz), 
4.31 (m, 4H), 4.34 (m, 2H). MS(ESI), m/z = 475.3 [M+Na]+. 
 
Diethyl 1,1-difluoro-2-oxododec-11-enylphosphonic acid (3.5j):  Using the above 
general procedure, n-butyl lithium (6.0 mmol), diisopropylamine (6.0 mmol), diethyl α,α-
difluromethyl phosphonate (6.0 mmol), methyl 10-undecanoate (2.0 mmol) and THF (30 
mL) were used to synthesize 3.5j as a colorless oil (39%).  TLC Rf = 0.5 (8:2, Pet 
Ether:EtOAc).  1H NMR (CDCl3, 500MHz):  δ 1.29 (bs, 10H), 1.40 (t. 6H, J = 7.0 Hz), 
1.64 (m, 2H), 2.04 ( q, 2H, J = 5.0 Hz), 2.78 (t, 2H, J = 7.0 Hz), 4.31 (m, 4H), 4.97 (dd, 
2H, J = 20Hz, 30 Hz), 5.81 (m, 1H).  MS(ESI), m/z = 377.2 [M+Na]+. 
 
General procedure for synthesis of acylphosphoramidate esters (3.10a-f).  Various 
esters or acids (1.0 eq) were treated with KOH (1.0 eq) in H2O:ACN (1:1).  The reaction 
mixture was stirred and heated at 110°C until dry, then subjected to high vacuum for 16h.  
DCM (25 mL) was added to the flask.  To the resulting suspension was added 
ethylchloroformate (1.0 eq) which was stirred for 7h, then chilled to        -78°C.  
Pretreatment of diethyl phosphoramidate (3.2 eq) with 1.6M n-butyl lithium (3.2 eq) to 
generate the anion was performed before slow addition to the activated acyl species. The 
reaction was allowed to stir until the temperature rose to 25°C.  The reaction mixture was 
quenched with glacial acetic acid (3 mL) until mildly acidic (pH = 5).  The reaction mix 
was extracted with ethyl acetate.  The organic layer was washed with brine, dried over 
Na2SO4, and then concentrated in vacuo.  Flash column purification (0-100%, Petroleum 
Ether/Ethyl Acetate) yielded the desired acylphosphoramide esters.   
 
(Diethyl) 1-oxohexadecylphosphoramidate (3.10a).  Using the above general 
procedure, methylpalmitate (10.0 mmol), ACN:H2O (20 mL), KOH (10.0 mmol), ethyl 
chloroformate (10.0 mmol),  n-butyl lithium (35.0 mmol), and diethyl phosphoramidate 
(35.0 mmol) were used to synthesize 3.10a as a white solid (25%), mp = 53-56ºC.  TLC 
Rf = 0.6 (Ethyl Acetate).  1H NMR (CDCl3, 500MHz):  δ 0.90 (t, 3H, J = 6.5 Hz), 1.27 
(bs, 24H) 1.38 (t, 6H, J = 7.0 Hz), 1.65 (m, 2H), 2.36 (t, 2H, J = 7.0 Hz), 4.22 (m, 4H), 
8.34 (s, 1H).  MS(ESI), m/z = 390.1 [M-H]-.   
 
(Diethyl) (Z)-1-oxooctadec-11-enylphosphoramidate (3.10b).  Using the above general 
procedure, vaccenic acid (1.0 mmol), ACN:H2O (10 mL), KOH (1.0 mmol), ethyl 
chloroformate (1.0 mmol),  n-butyl lithium (3.5 mmol), and diethyl phosphoramidate (3.5 
mmol) were used to synthesize 3.10b as a yellow syrup (20%).  TLC Rf = 0.5 (Ethyl 
Acetate).  1H NMR (CDCl3, 500MHz):  δ 0.91 (t, 3H, J = 7.0 Hz), 1.30-1.37(bs, 20H), 
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1.40 (t, 6H, J = 7.0 Hz), 1.60 (m, 2H), 2.04 (q, 4H, J = 8.5 Hz), 2.37 (t, 2H, J = 8.0 Hz), 
4.23 (m, 4H), 5.38 (m, 2H).  MS (ESI), m/z = 416.1 [M-H]-. 
 
(Diethyl) 1-oxooctylphosphoramidate (3.10c).  Using the above general procedure, 
methyl caprylate (5.0 mmol), ACN:H2O (20 mL), KOH (5.0 mmol), ethyl chloroformate 
(5.0 mmol),  n-butyl lithium (17.5 mmol), and diethyl phosphoramidate (17.5 mmol) 
were used to synthesize 3.10c as a colorless oil (32%).  TLC Rf = 0.3 (Ethyl Acetate).  1H 
NMR (CDCl3, 500MHz):  δ 0.90 (t, 3H, J = 7.5 Hz), 1.31 (bs, 8H) 1.39 (t, 6H, J = 7.5 
Hz), 1.66 (m, 2H), 2.37 (t, 2H, J = 7.5 Hz), 4.21 (m, 4H).   MS(ESI), m/z = 277.9 [M-H]- 
, 302.2 [M+Na]+. 
 
(Diethyl) 1-oxododecylphosphoramidate (3.10d).  Using the above general procedure, 
methyl laurate (5.0 mmol), ACN:H2O (20 mL), KOH (5.0 mmol), ethyl chloroformate 
(5.0 mmol),  n-butyl lithium (17.5 mmol), and diethyl phosphoramidate (17.5 mmol) 
were used to synthesize 3.10d as a white solid (10%).  TLC Rf = 0.5 (Ethyl Acetate).  1H 
NMR (CDCl3, 500MHz):  δ 0.85 ( t, 3H, J = 6.5 Hz), 1.23 (bs, 16H), 1.33 (t, 6H, J = 7.0 
Hz), 1.61 (m, 2H), 2.33 (t, 2H, J = 7.5 Hz), 4.16 (m, 4H).  MS(ESI), m/z = 334.1 [M-H]- , 
358.3 [M+Na]+. 
 
(Diethyl) 5-cyclohexyl-1-oxopentylphosphoramidate (3.10e).  Using the above general 
procedure, 5-phenylvaleric acid (5.0 mmol), ACN:H2O (20 mL), KOH (5.0 mmol), ethyl 
chloroformate (5.0 mmol),  n-butyl lithium (17.5 mmol), and diethyl phosphoramidate 
(17.5 mmol) were used to synthesize 3.10e as a white solid (35%).  TLC Rf = 0.6 (Ethyl 
Acetate).  1H NMR (CDCl3, 500MHz):  δ 0.85 (m, 2H), 1.11-1.33 (m, 8H), 1.36 (t, 6H, J 
= 7.0 Hz), 1.58 – 1.69 (m, 8H), 2.34 (t, 2H, J = 7.5 Hz), 4.20 (m, 4H).  MS(ESI), m/z = 
342.2 [M+Na]+ , 318.0 [M-H]-. 
 
(Diethyl) 1-oxo-11-phenoxyundecylphosphoramidate (3.10f).  Using the above general 
procedure, 11-phenoxyundecanoic acid (5.0 mmol), ACN:H2O (20 mL), KOH (5.0 
mmol), ethyl chloroformate (5.0 mmol),  n-butyl lithium (17.5 mmol), and diethyl 
phosphoramidate (17.5 mmol) were used to synthesize 3.10f as a white solid (15%).  
TLC Rf = 0.6 (Ethyl Acetate). 1H NMR (CDCl3, 500MHz):  δ 1.30 (bs, 10H), 1.36 (t, 6H, 
J = 7.5 Hz), 1.45 (m, 2H), 1.63 (m, 2H), 1.77 (m, 2H), 2.34 (t, 2H, J = 7.5 Hz), 3.95 (t, 
2H, J = 7.0 Hz), 4.20 (m, 4H), 6.89 (d, 2H, J = 8.0 Hz), 6.92 ( t, 1H, J = 7.0 Hz), 7.27 (t, 
2H, J = 7.5 Hz).  MS(ESI), m/z = 436.3 [M+Na]+ , 412.1 [M-H]-. 
 
General procedure for synthesis of acyl reverse amide phosphonate esters (3.13a-d).  
To DCM/DMF (1:1) was added HOBt (1.0 eq), diethylphosphonoacetic acid (1.0 eq), and 
EDCI (1.0 eq).  The mixture was allowed to stir for 30 min.  Drop-wise various amines 
(1.0 eq) were added.  The reaction mixture was allowed to stir at room temperature for 
16h.  The mixture was extracted with chloroform. The organic layer was washed with 
NaHCO3, water, and brine, then dried over Na2SO4, and concentrated in vacuo.  Flash 
column purification (0-100%, Petroleum Ether/Ethyl Acetate) yielded the desired reverse 
amide phosphonate esters. 
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Diethyl (Tetradecylcarbamoyl)methylphosphonic acid (3.13a).  Using the above 
general procedure, HOBt (5.0 mmol), EDCI (5.0 mmol), diethylphosphonoaceticacid (5.0 
mmol), DCM/DMF (50 mL), and tetradecylamine (5.0 mmol) were used to synthesize 
3.13a as a yellow solid (29%), mp = 32-34ºC.  TLC Rf = 0.3 (Ethyl Acetate).  1H NMR 
(CDCl3, 500MHz):  δ 0.84 (t, 3H, J = 6.5 Hz), 1.22 (bs, 22H) 1.31 (t, 6H, J = 7.0 Hz), 
1.47 (m, 2H), 2.82 (d, 2H, J = 20.5 Hz), 3.21 (q, 2H, J = 6.5 Hz), 4.11 (m, 4H), 6.91 (bt, 
1H)  MS(ESI), m/z = 390.1 [M-H]- , m/z = 414.4 [M+Na]+.   
 
Diethyl ((Z)-octadec-9-enylcarbamoyl)methylphosphonic acid (3.13b).  Using the 
above general procedure, HOBt (5.0 mmol), EDCI (5.0 mmol), diethylphosphonoacetic 
acid (5.0 mmol), DCM/DMF (50 mL), and oleylamine (5.0 mmol) were used to 
synthesize 3.13b as a colorless oil (18%).  TLC Rf = 0.3 (Ethyl Acetate).  1H NMR 
(CDCl3, 500MHz):  δ 0.88 (t, 3H, J = 6.5 Hz), 1.27 (bs, 22H), 1.34 (t, 6H, J = 7.0 Hz), 
1.51 (m, 2H), 2.01 (m, 4H), 2.83 (d, 2H, J = 22.0 Hz), 3.26 (t, 2H, J = 7.5 Hz), 4.14 (m, 
4H), 5.35 (m, 2H), 6.73 (bt, 1H).  MS(ESI), m/z = 444.1 [M-H]- , m/z = 468.3 [M+Na]+. 
 
Diethyl (N-dodecyl-N-methylcarbamoyl)methylphosphonic acid (3.13c).  Using the 
above general procedure, HOBt (5.0 mmol), EDCI (5.0 mmol), diethylphosphonoacetic 
acid (5.0 mmol), DCM/DMF (50 mL), and N-methyl dodecylamine (5.0 mmol) were 
used to synthesize 3.13c as a colorless oil (18%).  TLC Rf = 0.2 (Ethyl Acetate).  1H NMR 
(CDCl3, 500MHz):  δ 0.88 (t, 3H, J = 6.5 Hz), 1.26 (bs, 18H), 1.34 (t, 6H, J = 7.5 Hz), 
1.52 (m, 2H), 3.04 (d, 2H, J = 22.5 Hz), 3.01 (bd, 3H), 3.37 (t, 2H, J = 7.5 Hz), 4.18 (m, 
4H).  MS(ESI), m/z = 376.1 [M-H]- , m/z = 400.4 [M+Na]+. 
 
Diethyl (Heptylcarbamoyl)methylphosphonic acid (3.13d).  Using the above general 
procedure, HOBt (5.0 mmol), EDCI (5.0 mmol), diethylphosphonoacetic acid (5.0 
mmol), DCM/DMF (50 mL), and heptylamine (5.0 mmol) were used to synthesize 3.13d 
as a colorless oil (30%).  TLC Rf = 0.2 (Ethyl Acetate).  1H NMR (CDCl3, 500MHz):  δ 
0.88 (t, 3H, J = 6.5 Hz), 1.26 – 1.36 (m, 14H) 1.51 (m, 2H), 2.82 (d, 2H, J = 20.0 Hz), 
3.26 (q, 2H, J = 6.5 Hz), 4.14 (m, 4H), 6.72 (bt, 1H)  MS(ESI), m/z = 291.1 [M-H]- , m/z 
= 316.1 [M+Na]+. 
 
General procedure for ester deprotection (3.6a-h, 3.7a,e,i,j, 3.11a-d, and 3.14a-d).  
Each ester (1.0 eq) was treated with 2 ml of DCM.  The flask was flushed several times 
with Argon.  Bromotrimethylsilane (10.0 eq) was added slowly to the mixture.  The 
resulting solution was allowed to stir 16h at ambient temperature.  Excess TMSBr was 
removed in vacuo.  95% Ethanol (5 mL) was added to the reaction flask and allowed to 
stir for 1h after which the solvent was removed in vacuo.  The residue was triturated 
several times with diethyl ether and filtered.   
 
2-oxoheptadecylphosphonic acid (3.6a).  Using the above general procedure, dimethyl 
2-oxoheptadecylphosphonate (2.76 mmol), TMSBr (27.6 mmol) and DCM (2 mL) were 
used to synthesize 3.6a as a white solid (89% overall), mp = 91-93ºC.  1H NMR (d6-
DMSO, 500MHz):  δ 0.86 (t, 3H, J = 6.0 Hz), 1.25 (bs, 24H), 1.43 (m, 2H), 2.57 (t, 2H, J 
= 7.0 Hz), 2.92 (d, 2H, J = 22.5 Hz).  13C NMR (d6-DMSO, 500MHz):  δ 14.4, 22.6, 
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23.4, 29.0, 29.2, 29.4, 29.5, 29.6, 31.8, 43.1, 45.1, 46.1. 203.9.  MS(ESI), m/z = 333.4 
[M-H]-.  UPLC1: tR 1.18 min, Purity > 99%.   
 
(Z)-2-oxononadec-12-enylphosphonic acid (3.6b).  Using the above general procedure, 
(Z)-dimethyl 2-oxononadec-12-enylphosphonate (0.5 mmol), TMSBr (5.0 mmol) and 
DCM (2 mL) were used to synthesize 3.6b as a light yellow waxy solid (77% overall).  
1H NMR (CD3OD, 500MHz):  δ 0.93 (t, 3H, J = 7.0 Hz), 1.33 (bs, 20H), 1.58 (m, 2H), 
2.05 (q, 4H, J = 8.5 Hz), 2.67 (t, 2H, J = 7.5 Hz), 3.09 (d, 2H, J = 22.5 Hz), 5.36 (m, 2H). 
13C NMR (CD3OD, 500MHz):  δ  13.1, 22.3, 23.1, 26.8, 28.7, 28.9, 29.2, 29.4, 29.5, 31.5, 
39.0, 43.3, 129.5, 204.1.  MS(ESI), m/z =359.2 [M-H]-.  UPLC1: tR 1.25 min, Purity 
96%.    
 
2-oxononylphosphonic acid (3.6c).  Using the above general procedure, Dimethyl 2-
oxononylphosphonate (0.4 mmol), TMSBr (4.0 mmol) and DCM (2 mL) were used to 
synthesize 3.6c as a light yellow oil (14% overall).  1H NMR (CD3OD, 500MHz):  δ  0.92 
(t, 3H, J = 7.0 Hz), 1.32 (bs, 8H), 1.58 (m, 2H), 2.67 (t, 2H, J = 7.0 Hz), 3.08 (d, 2H, J = 
20 Hz).  13C NMR (d-MeOD, 500MHz):  δ  13.0, 22.3, 23.1, 28.7, 28.8, 31.5, 43.2, 204.1.  
MS(ESI), m/z = 223.1 [M+H]+, 221.2 [M-H]-.  UPLC1: tR 0.37 min, Purity 98%.     
 
2-oxopentylphosphonic acid (3.6d).  Using the above general procedure, Dimethyl 2-
oxopentylphosphonate (2.3 mmol), TMSBr (23.0 mmol) and DCM (2 mL) were used to 
synthesize 3.6d as a yellow oil (76% overall).  1H NMR (CDCl3, 500MHz):  δ 0.91 (t, 
3H, J = 7.5 Hz), 1.59 (m, 2H), 2.62 (t, 2H, J = 7.0 Hz), 3.20 (d, 2H, J = 22.5 Hz).  13C 
NMR (CDCl3, 500MHz):  δ 13.0, 16.6, 31.6, 43.2, 204.0.  MS(ESI), m/z =167.0 [M + 
H]+  164.7 [M-H]-.  UPLC1: tR 0.15 min, Purity > 99%. 
 
2-oxotridecylphosphonic acid (3.6e).  Using the above general procedure, Dimethyl 2-
oxotridecylphosphonate (3.0 mmol), TMSBr (30.0 mmol) and DCM (2 mL) were used to 
synthesize 3.6e as a white solid (73% overall), mp = 81-84ºC.  1H NMR (CD3OD, 
500MHz):  δ 0.92 (t, 3H, J = 6.0 Hz), 1.31 (bs, 16H), 1.57 (m, 2H), 2.67 (t, 2H, J = 7.0 
Hz), 3.09 (d, 2H, J = 22.5 Hz).  13C NMR (CD3OD, 500MHz):  δ  13.1, 22.4, 23.1, 28.7, 
29.1, 29.2, 29.3, 29.4, 31.7, 43.2, 204.1.  MS(ESI), m/z = 279.2 [M+H]+ , 277.0 [M-H]-.  
UPLC1: tR 0.73 min, Purity > 99%.   
 
6-cyclohexyl-2-oxohexylphosphonic acid (3.6f).  Using the above general procedure, 
Dimethyl 6-cyclohexyl-2-oxohexylphosphonate (2.7 mmol), TMSBr (27.0 mmol) and 
DCM (2 mL) were used to synthesize 3.6f as a light yellow oil (69% overall).  1H NMR 
(CDCl3, 500MHz):  δ 0.90 (m, 2H), 1.12-1.36 (m, 6H), 1.53- 1.68 (m, 10H), 2.69 (t, 2H, 
J = 7.0 Hz), 3.06 (d, 2H, J = 23.0 Hz).  13C NMR (CDCl3, 500MHz):  δ  23.7, 26.2, 26.3, 
26.7, 33.3, 37.2, 37.4, 44.2, 204.6.  MS(ESI), m/z =260.8 [M-H]-.  UPLC1: tR 0.51 min, 
Purity > 99%.   
 
2-oxo-6-phenylhexylphosphonic acid (3.6g).  Using the above general procedure, 
Dimethyl 2-oxo-6-phenylhexylphosphonate (2.2 mmol), TMSBr (22.0 mmol) and DCM 
(2 mL) were used to synthesize 3.6g as a light yellow oil (62% overall).  1H NMR 
(CD3OD, 500MHz):  δ 1.56 (m, 4H), 2.58 (m, 4H), 3.13 (d, 2H, J = 22.5 Hz), 7.14 (t, 3H, 
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J = 8.0 Hz), 7.24 (t, 2H, J = 8.0 Hz).  13C NMR (CD3OD, 500MHz):  δ  23.1, 30.6, 35.6, 
44.2, 47.3, 125.8, 128.4, 142.1, 205.0.  MS(ESI), m/z = 257.0 [M+H]+ , 254.8 [M-H]-.  
UPLC1: tR 0.36 min, Purity > 99%.   
 
2-oxo-12-phenoxydodecylphosphonic acid (3.6h).  Using the above general procedure, 
Dimethyl 2-oxo-12-phenoxydodecylphosphonate (2.7 mmol), TMSBr (27.0 mmol) and 
DCM (2 mL) were used to synthesize 3.6h as a white solid (66% overall), mp = 93-95ºC. 
1H NMR (CD3OD, 500MHz):  δ 1.34 (bs, 10H), 1.49 (m, 2H), 1.58 (m, 2H), 1.78 (m, 
2H), 2.67 (t, 2H, J = 7.0 Hz), 3.09 (d, 2H, J = 22.5 Hz), 3.97 (t, 2H, J = 6.5 Hz), 6.91 (d, 
2H, J = 8.0 Hz), 6.91 (t, 1H, J = 7.5 Hz), 7.26 (t, 2H, J = 7.0 Hz).  13C NMR (CD3OD, 
500MHz):  δ  23.1, 25.8, 28.7, 29.1, 29.2, 29.3, 43.3, 67.5, 114.1, 120.1, 129.0, 159.2, 
204.1.  MS(ESI), m/z =355.0 [M-H]-.  UPLC1: tR 0.78 min, Purity > 99%.   
 
1,1-difluoro-2-oxoheptadecylphosphonic acid (3.7a).  Using the above general 
procedure, Diethyl 1,1-difluoro-2-oxoheptadecylphosphonic acid (0.1 mmol), TMSBr 
(1.0 mmol) and DCM (2 mL) were used to synthesize 3.7a as a white solid (52% overall), 
mp = 45-48ºC.  1H NMR (d6-DMSO, 500MHz):  δ 0.87 (t, 3H, J = 6.5 Hz), 1.25 (bs, 
24H), 1.51 (m, 2H), 2.76 (t, 2H, J = 7.0 Hz).  13C NMR (d6-DMSO, 500MHz):  δ   13.2, 
22.3, 28.6, 29.1, 29.2, 29.3, 29.4, 199.8.  MS(ESI), m/z = 371.3 [M+H]+ , 369.1 [M-H]-.  
UPLC1: tR 1.19 min, Purity 63%.   
 
 1,1-difluoro-2-oxotridecylphosphonic acid (3.7e).  Using the above general procedure, 
Diethyl 1,1-difluoro-2-oxotridecylphosphonic acid (0.1 mmol), TMSBr (1.0 mmol) and 
DCM (2 mL) were used to synthesize 3.7e as a colorless oil (66% overall).  1H NMR (d6-
DMSO, 500MHz):  δ 0.92 (t, 3H, J = 7.0 Hz), 1.31 (bs, 16H), 1.62 (m, 2H), 2.85 (t, 2H, J 
= 7.0 Hz).  13C NMR (d6-DMSO, 500MHz):  δ   13.1, 22.4, 28.7, 29.1, 29.1, 29.2, 29.3, 
31.7, 37.4, 110.0.  MS(ESI), m/z = 312.9 [M-H]-.   
 
(Z)-1,1-difluoro-2-oxononadec-10-enylphosphonic acid (3.7i).  Using the above 
general procedure, Diethyl (Z)-1,1-difluoro-2-oxononadec-10-enylphosphonic acid (0.1 
mmol), TMSBr (1.0 mmol) and DCM (2 mL) were used to synthesize 3.7i as a colorless 
oil (74% overall).  1H NMR (d6-DMSO, 500MHz):  δ 0.92 (t, 3H, J = 6.5 Hz), 1.34 (bd, 
20H), 1.62 (m, 2H), 2.05 (q, 4H, J = 5.0 Hz), 2.86 (t, 2H, J = 7.0 Hz), 5.37 (m, 2H).  13C 
NMR (d6-DMSO, 500MHz):  δ   13.1, 22.4, 24.7, 26.7, 28.7, 28.8, 28.9, 29.0, 29.4, 31.7, 
37.4, 129.5, 156.0.  MS(ESI), m/z = 395.0 [M-H]-.  UPLC1: tR 0.70 min, Purity 96%.  
 
1,1-difluoro-2-oxododec-11-enylphosphonic acid (3.7j).  Using the above general 
procedure, Diethyl 1,1-difluoro-2-oxododec-11-enylphosphonic acid (1.0 mmol), TMSBr 
(10.0 mmol) and DCM (2 mL) were used to synthesize 3.7j as a colorless oil (37% 
overall).  1H NMR (CD3OD, 500MHz):  δ 1.27 (bs, 10H), 1.59 (m, 2H), 2.03 ( q, 2H, J = 
5.0 Hz), 2.78 (t, 2H, J = 7.0 Hz), 4.96 (dd, 2H, J = 25 Hz, 15 Hz), 5.80 (m, 1H).  13C 
NMR (CD3OD, 500MHz):  δ  22.4, 28.6, 28.7, 28.8, 29.0, 29.1, 33.5, 37.4, 113.3, 138.7.  
MS(ESI), m/z =  296.9 [M-H]-.  UPLC1: tR 0.51 min, Purity 80%. 
 
1-oxohexadecylphosphoramidic acid (3.11a).  Using the above general procedure, 
(Diethyl) 1-oxohexadecylphosphoramidate (1.0 mmol), TMSBr (1.0 mmol) and DCM (2 
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mL) were used to synthesize 3.11a as a white solid (24% overall), mp = 56-58ºC.  1H 
NMR (d6-DMSO, 500MHz):  δ 0.87 (t, 3H, J = 6.5 Hz), 1.25 (bs, 24H), 1.47 (m, 2H), 
2.18 (t, 2H, J = 7.0 Hz), 8.98 (d, 1H, J = 9.0 Hz). 13C NMR (d6-DMSO, 500MHz):  δ  
13.0, 22.3, 26.6, 28.9, 29.0, 29.3, 29.3, 29.4, 31.7, 35.6, 36.6, 39.4, 110.0, 166.7.  
MS(ESI), m/z = 334.3 [M-H]-.   
 
 (Z)-1-oxooctadec-11-enylphosphoramidic acid (3.11b).  Using the above general 
procedure, (Diethyl) (Z)-1-oxooctadec-11-enylphosphoramidate (0.1 mmol), TMSBr (1.0 
mmol) and DCM (2 mL) were used to synthesize 3.11b as a white solid (19% overall), 
mp = 76-80ºC.  1H NMR (d6-DMSO, 500MHz):  δ 0.93 (t, 3H, J = 7.0 Hz), 1.33(bs, 
20H), 1.64 (m, 2H), 2.05 (q, 4H, J = 9.0 Hz), 2.32 (t, 2H, J = 7.0 Hz), 5.37 (m, 2H).  13C 
NMR (d6-DMSO, 500MHz):  δ   13.1, 22.3, 24.9, 26.8, 28.6, 28.9, 29.0, 29.1, 29.2, 29.5, 
31.5, 129.5, 176.5.  MS (ESI), m/z = 360.1 [M-H]-.   
 
1-oxooctylphosphoramidic acid (3.11c).  Using the above general procedure, (Diethyl) 
1-oxooctylphosphoramidate (1.5 mmol), TMSBr (15.0 mmol) and DCM (2 mL) were 
used to synthesize 3.11c as a white solid (32% overall), mp = 75-77ºC.  1H NMR 
(CD3OD, 500MHz):  δ 0.93 (t, 3H, J = 7.0 Hz), 1.35 (bs, 8H), 1.64 (m, 2H), 2.32 (bs, 
2H); 13C NMR (CD3OD, 500MHz):  δ   13.1, 22.3, 24.8, 28.8, 31.5, 176.8.  MS(ESI), m/z 
= 221.9 [M-H]-, 224.0 [M+H]+.   
 
1-oxododecylphosphoramidic acid (3.11d).  Using the above general procedure, 
(Diethyl) 1-oxododecylphosphoramidate (0.6 mmol), TMSBr (6.0 mmol) and DCM (2 
mL) were used to synthesize 3.11d as a white solid (10% overall).  1H NMR (CD3OD, 
500MHz):  δ  0.92 ( t, 3H, J = 6.5 Hz), 1.32 (bs, 16H), 1.63 (m, 2H), 2.31 (t, 2H, J = 
7.5Hz).  13C NMR (CD3OD, 500MHz):  δ   13.0, 22.3, 24.8, 28.8, 29.0, 29.2, 29.3, 31.7, 
168.6.  MS(ESI), m/z = 277.9 [M-H]- , 280.1 [M+Na]+.   
 
5-cyclohexyl-1-oxopentylphosphoramidic acid (3.11e).  Using the above general 
procedure, (Diethyl) 5-cyclohexyl-1-oxopentylphosphoramidate (0.6 mmol), TMSBr (6.0 
mmol) and DCM (2 mL) were used to synthesize 3.11e as a white solid (35% overall).  
1H NMR (CD3OD, 500MHz):  δ 0.90 (m, 2H), 1.23 (m, 6H), 1.37 (m, 2H), 1.61 (m, 2H), 
1.73 (m, 2H), 2.32 (t, 2H, J = 7.5 Hz).  13C NMR (CD3OD, 500MHz):  δ 25.1, 26.1, 26.4, 
33.2, 37.0, 37.5, 176.7.  MS(ESI), m/z = 264.1 [M+H]+ , 261.9 [M-H]-. 
 
1-oxo-11-phenoxyundecylphosphoramidic acid (3.11f).  Using the above general 
procedure, (Diethyl) 1-oxo-11-phenoxyundecylphosphoramidate (0.5 mmol), TMSBr 
(5.0 mmol) and DCM (2 mL) were used to synthesize 3.11f as a white solid (15% 
overall), mp = 100-103ºC.  1H NMR (CD3OD, 500MHz):  δ 1.35 (bs, 10H), 1.49 (m, 2H), 
1.63 (m, 2H), 1.77 (m, 2H), 2.32 (bt, 2H, J = 7.5 Hz), 3.96 (t, 2H, J = 7.0 Hz), 6.91 (t, 
3H, 8.0 Hz), 7.26 (t, 2H, J = 7.5 Hz).  13C NMR (CD3OD, 500MHz):  δ 24.8, 25.8, 28.8, 
29.0, 29.1, 29.3, 67.5, 114.1, 120.1, 129.0, 159.2, 176.6.  MS(ESI), m/z = 358.3 [M+H]+ , 
356.0 [M-H]-.   
 
(Tetradecylcarbamoyl)methylphosphonic acid (3.14a).  Using the above general 
procedure, Diethyl (Tetradecylcarbamoyl)methylphosphonic acid (1.0 mmol), TMSBr 
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(30.0 mmol) and DCM (2 mL) were used to synthesize 3.14a as a white solid (10% 
overall), mp = 133-135ºC.  1H NMR (d6-DMSO, 500MHz):  δ 0.87 (t, 3H, J = 6.5 Hz), 
1.25 (bs, 22H), 1.38 (m, 2H), 2.57 (d, 2H, J = 20.5 Hz), 3.03 (q, 2H, J = 6.0 Hz), 7.74 (t, 
1H, J = 5.5 Hz). 13C NMR (d6-DMSO, 500MHz):  δ   13.0, 22.3, 26.6, 28.8, 29.0, 29.2, 
29.4, 31.7, 39.4,  MS(ESI), m/z = 334.1 [M-H]-, m/z = 336.3 [M+H]+.  UPLC1: tR 1.75 
min, Purity > 99%.     
 
((Z)-octadec-9-enylcarbamoyl)methylphosphonic acid (3.14b).  Using the above 
general procedure, Diethyl ((Z)-octadec-9-enylcarbamoyl)methylphosphonic acid (0.1 
mmol), TMSBr (3.0 mmol) and DCM (2 mL) were used to synthesize 3.14b as a white 
solid (17% overall), mp = 111-114ºC.  1H NMR (CD3OD, 500MHz):  δ 0.92 (t, 3H, J = 
6.5 Hz), 1.33 (bd, 22H), 1.54 (m, 2H), 2.05 (m, 4H), 2.81 (d, 2H, J = 21.0 Hz), 3.21 (t, 
2H, J = 7.5 Hz), 5.37 (m, 2H).  13C NMR (CD3OD, 500MHz):  δ 13.01, 22.4, 26.6, 26.8, 
28.9, 29.0, 29.1, 29.2, 29.4, 29.5, 31.7, 38.9, 39.5, 129.5, 166.7.   MS(ESI), m/z = 388.0 
[M-H]-.  UPLC1: tR 1.32 min, Purity 96%.  
 
(N-dodecyl-N-methylcarbamoyl)methylphosphonic acid (3.14c).  Using the above 
general procedure, Diethyl (N-dodecyl-N-methylcarbamoyl)methylphosphonic acid (0.1 
mmol), TMSBr (3.0 mmol) and DCM (2 mL) were used to synthesize 3.14c as a white 
solid (10% overall), mp = 80-83ºC.  1H NMR (CD3OD, 500MHz):  δ 0.92 (t, 3H, J = 6.5 
Hz), 1.31 (bs, 18H), 1.62 (m, 2H), 3.06 (d, 2H, J = 22.5 Hz), 3.06 (bd, 3H), 3.44 (dt, 2H, 
J = 7.5 Hz, 29.5 Hz).  13C NMR (CD3OD, 500MHz):  δ 13.1, 22.3, 26.5, 26.7, 27.9, 29.1, 
29.4, 31.7, 33.0, 36.0, 51.1, 167.4.   MS(ESI), m/z = 320.0 [M-H]- , m/z = 322.3 [M+H]+.  
UPLC1: tR 0.83 min, Purity > 99%. 
 
(Heptylcarbamoyl)methylphosphonic acid (3.14d).  Using the above general 
procedure, Diethyl (Heptylcarbamoyl)methylphosphonic acid (0.1 mmol), TMSBr (3.0 
mmol) and DCM (2 mL) were used to synthesize 3.14d as a white solid (28% overall), 
mp = 137-140ºC.  1H NMR (CD3OD, 500MHz):  δ 0.93 (t, 3H, J = 6.0 Hz), 1.34 (bm, 
8H) 1.54 (m, 2H), 2.81 (d, 2H, J = 21.0 Hz), 3.21 (t, 2H, J = 7.0 Hz).  13C NMR (CD3OD, 
500MHz):  δ  13.0, 22.3, 26.5, 28.7, 28.9, 31.5, 35.6, 39.4, 166.7.   MS(ESI), m/z = 
235.8[M-H]- , m/z = 238.0 [M+H]+.  UPLC1: tR 0.35 min, Purity > 99%. 
 
General procedure for synthesis of acylsulfamates (3.19a-d).  Anhydrous formic acid 
(99%, 2.0 eq) was added drop-wise to chlorosulfonyl isocyanate (2.0 eq) at 0°C under 
argon.  The mixture was allowed to rise to room temperature and stirred until gas 
evolution stopped (~2h).  The desired alcohol (1.0 eq) in DMA (30 mL) was added drop-
wise to the resulting sulfamoyl chloride at 0°C under argon.  The mixture was allowed to 
stir at 0°C for 10 min, then allowed to warm to room temperature and stirred an 
additional 3h.  The mixture was then poured into cold brine (100 mL) and extracted with 
ethyl acetate.  The combined extracts were washed with water and brine, then dried over 
Na2SO4 and concentrated in vacuo. The residue was purified via flash chromatography in 
Hexane/ EtOAc to afford the desired sulfamate ester (3.17).   Acid chlorides were 
generated by adding oxalyl chloride (2.0 eq) and DMF (2 drops) to appropriate acids (1.0 
eq) in THF (15 mL) at 0°C under argon. After gas evolution stopped (~20 min) the 
mixture was warmed to room temperature and allowed to stir for 2h.  The resulting 
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mixture was concentrated in vacuo then dissolved in DCM/DMF (1:1, 5 mL) and added 
drop-wise to a mixture of previously prepared sulfamate ester, 3.17 (1.0 eq), DMAP (cat., 
10%mol), triethylamine (3.0 eq) in DCM/DMF (1:1, 15 mL).  The mixture was allowed 
to stir for 16h under argon.  The mixture was diluted with DCM and washed with 1N 
HCl, water, and brine then dried over Na2SO4 and concentrated in vacuo.  The residue 
was purified via flash chromatography (0-100%, Hexane/Ethyl Acetate) to afford the 
desired acylsulfamate. 
 
Ethyl palmitoylsulfamate (3.19a).  Using the above general procedure, chlorosulfonyl 
isocyanate (40.0 mmol), formic acid (40.0 mmol), ethanol (20.0 mmol), DMA (30 mL), 
palmitic acid (6.0 mmol), oxalylchloride (12.0 mmol), triethylamine (18.0 mmol), and 
DMAP (0.6 mmol) were used to synthesize 3.19a as a white solid (25%), mp = 85-87ºC.  
TLC Rf = 0.5 (8:2, CHCl3:MeOH).  1H NMR (CDCl3, 500MHz):  δ 0.88 (t, 3H, J = 6.0 
Hz), 1.26 (bs, 24H), 1.43 (t, 3H, J = 7.0 Hz), 1.66 (m, 2H), 2.39 (t, 2H, J = 7.5 Hz), 4.48 
(q, 2H, J = 8.0 Hz), 8.39 (s, 1H).  13C NMR (CDCl3, 500MHz):  δ 14.1, 14.7, 22.7, 24.4, 
29.0, 29.3, 29.4, 29.6, 29.7, 31.9, 35.9, 70.8, 171.3. MS(ESI), m/z = 386.3 [M+Na]+ , 
362.1 [M-H]-.  UPLC1: tR 1.57 min, Purity > 99%.   
 
Butyl palmitoylsulfamate (3.19b).  Using the above general procedure, Chlorosulfonyl 
isocyanate (40.0 mmol), formic acid (40.0 mmol), butanol (20.0 mmol), DMA (30 mL), 
palmitic acid (6.0 mmol), oxalylchloride (12.0 mmol), triethylamine (18.0 mmol), and 
DMAP (0.6 mmol) were used to synthesize 3.19b as a white solid (46%), mp = 74-76ºC.  
TLC Rf = 0.5 (8:2, CHCl3:MeOH).  1H NMR (CDCl3, 500MHz):  δ 0.88 (t, 3H, J = 6.5 
Hz), 0.95 (t, 3H, J = 7.5 Hz), 1.26 (bs, 24H), 1.44 (m, 2H), 1.65 (m, 2H), 1.75 (m, 2H), 
2.39 (t, 2H, J = 7.5 Hz), 4.40(t, 2H, J = 6.5 Hz), 8.18 (s, 1H).  13C NMR (CDCl3, 
500MHz):  δ  13.4, 14.1, 18.6, 22.7, 24.4, 29.0, 29.3, 29.4, 29.6, 29.7, 30.8, 31.9, 35.9, 
74.4, 171.4.  MS(ESI), m/z = 414.4 [M+Na]+ , 390.1 [M-H]-.  UPLC1: tR 1.74 min, Purity 
> 99%. 
 
4-methoxyphenyl palmitoylsulfamate (3.19c). Using the above general procedure, 
Chlorosulfonyl isocyanate (40.0 mmol), formic acid (40.0 mmol), 4-methoxyphenol (20.0 
mmol), DMA (30 mL), palmitic acid (6.0 mmol), oxalylchloride (12.0 mmol), 
triethylamine (18.0 mmol), and DMAP (0.6 mmol) were used to synthesize 3.19c as a 
white solid (10%), mp = 74-76ºC.  TLC Rf = 0.9 (Ethyl Acetate).  1H NMR (CDCl3, 
300MHz):  δ 0.90 (t, 3H, J = 6.5 Hz), 1.27 (bs, 24H), 1.64 (m, 2H), 2.38 (t, 2H, J = 7.0 
Hz), 3.81(s, 3H), 6.89 (d, 2H, J = 9.0 Hz), 7.21, (d, 2H, J = 9.0 Hz).  13C NMR (CDCl3, 
500MHz):   δ 14.1, 22.7, 24.5, 29.0, 29.3, 29.4, 29.5, 29.6, 29.7, 31.9, 36.2, 55.6, 114.18, 
122.3, 143.2, 158.7, 171.4. MS(ESI), m/z = 464.2 [M+Na]+ , 440.0 [M-H]-.  UPLC1: tR 
1.58 min, Purity > 99%. 
 
4-methoxyphenyl 5-phenylpentanoylsulfamate (3.19d).  Using the above general 
procedure, Chlorosulfonyl isocyanate (40.0 mmol), formic acid (40.0 mmol), 4-
methoxyphenol (20.0 mmol), DMA (30 mL), 5-phenylpentanoic acid (6.0 mmol), 
oxalylchloride (12.0 mmol), triethylamine (18.0 mmol), and DMAP (0.6 mmol) were 
used to synthesize 3.19d as a colorless waxy solid (10%).  TLC Rf = 0.8 (Ethyl Acetate).  
1H NMR (CDCl3, 300MHz):  δ 1.60 (bs, 4H), 2.32 (t, 2H, J = 6.0 Hz), 2.57 (t, 2H, J = 7.0 
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Hz), 3.73 (s, 3H), 6.81 (d, 2H, J = 9.0 Hz), 7.22 (m, 7H).  13C NMR (CDCl3, 500MHz):  
δ 24.2, 30.7, 35.5, 36.5, 55.6, 114.8, 122.9, 125.9, 128.4, 141.9, 143.4, 158.6, 171.3.  
MS(ESI), m/z = 386.1 [M+Na]+ , 361.9 [M-H]-.  UPLC1: tR 0.61 min, Purity > 99%. 
 
Synthesis of acylsulfamide (3.20a,b).  Anhydrous formic acid (99%, 2.0 eq) was added 
drop-wise to chlorosulfonyl isocyanate (2.0 eq) at 0°C under argon.  The mixture was 
allowed to rise to room temperature and stirred until gas evolution stopped (~2h).  
Propylamine (1.0 eq) was added drop-wise to the resulting sulfamoyl chloride at 0°C 
under argon.  The mixture was allowed to stir at 0°C for 30 min, and then warmed to 
room temperature.  NaOH (5 mL) was added to the mixture and stirred for 1h.  The 
mixture was then extracted with Ethyl Acetate.  The combined extracts were washed with 
brine, then dried over Na2SO4 and concentrated in vacuo to afford the propylsulfamide 
ester (3.18 a,b).  The acid chloride was generated by adding oxalyl chloride (2.0 eq) and 
DMF (10% mol) to the appropriate acid (1.0 eq) in THF (15 mL) at 0°C under argon. 
After gas evolution stopped (~20 min) the mixture was warmed to room temperature and 
allowed to stir for 2h.  The resulting mixture was concentrated in vacuo then dissolved in 
DCM/DMF (1:1, 5 mL) and added drop-wise to a mixture of previously prepared 
propylsulfamide ester, 3.18a,b (1.0 eq), DMAP (10% mol), triethylamine (3.0 eq) in 
DCM/DMF (1:1, 15 mL).  The mixture was allowed to stir for 16h under argon.  The 
mixture was diluted with DCM and washed with 1N HCl, water, and brine then dried 
over Na2SO4 and concentrated in vacuo.  The residue was purified via flash 
chromatography (0-100%, Hexane/Ethyl Acetate) to afford the desired acylsulfamide.   
 
Palmitoyl N-propylsulfamide (3.20a).  Using the above general procedure, 
chlorosulfonyl isocyanate (40.0 mmol), formic acid (40.0 mmol), propanol (20.0 mmol), 
palmitic acid (6.0 mmol), oxalylchloride (12.0 mmol), triethylamine (18.0 mmol), and 
DMAP (0.6 mmol) were used to synthesize 3.20a as a white solid (15%),  1H NMR 
(CDCl3, 500MHz):  δ 0.88 (t, 3H, J = 7.0 Hz), 0.92 (t, 3H, J = 7.5 Hz), 1.25 (bs, 24H), 
1.51 (m, 2H), 1.62 (m 2H), 2.15 (t, 2H, J = 8.0 Hz), 3.21 (q, 2H, J = 9.0 Hz), 5.43 (bs, 
1H).  13C NMR (CDCl3, 500MHz):  δ 11.4, 14.1, 22.7, 22.9, 25.9, 29.3, 29.4, 29.5, 29.6, 
29.7, 31.9, 36.9, 41.2, 173.2.  MS(ESI), m/z = 375.1 [M-H]-. 
 
Oleoyl N-propylsulfamide (3.20b).   Using the above general procedure, chlorosulfonyl 
isocyanate (40.0 mmol), formic acid (40.0 mmol), propanol (20.0 mmol), oleic acid (6.0 
mmol), oxalylchloride (12.0 mmol), triethylamine (18.0 mmol), and DMAP (0.6 mmol) 
were used to synthesize 3.20b as a waxy solid (8%).  Rf = 0.7 (8:2, CHCl3:MeOH)  1H 
NMR (CDCl3, 500MHz):  δ 0.88 (t, 3H, J = 6.5 Hz), 0.94 (t, 3H, J = 7.0 Hz), 1.28 (bs, 
20H), 1.59 (m, 4H), 2.00 (m, 4H), 2.62 (t, 2H, J = 7.5 Hz), 2.95 (t, 2H, J = 6.5 Hz),  5.34 
(m, 2H).  13C NMR (CDCl3, 500MHz):  δ 11.3, 14.1, 22.5. 22.7, 27.2, 29.2, 29.3, 29.5, 
29.7, 29.8, 31.9, 45.6, 129.6, 130.1, 174.8.  MS(ESI), m/z = 401.1 [M-H]-.  UPLC1: tR 
2.01 min, Purity > 99%.   
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Preparation and Assay of Acyltransferase Activity 
 
E. coli membranes were purified and acyltransferase activity was measured as 
described previously.153  Briefly, the reaction buffer contained 100mM Tris-HCL, pH 7.4, 
150mm NaCl, 1mg/ml BSA, 5mM Na3VO4, 200 µM inhibitor and purified membranes.  
16:0PO4 was added to 50µM start the reaction.  Reactions were terminated after 
incubation at 37°C for 20 min by pipetting 20µl of the reaction mixture onto a Whatman 
3MM cellulose filter disc.  Filter discs were washed in 10%, 5%, and 1% ice-cold 
trichloroacetic acid (20min, 20 ml/disk) prior to scintillation counting.  The KM for 16:0-
PO4 was obtained by varying the concentration of 16:0-PO4 from 3.125 to 50µM at a 
fixed [14C]G3P concentratin of 200µM. 
 
 
MIC Determinations 
 
The MIC of each test compound was determined by the microbroth dilution 
method in Mueller-Hinton (MH) media according to the Clinical Laboratory Standards 
Institute (CLSI) document M7-A7 for testing of the antibiotic susceptibility of aerobic 
bacteria. For growth of S. pneumoniae and S. pyogenes, MH broth was supplemented 
with 5% lysed horse blood from BD Diagnostic Systems.  All test compounds were 
dissolved in DMSO at a concentration of 10mg/ml and stored at – 80° C. Two fold serial 
dilutions of test compound were prepared in MH broth in 96-well plates to give drug 
concentrations ranging from 400 to 0.025µg/ml. Bacterial inoculum was prepared by 
streaking a -80°C stock bacterial culture onto an MH agar plate, which was incubated 
overnight at 37°C. 2-3 colonies were picked from the plate and used to establish a 
bacterial inoculum at an optical density of λ600=0.1 in MH broth, which was further 
diluted to an ODλ600= 0.001. 100µl of culture was then added to each well of the 96-well 
plate resulting in an ODλ600= 0.0005, which corresponds to about 105 CFU/ml, and final 
antibiotic concentrations ranging from 200 to 0.0125µg/ml. The 96-well plates were 
incubated overnight at 37°C and the MIC was recorded as the lowest concentration of 
drug that inhibited visible bacterial growth. 
 
 
Cytotoxicity Assay 
 
Vero monkey epithelial cells (ATCC CCL-81) were cultured in Dulbecco’s 
Modified Eagle’s Medium supplemented with 10% fetal bovine serum and maintained in 
a humidified incubator (37°C, 5% CO2).  Cells were dislodged with a cell scraper, 
collected by centrifugation, resuspended in fresh medium at ~106 cells/mL, dispensed 
into 96-well microtiter plates (100 µl/well) and incubated for 18 h at 37°C.  Two-fold 
serial dilutions of test compounds (400-0.2 µg/mL) in DMEM with FBS were 
subsequently added and cells incubated for another 72 hours.  The cytopathic effects of 
compounds were evaluated colorimetrically using the MTT Cell Proliferation Assay 
(ATCC).  IC50 data were obtained from dose response curves plotted as percentage 
activity versus log10 concentration. 
 
 104  
CHAPTER 4:  OVERALL DISCUSSION OF RESEARCH PROJECTS 
 
 
Introduction 
 
 Both projects discussed in this dissertation involved the discovery of new 
antimicrobials to address the concerns associated with the increasing prevalence of drug-
resistant bacteria.  The development of new antimicrobials is a major strategy toward 
overcoming the problems with drug resistance, as new compounds offer novel modes of 
action to which target pathogens are initially susceptible.  My work involved the targeting 
of two different pathways:  (1) the cell wall via inhibition of rhamnose biosynthesis, a 
key sugar in the makeup of the Mycobacterium tuberculosis cell wall; and (2) 
phospholipids via inhibition of phosphatidic acid biosynthesis, a key intermediate in the 
biosynthesis of bacterial phospholipids.  Both of these projects involved the use of cross-
disciplinary techniques from medicinal and organic chemistry, structural biology, 
computer modeling, biochemistry, and microbiology to discovery novel inhibitors of 
these pathways.  The purpose of this chapter is to discuss some key themes throughout 
these projects and discuss future goals that will continue the success of this work. 
 
 
RmlC Project 
 
The first project reported in Chapter 2 discussed the discovery of novel inhibitors 
of cell wall biosynthesis in M. tuberculosis.  The key concept in this project involved the 
use of structure based drug design, specifically computer aided drug design techniques.  
This work successfully combined the use of high throughput screening, database 
searching, virtual screening, and combinatorial chemistry to discovery novel inhibitors of 
RmlC as potential anti-TB drug candidates.  High throughput screening was used to 
discover a hit molecule; 2D database searching was performed to find better high affinity 
hits; 3-D database searching provided new scaffolds for library development in the 
discovery of a lead; co-crystallography was performed in the development of a 
pharmacophore model as well as gain structural knowledge for rounds of virtual 
screening;  virtual screening and docking were performed to generate and filter in silico 
libraries to produce a more focused and prioritized list of compounds for synthesis;  
synthesis of the compound libraries involved a combination of modern high throughput 
synthesis techniques:  solution phase parallel synthesis with the use of solid phase 
reagents and microwave technology to expedite the reaction process.   
 
In the synthesis of bi-aryl sulfonamides, modern technologies were used.  It was 
very important to find a practical approach for rapid synthesis of these libraries.  We 
discovered that the use of polymer supported catalysts142, 143 in combination with 
microwave technology139, 147 expedited the synthesis of this library.  Not only did it 
reduce the time to complete a normally sluggish reaction, but also cut down on 
purification of final products.  With the polymer-supported catalysts for Suzuki cross 
coupling, we were able to work with mild, non-toxic reagents that were air and moisture 
stable.142, 143  Also, at the completion of the reactions, the workup involved a simple 
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filtration.  The addition of microwave technology, not only decreased the time for 
synthesis, but helped the reactions go to completion with fewer by-products.  In most 
cases, the reactions did not require further purification.  These techniques were very 
successful in the rapid development of a 99-member bi-aryl sulfonamide library. 
 
Both libraries of bi-aryl sulfonamides produced compounds that were found to 
inhibit RmlC in M. tuberculosis. These inhibitors contained important structural features 
observed with our pharmacophore model.  However, the enzyme activity was generally 
weak (< 50% inhibition) and they did not present significant whole cell antimicrobial 
activity (MIC ≥ 25 µg/mL).  The lack of anti-tuberculosis activity is potentially due to 
poor penetration in the M. tuberculosis cell wall and low target enzyme inhibition.  This 
is not unexpected owing to the nature of the complex cell wall of mycobacteria.   
 
Although virtual screening is a successful in the discovery of high affinity leads, 
there are potential problems that prevent this method from being used solely in drug 
design.99, 171-173  There are issues with the selection of target structure, selection of the 
most favorable docking program and selection of scoring functions.  Particularly, there 
are many docking and scoring programs where the choice of program will have a major 
impact on the ultimate success of the study to identify validated leads.173  Major 
drawbacks involve the use of rigid body docking that cannot incorporate induced fit 
mechanisms and poor sampling over entropy which limits the success of these 
techniques.171, 173  Previous work in our lab performed by Kerim Baboglu et al, using the 
aforementioned methods in this project, proved the success of our chosen docking and 
scoring programs.133  Many reviews have covered these issues and scientists are 
continually trying to improve these methods for their use in structure-based drug 
design.171, 174-176  The development of leads in drug discovery programs generally 
involves the high throughput screening of libraries that exist in a particular collection 
which is often limited in chemical space and diversity.173  In silico library generation, 
associated with virtual screening, expands the possibilities of molecules that may not 
exist physically but can be readily obtained from commercial sources or through 
synthesis.     
 
 One of the shortcomings from both bi-aryl sulfonamide libraries were the 
selection of starting materials.  The first library only offered a small select number of 
sulfonyl chlorides that could be obtained commercially and used in this library.  The 
second library, a product of three points of diversity rather than the two in the first 
library, was more diverse in nature but was limited by the availability of building blocks 
that we possessed in-house for this pilot library.  Future work in this project involves an 
attempt to enhance the diversity through expansion of this pilot library to a full library 
using our structure-guided approach of in silico library generation and docking to 
prioritize compounds for synthesis.  In this library three points of diversity are 
introduced:  boronic acids that mimic the thymine moiety, various sulfonyl chloride 
spacer groups to aid in proper binding conformations, and primary amines to further 
explore the sugar pocket.  Using similar techniques in the generation of the first library, 
new compounds for synthesis were chosen.  Three virtual libraries of 22,770 compounds 
were docked and scored.  The top 2% compounds from each library were visually 
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inspected and selected based on the following criteria:  (1) MW ≤ 500; (2) ClogP ≤ 5; and 
(3) binding mode similar to dTDP-rhamnose with appropriate amino acid interactions.  
15 representative compounds are proposed for synthesis to further this research (Figures 
4.1- 4.3).  The synthesis of these compounds has been passed on to one of my lab mates 
and will be reported in due course.   
 
 
 PlsY Project 
 
Chapter 3 described the discovery of novel inhibitors of the biosynthesis of 
phospholipids in Gram-positive bacteria.  Due to the lack of structural knowledge of the 
PlsY enzyme, we employed a ligand-based drug design approach that involved the 
synthesis of substrate mimics using a bioisosteric replacement strategy to obtain a 
preliminary structure activity relationship.  These compounds were tested for their 
enzyme inhibition activity and whole cell antimicrobial activity across a panel of 
clinically relevant bacteria.  Several key inhibitors were discovered with good enzyme 
inhibition, good antimicrobial activity, and low cytotoxicity.   
 
A recent publication of Paoletti et al demonstrated that plsX and plsY is essential 
in Gram-positive bacteria such as Bacillus subtilis.155  Deletion of the genes associated 
with plsX and plsY block phospholipids biosynthesis.155  PlsX depletion results in the 
inhibition of total lipid synthesis without accumulation of fatty acids or other 
intermediates.155  This suggests a role of this pathway in fatty acid synthesis.  The 
competitive inhibition of our compounds to PlsY causes a build up of acylphosphate 
which can be used in the reversible PlsX reaction to generate acyl-ACP.152  Acyl-ACP 
can then re-enter and block fatty acid synthesis.152  Additionally, the inhibitors of PlsY 
have long chains that are similar to those that are accumulated during fatty acid synthesis 
implying their potential to act as inhibitors of fatty acid biosynthesis causing a build up of 
intermediates which in turn will cause inhibition of the enzymes.177   
 
I feel we have only scratched the surface toward the successful development of 
substrate mimics as inhibitors of phospholipids biosynthesis in Gram-positive bacteria.  
We have designed and synthesized the first known potent inhibitors of the PlsX/PlsY 
pathway which have significant antimicrobial activity in B. anthracis.  The excellent 
activity in B. anthracis led us to do more research on B. anthracis and why the 
compounds had such a narrow spectrum activity, which revealed that B. anthracis has 
three plsY homologs in its genome. One of our current goals is to determine which 
enzyme or enzymes are responsible for the potent MIC activity.   
 
The preliminary SAR studies led to the discovery of novel inhibitors for PlsY; 
however we need to further expand the library to include functional groups with more 
drug-like properties.  There are two types of compounds I suggest that could further this 
project: reverse amide phosphonates and acylsulfamates.  I would choose these two 
scaffolds because: (1) they are synthetically very tractable and it should be easy to 
synthesize expanded libraries in parallel; and (2) compounds with these scaffolds have 
already been synthesized, and were good inhibitors with good whole cell antimicrobial 
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Figure 4.1:  Compounds from Lib_1 
 
 
 
 
Figure 4.2:  Compounds from Lib_2 
 
 
 
 
 
Figure 4.3:  Compounds from Lib_3 
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activity.  In addition to the synthesis of more drug-like analogues of PlsY inhibitors, 
future work should also include inhibitors of PlsX.  As discussed above, PlsX inhibition 
not only leads to blockade of phospholipid biosynthesis in Gram-positive bacteria, but 
also blocks total lipid synthesis.155  This shows the potential of inhibitors that can block 
fatty acid synthesis which is a proven target for antimicrobial design.  There are crystal 
structure of two PlsX enzymes176 available, however not much is known about the 
specific active site of this enzyme.  I believe the search for inhibitors of PlsX enzyme will 
be fertile ground for the development of new antimicrobial agents. 
  
 
Final Thoughts  
 
Medicinal chemistry is defined as a highly interdisciplinary science combining 
organic chemistry with biochemistry, computational chemistry, pharmacology, 
pharmacognosy, molecular and structural biology, statistics, and physical chemistry.96  
The work outlined in these two projects utilized strategies and technologies from these 
areas in the successful discovery of potential candidates for antimicrobial drug design 
showing that no one discipline can work alone as it is important to have collaborations 
amongst other fields of study to flourish in any given project.  Each discipline plays a 
critical role from the discovery of new therapeutic targets for which drugs can be 
designed and synthesized to the manufacturing and implement of these drugs to the 
market.  Being a part of an interdisciplinary environment allows you to share your 
expertise in your field while learning more about other fields which is an important 
quality for continued success.  I’ve had the opportunity to be exposed to several 
disciplines that have definitely broadened my understanding of the sciences and my 
effectiveness as a medicinal chemist.  My hopes are that the importance of an 
interdisciplinary approach to drug design is incorporated in more graduate programs in 
order to produce a flood of well-rounded scientists that influence the field. 
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